Anti-ceacam5 antibody drug conjugates and uses thereof
Anti-CEACAM5 antibody conjugates with specific CDR sequences and linkers enhance tumor inhibition efficacy by targeting CEACAM5, addressing the limitations of existing therapies by improving selectivity and stability.
Patent Information
- Application Number
- PCT/IB2026/000253
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cancer therapies lack selectivity towards cancer cells, leading to adverse effects on healthy cells and the development of treatment resistance, necessitating the development of novel antibody-drug conjugates that target carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with improved specificity and stability.
Development of antibody conjugates comprising anti-CEACAM5 antibodies or antigen-binding fragments with specific CDR sequences, linked to active agents through various linkers, enabling selective delivery and release of drugs in cancer cells.
The antibody conjugates exhibit improved stability and efficacy, effectively inhibiting tumor growth in various cancer models while minimizing impact on healthy tissues and maintaining body weight of treated animals.
Smart Images

Figure IB2026000253_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket: LCH-04425
[0002] ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES AND USES THEREOF Related Applications
[0003] This application claims the benefit of priority to U.S. Provisional Application Serial No. 63 / 802563, filed May 8, 2025, the content of which is hereby incorporated by reference in its entirety.
[0004] Background
[0005] Cancer is a disease caused by abnormal and uncontrolled cell growth in the tissues of the body. Cancer therapies comprise a wide range of therapeutic approaches, including surgery, radiation, and chemotherapy. Existing therapeutics often suffer from a number of disadvantages, such as a lack of selectivity of targeting cancer cells over normal, healthy cells, and the development of resistance by the cancer to the treatment. Accordingly, the focus of development has been on developing novel therapeutics to achieve improved efficacy and minimal toxicity / adverse effects through improved and selective action of the therapeutics on tumor cells or immediately adjacent tissues.
[0006] An antibody-drug conjugate (ADC) is a targeted technology that involves bonding a toxin or drug to an antibody. The antibody specifically recognizes and binds to an antigen present on the surface of a cancer cell. Once bound, the drug is released into or near the target cancer cell causing its death. The technology has superior efficacy over antibody therapies and substantially reduces the risk of adverse effects compared to conventional anti-cancer treatments. This is because ADCs deliver drugs to the target cancer cells with minimal impact to healthy cells, and only releases drugs under specific conditions. Despite these advantages, there remains a continuous need to develop new antibody-drug conjugates for cancer treatment.
[0007] Summary
[0008] In certain aspects, the present disclosure provides antibody conjugates comprising anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibodies or antigen-binding fragments thereof that bind to CEACAM5. In certain embodiments, the antibodies disclosed herein bind to CEACAM5 expressed in a cancer cell and may be used to deliver an active agent to the cell. In certain embodiments, the antibodies disclosed herein bind to and have improved specificity for CEACAM5 on cell surface compared to soluble CEACAM5, enabling improved selective delivery of the active agent. In certain embodiments,
[0009] 1
[0010] FH30010189.1Attorney Docket: LCH-04425
[0011] the antibody conjugates disclosed herein have improved stability and efficacy as compared to antibody conjugates known in the art.
[0012] In certain aspects, the present disclosure provides a conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:
[0013] [General Formula I]
[0014] Ab-[LAb-(B)i]m
[0015] wherein,
[0016] Ab is an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein
[0017] (i) CDRH1 comprises an amino acid sequence of SEQ ID NO: 2,
[0018] CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,
[0019] CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,
[0020] CDRL1 comprises an amino acid sequence of SEQ ID NO: 9,
[0021] CDRL2 comprises an amino acid sequence of SEQ ID NO: 11, and
[0022] CDRL3 comprises an amino acid sequence of SEQ ID NO: 13;
[0023] (ii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 25,
[0024] CDRH2 comprises an amino acid sequence of SEQ ID NO: 27,
[0025] CDRH3 comprises an amino acid sequence of SEQ ID NO: 29,
[0026] CDRL1 comprises an amino acid sequence of SEQ ID NO: 34,
[0027] CDRL2 comprises an amino acid sequence of SEQ ID NO: 36, and
[0028] CDRL3 comprises an amino acid sequence of SEQ ID NO: 38; or
[0029] (iii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 44,
[0030] CDRH2 comprises an amino acid sequence of SEQ ID NO: 46,
[0031] CDRH3 comprises an amino acid sequence of SEQ ID NO: 48,
[0032] CDRL1 comprises an amino acid sequence of SEQ ID NO: 53,
[0033] CDRL2 comprises an amino acid sequence of SEQ ID NO: 55, and
[0034] CDRL3 comprises an amino acid sequence of SEQ ID NO: 57;
[0035] each LAbis independently a linker;
[0036] 2
[0037] FH30010189.1Attorney Docket: LCH-04425
[0038] each B is independently an active agent; and
[0039] 1 and m are each independently 1 to 20.
[0040] Brief Description of the Drawings
[0041] FIG. 1 shows the production process of ADC1 and structure thereof. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0042] FIG. 2 shows the production process of ADC2 and structure thereof, which is also representative for ADC8 and ADC10. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0043] FIG. 3 shows the production process of ADC3 and structure thereof. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0044] FIG. 4 shows the production process of ADC4 and structure thereof. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0045] FIG. 5 shows the production process of ADC5 and structure thereof. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0046] FIG. 6 shows the production process of ADC6 and structure thereof. Amino acid sequence CVIM is of SEQ ID NO: 20.
[0047] FIG. 7 shows that ADC1 and ADC6 exhibited significant and superior tumor growth inhibition in the H3122 tumor xenograft model of lung cancer cell line compared to vehicle control or the reference ADC7.
[0048] FIG. 8 shows that ADC2 and ADC5 exhibited significant tumor growth inhibition in the HPAF-II tumor xenograft model of pancreatic cancer cell line compared to vehicle control.
[0049] FIGs. 9A-9C show that ADC2 and ADC8 (FIG. 9A) and ADC5 (FIG. 9B) exhibited significant tumor growth inhibition in the MKN-45 tumor xenograft model of gastric cancer cell line compared to vehicle control, and that tested ADCs did not affect body weight of treated mice (FIG. 9C). ADC2 and ADC8 (FIG. 9A) showed higher efficacy compared to ADC9 of higher drug antibody ratio (DAR).
[0050] FIGs. 10A-10B show that ADC2 and ADC8 exhibited potent anti-tumor efficacy in the NCI-H2122 tumor xenograft model of lung cancer cell line compared to vehicle control or the reference ADC9 (FIG. 10A) and did not affect body weight of treated mice (FIG. 10B).
[0051] FIGs. 11A-11C show that ADC2 (FIG. 11 A) and ADC5 (FIG. 11B) exhibited significant tumor growth inhibition in the SW1463 tumor xenograft model of colorectal cancer cell line compared to vehicle control, and that tested ADCs did not affect body weight of treated mice (FIG. 11C)
[0052] FH30010189.1Attorney Docket: LCH-04425
[0053] FIG. 12 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a lung cancer patient-derived xenograft (PDX) model NIC-0087.
[0054] FIG. 13 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a lung cancer PDX model NIC-0011.
[0055] FIG. 14 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a lung cancer PDX model NIC-0084.
[0056] FIG. 15 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a colon cancer PDX model LRB-004P.
[0057] FIG. 16 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a colon cancer PDX model IGR-048M.
[0058] FIG. 17 shows the tumor growth inhibition comparison between ADC2 and reference ADC9 or control in a colon cancer PDX model LRB-010P.
[0059] FIG. 18 shows the pharmacokinetic analysis results of plasma concentrations of ADC2 and total antibody after a single dose of ADC2 at 3 mg / kg in Sprague Dawley (SD) rats.
[0060] FIG. 19 shows the toxicokinetic analysis results of plasma concentrations of ADC1, free drug, and total antibody after a single dose of ADC1 at 200 mg / kg in B6-hCEACAM5 transgenic mice.
[0061] FIG. 20 shows the toxicokinetic analysis results of plasma concentrations of ADC5 and total antibody after a single dose of ADC5 at 3 mg / kg in B6-hCEACAM5 transgenic mice.
[0062] Detailed Description
[0063] An antibody-drug conjugate (ADC) is a targeted technology for conjugating a toxin or a drug to an antibody that binds to an antigen, by which the toxin or drug is released in or near target cancer cells to cause cell death. The ADC enables a drug to be accurately delivered to target cancer cells while minimally affecting healthy cells, and to be released only under specific conditions, and thus has excellent efficacy compared to antibody therapeutic agents themselves and can remarkably reduce the risk of side effects compared to existing anticancer agents.
[0064] The basic structure of these ADCs is “antibody-linker-small molecule drug (toxin).” In this structure, the linker plays a functional role in linking the antibody and the drug, but in some cases also ensures that the drug is released from the antibody at the appropriate time, for example after reaching target cells. That is, the stability of the linker can play a very important
[0065] 4
[0066] FH30010189.1Attorney Docket: LCH-04425
[0067] role in the efficacy and safety such as systemic toxicity of an antibody-drug conjugate (Discovery Medicine 2010, 10(53): 329-39).
[0068] The use of monoclonal antibodies for cancer treatment has had substantial success. For example, monoclonal antibodies are suitable for target-directed addressing of tumor tissue and cancer cells. ADCs have become a novel and powerful option for the treatment of lymphomas and solid cancers, and immunomodulatory antibodies also have recently had considerable success in clinical trials. The development of therapeutic antibodies is based on deep understanding of cancer serology, protein engineering technology and the action thereof, mechanisms of resistance, and interactions between immune systems and cancer cells.
[0069] Antigens which are expressed on the surface of human cancer cells are defined as a broad range of targets which are over-expressed compared to normal tissues, mutated and selectively expressed. The key challenge is to identify antigens suitable for antibody-based therapies. These therapeutic agents mediate changes in antigen or receptor function ( / .<?., function as a stimulant or an antagonist), regulate the immune system through Fc and T cell activation, and exhibit efficacy through the delivery of specific drugs that bind to antibodies targeting specific antigens. Molecular techniques that can alter antibody pharmacokinetics, action function, size and immune stimulation are emerging as key factors in the development of novel antibody-based therapies. Evidence from clinical trials of therapeutic antibodies in cancer patients highlights the importance of approaches for selecting optimized antibodies, including affinity and binding of target antigens and antibodies, selection of an antibody structure, and therapeutic approaches (signaling blockade or immune function).
[0070] Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. CEA was first identified as a protein normally expressed by fetal gut during the first six months of gestation, and found in cancers of the pancreas, liver and colon (Gold & Freedman. J Exp Med.
[0071] 122(3): 467-481. 1965). The CEA family belongs to the immunoglobulin superfamily. The CEA family is subdivided in two sub-groups of proteins: the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) sub-group and the pregnancy-specific glycoprotein subgroup (Kammerer & Zimmermann. BMC Biology. 8: 12. 2010). In humans, the CEACAM sub-group includes: CEACAM1, CEACAM 3, CEACAM4, CEACAM5, CEACAM 6, CEACAM 7, and CEACAM8 (Kuespert et al. Curr Opin Cell Biol. 18(5): 565-571. 2006). Studies have shown that CEACAM5 is overexpressed in a majority of carcinomas, including those of the gastrointestinal tract, the respiratory and genitourinary systems, and breast cancer (Blumenthal et al. BMC Cancer 7(2). 2007).
[0072] 5
[0073] FH30010189.1Attorney Docket: LCH-04425
[0074] In certain aspects, the present disclosure provides antibody conjugates comprising an anti-CEACAM5 antibody or antigen-binding fragment thereof. In certain embodiments, the antibody or antigen-binding fragment disclosed herein binds to CEACAM5, or preferably binds specifically to CEACAM5 expressed on cell surface compared to soluble CEACAM5, enabling improved selective delivery of active agents (e.g., toxins) to cancer cells expressing CEACAM5. In certain embodiments, the antibody conjugates disclosed herein have improved stability and efficacy as compared to antibody conjugates known in the art.
[0075] In certain aspects, the present disclosure provides a conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:
[0076] [General Formula I]
[0077] Ab-[LAb-(B)i]m
[0078] wherein,
[0079] Ab is an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein
[0080] (i) CDRH1 comprises an amino acid sequence of SEQ ID NO: 2,
[0081] CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,
[0082] CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,
[0083] CDRL1 comprises an amino acid sequence of SEQ ID NO: 9,
[0084] CDRL2 comprises an amino acid sequence of SEQ ID NO: 11, and
[0085] CDRL3 comprises an amino acid sequence of SEQ ID NO: 13;
[0086] (ii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 25,
[0087] CDRH2 comprises an amino acid sequence of SEQ ID NO: 27,
[0088] CDRH3 comprises an amino acid sequence of SEQ ID NO: 29,
[0089] CDRL1 comprises an amino acid sequence of SEQ ID NO: 34,
[0090] CDRL2 comprises an amino acid sequence of SEQ ID NO: 36, and
[0091] CDRL3 comprises an amino acid sequence of SEQ ID NO: 38; or
[0092] (iii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 44,
[0093] 6
[0094] FH30010189.1Attorney Docket: LCH-04425
[0095] CDRH2 comprises an amino acid sequence of SEQ ID NO: 46,
[0096] CDRH3 comprises an amino acid sequence of SEQ ID NO: 48,
[0097] CDRL1 comprises an amino acid sequence of SEQ ID NO: 53,
[0098] CDRL2 comprises an amino acid sequence of SEQ ID NO: 55, and
[0099] CDRL3 comprises an amino acid sequence of SEQ ID NO: 57;
[0100] each LAbis independently a linker;
[0101] each B is independently an active agent; and
[0102] 1 and m are each independently 1 to 20.
[0103] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising: the amino acid sequence of SEQ ID NO: 15; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 15.
[0104] In some embodiments, Ab comprises a light chain variable region (VL) comprising: the amino acid sequence of SEQ ID NO: 16; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13. In some embodiments, Ab comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 16.
[0105] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 15 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 16.
[0106] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising: the amino acid sequence of SEQ ID NO: 31; a sequence having at least 90% sequence identity
[0107] 7
[0108] FH30010189.1Attorney Docket: LCH-04425
[0109] to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 29; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 29. In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 31.
[0110] In some embodiments, Ab comprises a light chain variable region (VL) comprising: the amino acid sequence of SEQ ID NO: 40; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 40 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38. In some embodiments, Ab comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 40.
[0111] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 40.
[0112] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising: the amino acid sequence of SEQ ID NO: 50; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48. In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 50.
[0113] In some embodiments, Ab comprises a light chain variable region (VL) comprising: the amino acid sequence of SEQ ID NO: 59; a sequence having at least 90% sequence identity to
[0114] 8
[0115] FH30010189.1Attorney Docket: LCH-04425
[0116] the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, Ab comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 59.
[0117] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 59.
[0118] In some embodiments, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
[0119] (i) VH comprises the amino acid sequence of SEQ ID NO: 15; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; and VL comprises the amino acid sequence of SEQ ID NO: 16; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13;
[0120] (ii) VH comprises the amino acid sequence of SEQ ID NO: 31; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid
[0121] 9
[0122] FH30010189.1Attorney Docket: LCH-04425
[0123] sequence of SEQ ID NO: 29; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 29; and VL comprises the amino acid sequence of SEQ ID NO: 40; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38; or
[0124] (iii) VH comprises the amino acid sequence of SEQ ID NO: 50; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48; and VL comprises the amino acid sequence of SEQ ID NO: 59; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57.
[0125] In some embodiments, Ab comprises (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 15 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 16; (ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 40; or (iii) a heavy chain variable region
[0126] 10
[0127] FH30010189.1Attorney Docket: LCH-04425
[0128] (VH) comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 59.
[0129] In some embodiments, Ab specifically binds to CEACAM5. In some embodiments, Ab specifically binds to membrane-bound CEACAM5. In some embodiments, Ab specifically binds to soluble CEACAM5. In some embodiments, Ab specifically binds to membrane-bound CEACAM5 and soluble CEACAM5. In some embodiments, Ab specifically binds to either membrane-bound CEACAM5 or soluble CEACAM5. In some embodiments, Ab is a humanized antibody or a human antibody. In some embodiments, Ab is selected from a monoclonal antibody, a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.
[0130] In some embodiments, Ab comprises an IgA, IgG, IgM, IgE, or IgD constant domain or is an IgA, IgG, IgM, IgE, or IgD antibody. In some embodiments, Ab comprises an IgG constant domain or is an IgG antibody. In some embodiments, Ab comprises an IgGl, IgG2, IgG3, or IgG4 constant domain or is an IgGl, IgG2, IgG3, or IgG4 antibody. In some embodiments, Ab comprises an IgGl constant domain or is an IgGl antibody. In some embodiments, Ab comprises LALA mutations in a heavy chain constant domain. In some embodiments, the LALA mutations comprise L234A and L235A substitutions according to EU numbering convention. In some embodiments, Ab comprises leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 236-237 in SEQ ID NO: 17 (or amino acids 237-238 in SEQ ID NO: 51). In some embodiments, Ab comprises a P329G substitution according to EU numbering convention. In some embodiments, Ab comprises a proline-to-glycine substitution in a heavy chain constant region in place of an amino acid corresponding to amino acid 331 in SEQ ID NO: 17. In some embodiments, Ab comprises (a) L234A, L235A, and P329G substitutions according to EU numbering convention, or (b) leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 236-237 in SEQ ID NO: 17 (or amino acids 237-238 in SEQ ID NO: 51) and a proline-to-glycine substitution in the heavy chain constant region in place of an amino acid corresponding to amino acid 331 in SEQ ID NO: 17.
[0131] In some embodiments, Ab at the C-terminus comprises an amino acid motif that is recognized by an isoprenoid transferase. In some embodiments, the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase). In some
[0132] 11
[0133] FH30010189.1Attorney Docket: LCH-04425
[0134] embodiments, LAbis covalently bonded to Ab by a thioether bond and the thioether bond comprises a sulfur atom of a cysteine of the amino acid motif. In some embodiments, the amino acid motif comprises a CYaYaX sequence, wherein: C is cysteine; each Yais independently an aliphatic amino acid; and X is selected from glutamine, glutamate, serine, cysteine, methionine, alanine, and leucine. In some embodiments, each Yais independently selected from alanine, isoleucine, leucine, methionine, and valine. In some embodiments, the amino acid motif comprises a CVIM (SEQ ID NO: 20) or CVLL (SEQ ID NO: 21). In some embodiments, at least one of the 1 to 20 amino acids preceding the amino acid motif is glycine. In some embodiments, the amino acid motif has the sequence GGGGGGGCVIM (SEQ ID NO: 22).
[0135] In some embodiments, Ab comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 41 ; (f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 42; (g) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 60; (h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 62; (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 60; or (j) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 62.
[0136] In some embodiments, Ab comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; or (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 19. In some
[0137] 12
[0138] FH30010189.1Attorney Docket: LCH-04425
[0139] embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 19.
[0140] In some embodiments, Ab comprises: (e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 41; (f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 42. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 41.
[0141] In some embodiments, Ab comprises: (g) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 60; (h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 62; (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 60; or (j) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 62. In various embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 60.
[0142] In various embodiments, the present disclosure provides linkers, and conjugates comprising those linkers, as well as methods for their synthesis and for their use in therapeutic applications. In particular, the disclosure describes conjugates comprising a structure represented by a formula disclosed herein (e.g., Formula la, or Formula X). These structures incorporate multiple attachment points for coupling to active agents, allowing for the delivery of multiple payloads or the combination of different functionalities within a single conjugate. The branched structure may enhance the therapeutic efficacy, improve pharmacokinetic properties, or allow for the co-delivery of synergistic agents. The conjugates described herein may be particularly useful in the context of antibody-drug conjugates, but the technology is broadly applicable to various targeting moieties and payloads. Indeed, the linkers disclosed herein may be used with existing linker technology in multiple ways, as it sits within a well-developed field with numerous available techniques for assembly of conjugates:
[0143] 1. Maleimide conjugation: This method utilizes the reaction between maleimide groups and thiol groups. For example, antibodies can be partially reduced to expose cysteine residues, which then react with maleimide-functionalized linkers or payloads.
[0144] 13
[0145] FH30010189.1Attorney Docket: LCH-04425
[0146] 2. Cysteine Re-bridging: This technology creates homogeneous and stable ADCs by re-bridging reduced interchain disulfide bonds with bifunctional linkers, without the need for antibody engineering.
[0147] 3. N-Hydroxysuccinimide (NHS) ester conjugation: NHS esters react with primary amines, such as lysine residues on proteins. This method is commonly used for attaching linkers or payloads to antibodies or other targeting moieties.
[0148] 4. Click chemistry: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain-promoted azide-alkyne cycloaddition (SPAAC) are widely used for bioorthogonal conjugation. These reactions allow for site-specific attachment of payloads to modified targeting moieties. Click chemistry offers high specificity and can be performed under mild conditions, making it suitable for a wide range of biomolecules. Recently, metal-free SPAAC cycloaddition reactions have been investigated, including dibenzocyclooctyne (DBCO)-derived molecules covalently linked to the azide group of a functionalized phenylalanine such as para- azidophenlyalanine (pAzF) or para-azidomethylphenylalanine (pAMF). Metal-free SPAAC reactions have been shown as promising conjugation reactions for homogeneous, highly stable conjugates with desirable pharmacokinetics and controlled delivery of the potent payload. See e.g., Xenobiotica 2024, Vol. 54, No.
[0149] 8, 469-491.
[0150] 5. Enzymatic conjugation: Methods such as sortase-mediated ligation or transglutaminase-catalyzed conjugation enable site-specific attachment of payloads to targeting moieties under mild conditions. Sortase A (SrtA) catalyzes transpeptidation to insert recognition peptides at the C-terminus of antibody chains, followed by payload attachment. Bacterial transglutaminases (BTGs) form amide bonds between lysine and glutamine residues, enabling stable payload attachment. Additional examples include (i) conjugation via formyl glycine-generating enzyme, which inserts a specific sequence, converting cysteine to formyl glycine, that can then be conjugated to aldehyde-containing payloads; and (ii) prenyltransferase- mediated conjugation, wherein farnesyl transferase attaches a ketone-functionalized isoprenoid to a C-terminal CaaX motif, which is then linked to a hydroxylamine- bearing payload via oxime ligation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.
[0151] 14
[0152] FH30010189.1Attorney Docket: LCH-04425
[0153] 6. Hydrazone and oxime ligation: These methods involve the reaction between aldehydes or ketones with hydrazides or aminooxy groups, respectively. Exemplary methods include using amino-terminal engineered serine at the N-terminus, which is oxidized to an aldehyde for oxime ligation.
[0154] 7. Thiol-ene and thiol-yne reactions: These photoinitiated reactions allow for the conjugation of thiol-containing molecules to alkene or alkyne-functionalized components. These methods offer rapid reaction kinetics and can be performed under mild conditions, making them suitable for sensitive biomolecules.
[0155] 8. Diels-Alder cycloaddition: This reaction between a diene and a dienophile can be used for bioconjugation, particularly when using cyclic dienes like transcyclooctene. The reaction proceeds rapidly and specifically under physiological conditions.
[0156] 9. Staudinger ligation: This method involves the reaction between an azide and a phosphine to form an amide bond; the method offers high chemoselectivity and can be performed in aqueous media, making it suitable for bioconjugation.
[0157] 10. Photoclick chemistry: Light-induced cycloadditions, such as the reaction between tetrazoles and alkenes, provide spatiotemporal control over the conjugation process. This can be particularly useful for in situ labeling or activation of conjugates. 11. Ligation to Fab nucleotide-binding sites: A method which uses indole-based linkers to target lysine residues in the Fab region’s nucleotide-binding pocket for sitespecific conjugation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.
[0158] Each conjugation method offers unique advantages and presents specific challenges, and the choice of conjugation method may depend on factors, as readily appreciated by the skilled artisan, such as the nature of the targeting moiety, the payload, and the desired properties of the final conjugate. In many cases, the targeting moiety or payload may be modified to introduce specific functional groups that facilitate conjugation. For example, antibodies may be engineered to incorporate non-natural amino acids with bioorthogonal reactive groups, allowing for conjugation.
[0159] The assembly of conjugates, including antibody-drug conjugates, is a well-established process in the art which can readily be adapted and applied to the embodiments disclosed herein. Those of ordinary skill in the art can readily employ various existing chemistry methods to assemble conjugates efficiently and reliably; such methods allow for the controlled
[0160] 15
[0161] FH30010189.1Attorney Docket: LCH-04425
[0162] attachment of payloads to targeting moieties through linkers. Several known chemistry methods for assembling conjugates include:
[0163] The skilled artisan can modulate reaction conditions, such as pH, temperature, and reagent concentrations, to achieve desired conjugation efficiencies and product homogeneity. The use of organic co-solvents, catalysts, or additives may be employed to enhance reaction rates or selectivity. In some cases, multiple conjugation steps may be used to assemble complex conjugates with multiple payloads or functionalities.
[0164] Simply put, notwithstanding the challenges associated with particular linker designs, the conjugation chemistry used to assemble targeting moieties, linkers, and payloads into functional conjugates is a mature field. Indeed, numerous well-characterized methods, such as the methods mentioned above (e.g., such as maleimide-thiol reactions, click chemistry, NHS ester conjugation, and enzymatic ligation) are available and routinely employed by those of skill in the art. Thus, once the structure and properties of a linker and a synthetic route to the linker are established, the selection and application of appropriate conjugation chemistry to assemble a conjugate is generally routine and predictable.
[0165] In some embodiments, the conjugate has a structure represented by Formula la or a pharmaceutically acceptable salt thereof:
[0166]
[0167] Formula la
[0168] wherein
[0169] each instance of G is independently a sugar or a sugar acid (e.g., a glucuronic acid or galactoside);
[0170] R1and R2are each independently hydrogen, Ci-s alkyl, or C3-8 cycloalkyl; or R1and R2combine to complete a (Cs-Cs) cycloalkyl ring;
[0171] each instance of W is independently -C(O)-, -C(O)N(R’)-, -C(O)O-, -SC>2N(R’)-, -P(O)(R”)N(R’)-, -SON(R’)-, or -PO2N(R’)-;
[0172] 16
[0173] FH30010189.1Attorney Docket: LCH-04425
[0174] each instance of R’ and R” is independently H, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl or aryl;
[0175] each instance of Z is independently alkyl, halo, cyano, or nitro;
[0176] nl and n2 are each independently 1 to 20;
[0177] each instance of n3 is independently 0, 1, 2, or 3; and
[0178] Y1is absent, C1-C50 alkylene, C1-C50 alkenylene, 1-50 atom heterocyclylene, or 1-50 atom heteroalkylene.
[0179] In some embodiments, R1is H or methyl. In some embodiments, R1is H. In some embodiments, R1is methyl. In some embodiments, R2is H or methyl. In some embodiments, R2is H. In some embodiments, R2is methyl. In some embodiments, G has a structure represented by Formula II or a pharmaceutically acceptable salt thereof:
[0180]
[0181] II
[0182] wherein
[0183] R3and each R4is independently H, alkyl, aralkyl, or an oxygen protecting group;
[0184] R3ais H or alkyl;
[0185] R3bis H or alkyl; or
[0186] R3aand R3bcombine to form an oxo;
[0187] R3Ais H or a hydroxyl protecting group; and
[0188] R3Bis H or a carboxyl protecting group.
[0189] In some embodiments, R3is H or methyl. In some embodiments, R3is H. In some embodiments, R4is H. In some embodiments, W is -C(O)N(R’)- and the C(O) is bonded to the phenyl ring and N(R’) is bonded to Y1. In some embodiments, R’ is H. In some embodiments, R” is H. In some embodiments, Z is halo (e.g., bromo) or cyano. In some embodiments, n3 is 0 or 1. In some embodiments, n3 is 1. In some embodiments, n3 is 0.
[0190] In some embodiments, Y1comprises an alkylene (e.g., a C1-50 alkylene). In some embodiments, Y1comprises a heteroalkylene (e.g., a C1-50 heteroalkylene). In some embodiments, Y1comprises an unsaturated bond (e.g., 1, 2, 3, 4 or 5 unsaturated bonds). In
[0191] 17
[0192] FH30010189.1Attorney Docket: LCH-04425
[0193] some embodiments, Y1is substituted with alkyl (e.g., a C1-20 alkyl). In some embodiments, Y1comprises an isoprenyl group having a structure represented by Formula III:
[0194]
[0195] wherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, n4 is 1, 2, 3, or 4.
[0196] In some embodiments, Y1comprises a C1-50 alkylene or C1-50 heteroalkylene wherein the Ci -50 alkylene or C1-50 heteroalkylene comprises one or more of:
[0197] (i) one or more unsaturated bonds;
[0198] (ii) a heteroarylene (e.g., a heteroarylene in the alkylene or heteroalkylene chain); (iii) at least one C1-20 alkyl substituent; and
[0199] (iv) at least one isoprenyl group having a structure represented Formula III:
[0200]
[0201] wherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, n4 is 1, 2, 3, or 4.
[0202] In some embodiments, Y1comprises a peptide comprising at least one hydrophilic amino acid. In some embodiments, the peptide comprises an amino acid having a side chain having a moiety that bears a charge at neutral pH in aqueous solution (e.g., an amine, guanidine, or carboxyl moiety). In some embodiments, the peptide comprises an amino acid selected from alanine, aspartate, asparagine, glutamate, glutamine, glycine, lysine, ornithine, proline, serine, histidine, arginine and threonine.
[0203] In some embodiments, Y1comprises a unit having a structure represented by Formula IVa or IVb:
[0204] -(CH2)r(V(CH2)P)q- Formula IVa,
[0205] -(CH2CH2X)W- Formula IVb;
[0206] wherein
[0207] 18
[0208] FH30010189.1Attorney Docket: LCH-04425
[0209] V is a single bond, -O-, -S-, -NR5-, -C(O)NR6-, -NR7C(O)-, -NR8SO2-, or -SO2NR9-, preferably -O-;
[0210] X is -O-, C1-8 alkylene, or -NR5-, preferably -O-;
[0211] R5to R9are each independently H, C1-6 alkyl, C1-6 alkyl C6-20 aryl, or C1-6 alkyl C3-20 heteroaryl;
[0212] r is an integer of 1 to 10, preferably 2;
[0213] p is an integer of 0 to 12, preferably 2;
[0214] q is an integer of 1 to 20, preferably 2, 5, or 11; and
[0215] w is an integer of 1 to 20, preferably 6 to 20.
[0216] In some embodiments, V is -O-. In some embodiments, X is -O-. In some embodiments, R5is H. In some embodiments, R6is H. In some embodiments, R7is H. In some embodiments, R8is H. In some embodiments, R9is H. In some embodiments, each R5, R6, R7, R8, and R9is H. In some embodiments, r is 2. In some embodiments, p is 2. In some embodiments, q is 2, 5, or 11. In some embodiments, w is 6 to 20. In some embodiments, r is 2; p is 2; q is 2, 5, or 11; and w is 6 to 20.
[0217] In some embodiments, Y1further comprises a binding unit formed by a reaction between an alkyne and an azide or between an aldehyde or ketone group and hydrazine or hydroxylamine. In some embodiments, Y1further comprises a unit having a structure represented by Formula Va, Vb, Vc, Vd, or Ve:
[0218]
[0219] wherein
[0220] L1is a single bond or C1-30 alkylene; and
[0221] R10is H or Ci-10 alkyl.
[0222] In some embodiments, L1is a single bond. In some embodiments, L1is C1-30 alkylene. In some embodiments, R10is H. In some embodiments, R10is C1-10 alkyl (e.g., methyl).
[0223] In some embodiments, Y1comprises an oxime. In some embodiments, the oxygen atom of the oxime is on the side of Y1that is linked to W and the carbon atom of the oxime is on the side of Y1that is linked to Ab. In some embodiments, the carbon atom of the oxime is on the
[0224] FH30010189.1Attorney Docket: LCH-04425
[0225] side of Y1that is linked to W and the oxygen atom of the oxime is on the side of Y that is linked to Ab.
[0226] In some embodiments, the oxime has a structure represented by Formula Via:
[0227]
[0228] Via
[0229] wherein
[0230] R11is H, alkyl or cycloalkyl; and
[0231] R12is H, alkyl or cycloalkyl; or
[0232] R11and R12combine to form a cycloalkyl.
[0233] In some embodiments, each R11and R12is independently H or alkyl. In some embodiments, R11is alkyl, preferably methyl. In some embodiments, R11is H. In some embodiments, R12is alkyl, preferably methyl. In some embodiments, R12is H. In some embodiments, R11and R12combine to form a cycloalkyl, preferably cyclobutyl.
[0234] In some embodiments, the oxime has a structure represented by formula VIb:
[0235] X2
[0236]
[0237] VIb
[0238] wherein
[0239] R11and R12are independently H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl;
[0240] X1and X2are each independently N(R13), O, or S; and
[0241] R13is H, alkyl, aryl, or aralkyl. In some embodiments, X1is N(R13). In some embodiments, R13is H. In some embodiments, X1is N(R13), and R13is H. In some embodiments, X2is O.
[0242] In some embodiments, Y1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene
[0243] glycol moieties represented byL-1or
[0244]
[0245] 20 FH30010189.1Attorney Docket: LCH-04425
[0246] (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties represented
[0247]
[0248] (e.g, 1, 2, 3, or 4 ethylene glycol moieties).
[0249] In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, Y1comprises an oxime and the oligoethylene glycol covalently bonds the oxime to W.
[0250] In some embodiments, Y1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, Y1is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).
[0251] In some embodiments, Y1further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, Y1further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, Y1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine.
[0252] In some embodiments, Y1is linear. In some embodiments, Y1is branched. In some embodiments, Y1comprises:
[0253] i) a branching unit covalently coupled to Ab by a primary linker;
[0254] ii) a first branch, covalently coupled to W; and
[0255] FH30010189.1Attorney Docket: LCH-04425
[0256] iiia) a second branch which couples an active agent, via a cleavage group, to the branching unit; or
[0257] iiib) a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.
[0258] In some embodiments, Y1comprises a second branch which couples an active agent, via a cleavage group, to the branching unit. In some embodiments, Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.
[0259] In some embodiments, Y1comprises:
[0260] i) a branching unit covalently coupled to Ab by a primary linker;
[0261] ii) a first branch which couples a first B to the branching unit; and
[0262] iiia) a second branch which couples a second B to the branching unit; or
[0263] iiib) a second branch comprising an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) is covalently coupled to the branching unit.
[0264] In some embodiments, Y1comprises a second branch which couples a second B, via a cleavage group, to the branching unit. In some embodiments, Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.
[0265] In some embodiments, the branching unit comprises an amino acid. In some embodiments, the branching unit comprises a lysine residue. In some embodiments, the branching unit has a structure represented by Formula Vila, Vllb, Vile, or Vlld:
[0266] o
[0267]
[0268] Vila Vlld wherein
[0269] FH30010189.1Attorney Docket: LCH-04425
[0270]
[0271] R14• R14is H or alkyl;
[0272] R15is H, alkyl or L5-CO2R16
[0273] R16is H or alkyl; and
[0274] L2, L3, L4, and L5are each independently a bond or alkylene.
[0275] In some embodiments, the branching unit has a structure represented by Formula Villa:
[0276] O
[0277]
[0278] Villa
[0279] wherein R14is H or alkyl.
[0280] In some embodiments, the branching unit has a structure represented by Formula Vlllb:
[0281]
[0282] Vlllb
[0283] wherein R14is H or alkyl.
[0284] In some embodiments, the cleavage group has a structure represented by Formula IX or a pharmaceutically acceptable salt thereof:
[0285] FH30010189.1Attorney Docket: LCH-04425
[0286]
[0287] o
[0288] IX
[0289] wherein
[0290] Bw is an active agent;
[0291] each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group;
[0292] each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkyl sulfonyl, or sulfonamido;
[0293] each Ww1is independently -*C(O)-, -*C(O)N(Rw7)-, -*N(Rw7)C(O)-, - *(CH2)twiN(Rw7)C(O)-, -*C(O)O-, -*S(O2)N(RW7)-, -*P(O)( RW8)N(RW7)-, - *S(O)N(Rw7)-, or
[0294] -*P(O2)N(RW7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula IX;
[0295] Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;
[0296] twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0297] nwl is 0, 1, 2, or 3;
[0298] Jw1is H or alkyl;
[0299] Jw2is H or alkyl; or
[0300] Jw1and Jw2combine to form an oxo; and
[0301] Aw2represents a linkage to the secondary linker.
[0302] In some embodiments, at least one branched linker is covalently coupled to Ab; and at least two B are covalently coupled to the branched linker. The two B may be the same or are 24
[0303] FH30010189.1Attorney Docket: LCH-04425
[0304] different from each other. In some embodiments, the conjugate comprises 1, 2, 3, or 4 branched linkers and each branched linker comprises two B.
[0305] In some embodiments, the conjugate comprises a structure represented by:
[0306]
[0307] or a pharmaceutically acceptable salt thereof; wherein
[0308] B' and B" are each an active agent;
[0309] nil, n22, and n33 are each independently 0 to 30;
[0310] AA is an amino acid group (e.g., a lysine); and
[0311] the wavy bond represents a connection to Ab.
[0312] In some embodiments, the conjugate comprises a structure represented by Formula X or a pharmaceutically acceptable salt thereof:
[0313] 25
[0314] FH30010189.1Attorney Docket: LCH-04425
[0315] Bl
[0316] Ab
[0317]
[0318] wherein
[0319] L6comprises an alkylene;
[0320] Y2and Y4are each independently O, N(R17), or S;
[0321] Yxis H;
[0322] X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,
[0323] -OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;
[0324] R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;
[0325] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0326] V1and V3are each independently a bond, N, NH, C, CH, or CH2;
[0327] L7and L9each independently comprise an alkylene;
[0328] T1and T3are each independently a bond, -O-, or a self-immolative moiety;
[0329] B1and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; or
[0330] V1, T1and B1or V3, T3and B3together represent a branched moiety; and
[0331] ml and m3 are each independently 1, 2, or 3.
[0332] In some embodiments, the conjugate has a structure represented by Formula XI or a pharmaceutically acceptable salt thereof:
[0333] L6
[0334] Ab
[0335]
[0336] FH30010189.1Attorney Docket: LCH-04425
[0337] Formula XI
[0338] wherein
[0339] L6comprises an alkylene;
[0340] Y2, Y3, and Y4are each independently O, N(R17), or S;
[0341] X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,
[0342] -OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;
[0343] R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;
[0344] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0345] V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;
[0346] L7, L8, and L9each independently comprise an alkylene;
[0347] T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;
[0348] B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; or
[0349] V1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.
[0350] Those of skill in the art will recognize that variables V1and ml, V2and m2, and V3and m3 are related. For example, those of skill in the art will understand that if ml is 3, then V3will have 3 open valencies. Likewise, if ml is 1, then V1will have at least one open valency. Simply put, the skilled artisan will understand that V1and ml, V2and m2, and V3and m3 will be combined in such a way that stable configurations are obtained based on the valencies required.
[0351] In some embodiments, Y2is O. In some embodiments, Y3is O. In some embodiments, Y4is O. In some embodiments, each of Y2, Y3, and Y4is O. In some embodiments, X1is -N(R18)C(O)-. In some embodiments, X1is -C(O)N(R18)-. In some embodiments, R18is H. In some embodiments, X1is -C(O)N(R18)-, and R18is H. In some embodiments, L6comprises a Ci-Cioo alkylene. In some embodiments, L6comprises a C1-C50 alkylene. In some embodiments, L6further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol
[0352] 27
[0353] FH30010189.1Attorney Docket: LCH-04425
[0354] moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0355] In some embodiments, L6is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, L6further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L6further comprises a structure represented by Formula Xia:
[0356] X4
[0357] XA I?
[0358] R20R21L
[0359]
[0360] R22A\2
[0361] Xia
[0362] wherein
[0363] A1represents a linkage to X1;
[0364] A2represents a linkage to Ab;
[0365] X3and X4are each independently O, S, or N(R23);
[0366] R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl;
[0367] R22is H or alkyl; and
[0368] R23is H, alkyl, aryl, or aralkyl.
[0369] In some embodiments, X3is N(R23). In some embodiments, R23is H. In some embodiments, X3is N(R23), and R23is H. In some embodiments, X4is O. In some embodiments, R20is alkyl (e.g., methyl). In some embodiments, R21is H. In some embodiments, R21is alkyl (e.g., methyl). In some embodiments, R20and R21combine to form a cycloalkyl (e.g., cyclobutyl). In some embodiments, R22is H. In some embodiments, R22is alkyl.
[0370] In some embodiments, L6further comprises a structure represented by formula Xlb:
[0371] At
[0372] N
[0373] R20R21!L
[0374]
[0375] R227\2
[0376] Xlb
[0377] wherein
[0378] A1represents a linkage to X1;
[0379] A2represents a linkage to Ab;
[0380] 28
[0381] FH30010189.1Attorney Docket: LCH-04425
[0382] R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl; and
[0383] R22is H or alkyl.
[0384] In some embodiments, R20is alkyl (e.g., methyl). In some embodiments, R21is H. In some embodiments, R21is alkyl (e.g., methyl). In some embodiments, R20and R21combine to form a cycloalkyl (e.g., cyclobutyl). In some embodiments, R22is H. In some embodiments, R22is alkyl.
[0385] In some embodiments, L6further comprises a structure represented by Formula Xia or Formula Xlb:
[0386] .O.
[0387] N
[0388] Xia
[0389] Al Z)
[0390] N
[0391]
[0392] R227\2
[0393] Xlb.
[0394] In some embodiments, L6further comprises a structure represented by Formula Xlla, Xllb, or XIIc:
[0395] A! Al
[0396] N A2N
[0397] -N :N N
[0398] ,,N
[0399] N N N
[0400] A2
[0401]
[0402] Xlla Xllb XIIc wherein
[0403] each A1represents a linkage to X1;
[0404] each A2represents a linkage to Ab.
[0405] In some embodiments, L6further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L6further comprises a structure represented by Formula Xllla or XIIIb:
[0406] N=N
[0407] \
[0408] .N
[0409]
[0410] AU.
[0411] Xllla Xlllb
[0412] FH30010189.1Attorney Docket: LCH-04425
[0413] wherein
[0414] each A1represents a linkage to X1; and
[0415] each A2represents a linkage to Ab.
[0416] In some embodiments, L6further comprises a structure represented by Formula XIV:
[0417]
[0418] XIV
[0419] wherein n5 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;
[0420] each A1represents a linkage to X1; and
[0421] each A2represents a linkage to Ab. In some embodiments, n5 is 1, 2, 3, 4, or 5.
[0422] In some embodiments, L6is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino e.g., dimethylamino). In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, L6further comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L6comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl). In some embodiments, L6further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L6further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine. In some embodiments, L6further comprises a polypeptoid (e.g., polysarcosine).
[0423] 30
[0424] FH30010189.1Attorney Docket: LCH-04425
[0425] In some embodiments, L7comprises a C1-C100 alkylene. In some embodiments, L7comprises a C1-C50 alkylene. In some embodiments, L7further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, L7further comprises an amido moiety. In some embodiments, L7further comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, L7further comprises 1 or 2 amido moieties. In some embodiments, L7further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L7further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L7further comprises a structure represented by Formula XVa or XVb:
[0426] N=N N=N
[0427]
[0428] XVa XVb
[0429] wherein:
[0430] each Ax1represents a linkage to V1; and
[0431] each Ax2represents a linkage to Y2.
[0432] In some embodiments, L7is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g, carboxyethyl) or amino (e.g, dimethylamino). In some embodiments, L7is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, L7comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L7further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L7further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline,
[0433] 31
[0434] FH30010189.1Attorney Docket: LCH-04425
[0435] sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.
[0436] In some embodiments, V1is a bond. In some embodiments, V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIa or a pharmaceutically acceptable salt thereof:
[0437] Ax3
[0438] / 'Tx1 / N / Tx2
[0439] B
[0440]
[0441] x1^ ^Lx1^Lx2^Bx2
[0442] XVIa
[0443] wherein:
[0444] Ax3represents a linkage to L7;
[0445] Lx1and Lx2each independently comprise an alkylene;
[0446] Tx1and Tx2are each independently a bond or a self-immolative moiety; and
[0447] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0448] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb, Formula XVIc, or Formula XVId, or a pharmaceutically acceptable salt thereof:
[0449] Ax3
[0450] ^Tx1 / L / Tx2
[0451] Bx1\x1Tx2^Bx2
[0452] XVIb,
[0453] Ax3
[0454] X3x1
[0455] Bx1 / Lx1 / L / Lx2 / Bx2
[0456]
[0457] ^Tx1^Gx2XSx3^Tx2
[0458] XVIc,
[0459] FH30010189.1Attorney Docket: LCH-04425
[0460]
[0461] XVId,
[0462] wherein:
[0463] Ax3represents a linkage to L7;
[0464] Lx1, Lx2, and Lx3each independently comprise an alkylene;
[0465] 0 O \ y
[0466] Gx1, Gx2, and Gx3are each independently an alkylene, , or ;
[0467] each Rx1is independently H, alkyl, or aralkyl;
[0468] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and
[0469] Bx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0470] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb or a pharmaceutically acceptable salt thereof:
[0471] Ax3
[0472] / 'Tx1 / Tx2
[0473]
[0474] Bx1^ ^Lx1^Lx2^Bx2
[0475] XVIb
[0476] wherein:
[0477] Ax3represents a linkage to L7;
[0478] Lx1and Lx2each independently comprise an alkylene;
[0479] Tx1and Tx2are each independently a bond or a self-immolative moiety; and
[0480] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0481] FH30010189.1Attorney Docket: LCH-04425
[0482] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIc or a pharmaceutically acceptable salt thereof:
[0483] Ax3
[0484] X3x1
[0485] Bx1 / Lx1 / L / Lx2 / Bx2
[0486]
[0487] ^Tx1^Gx2X3x3^Tx2
[0488] XVIc
[0489] wherein:
[0490] Ax3represents a linkage to L7;
[0491] Lx1and Lx2each independently comprise an alkylene;
[0492] O O
[0493] Gx1, Gx2, and Gx3are each independently an alkylene,
[0494]
[0495] ™ , or ™ ;
[0496] each Rx1is independently H, alkyl, or aralkyl;
[0497] Tx1and Tx2are each independently a bond or a self-immolative moiety; and
[0498] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0499] In some embodiments, V1is CH or C, valence permitting, and V1, T1and B1together represent a branched moiety having a structure represented by Formula XVId or a pharmaceutically acceptable salt thereof:
[0500]
[0501] Bx3
[0502] XVId
[0503] wherein:
[0504] Ax3represents a linkage to L7;
[0505] Lx1, Lx2, and Lx3each independently comprise an alkylene;
[0506] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and
[0507] Bx1, Bx2, Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0508] 34
[0509] FH30010189.1Attorney Docket: LCH-04425
[0510] In some embodiments, Lx1comprises a C1-C100 alkylene. In some embodiments, Lx1comprises a C1-C50 alkylene. In some embodiments, Lx1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol comprises 4 ethylene glycol moieties.
[0511] In some embodiments, Lx2comprises a C1-C100 alkylene. In some embodiments, Lx2comprises a C1-C50 alkylene. In some embodiments, Lx2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0512] In some embodiments, Lx3comprises a C1-C100 alkylene. In some embodiments, Lx3comprises a C1-C50 alkylene. In some embodiments, Lx3further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0513] In some embodiments, T1, Tx1, Tx2, or Tx3has a structure represented by Formula XVII or a pharmaceutically acceptable salt thereof:
[0514]
[0515] wherein
[0516] each Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group;
[0517] 35
[0518] FH30010189.1Attorney Docket: LCH-04425
[0519] each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;
[0520] Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)txiN(Rx7)C(O)-, -*C(O)O-, -*S(O2)N(RX7)-, -*P(O)(RX8)N(RX7)-, -*S(O)N(RX7)-, or -*P(O2)N(RX7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;
[0521] Ja1is H or alkyl;
[0522] Ja2is H or alkyl; or
[0523] Ja1and Ja2combine to form an oxo;
[0524] tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0525] nxl is 0, 1, 2, or 3;
[0526] Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; and
[0527] Ax5represents a linkage to L7, Lx1, Lx2, or Lx3.
[0528] In some embodiments, Rx2is H. In some embodiments, Rx3is H. In some embodiments, Rx4is H. In some embodiments, Rx5is H. In some embodiments, each Rx2, Rx3, Rx4, and Rx5is H. In some embodiments, nxl is 0. In some embodiments, Wx1is -*C(O)N(Rx7)-. In some embodiments, Rx7is H. In some embodiments, Wx1is -*C(O)N(Rx7)-, and Rx7is H. In some embodiments, Ja1is H. In some embodiments, Ja2is H. In some embodiments, Ja1and Ja2combine to form oxo.
[0529] In some embodiments, B1is an active agent. In some embodiments, ml is 1. In some embodiments, ml is 2. In some embodiments, ml is 3. In some embodiments, each T1is a bond. In some embodiments, each B1is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).
[0530] In some embodiments, L8comprises a C1-C100 alkylene. In some embodiments, L8comprises a C1-C50 alkylene. In some embodiments, L8further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In some embodiments, L8further comprises an amido moiety. In some embodiments, L8further
[0531] 36
[0532] FH30010189.1Attorney Docket: LCH-04425
[0533] comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, L8further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L8further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L8further comprises a structure represented by Formula XVIIIa or XVIIIb:
[0534] N=N
[0535] \
[0536]
[0537] Ay
[0538] XVIIIa XVIIIb
[0539] wherein:
[0540] each Ay1represents a linkage to V2; and
[0541] each Ay2represents a linkage to Y3.
[0542] In some embodiments, L8is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g, carboxyethyl) or amino (e.g, dimethylamino). In some embodiments, L8is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, L8further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L8further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.
[0543] FH30010189.1Attorney Docket: LCH-04425
[0544] In some embodiments, V2is a bond. In some embodiments, V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXa or a pharmaceutically acceptable salt thereof:
[0545] Ay3
[0546] / 'Ty1 / Ty2
[0547] B
[0548]
[0549] y1^ """'Ly1^Ly2^By2
[0550] XIXa
[0551] wherein:
[0552] Ay3represents a linkage to L8;
[0553] Ly1and Ly2each independently comprise an alkylene;
[0554] Ty1and Ty2are each independently a bond, or a self-immolative moiety; and
[0555] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0556] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb, Formula XIXc, or Formula XlXd, or a pharmaceutically acceptable salt thereof:
[0557] Ay3
[0558] / 'Ty1 / Ty2
[0559] By1^ """'Ly1^Ly2^By2
[0560] XlXb,
[0561]
[0562] XlXd,
[0563] wherein:
[0564] FH30010189.1Attorney Docket: LCH-04425
[0565] Ay3represents a linkage to L8;
[0566] Ly1, Ly2, and Ly3each independently comprise an alkylene;
[0567] O O
[0568] 1111
[0569] Gy1, Gy2, and Gy3are each independently an alkylene,
[0570]
[0571] ^z, or ;
[0572] each Ry1is independently H, alkyl, or aralkyl;
[0573] Ty1, Ty2, andTy3are each independently a bond or a self-immolative moiety; and
[0574] By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0575] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb or a pharmaceutically acceptable salt thereof:
[0576] Ay3
[0577]
[0578] XlXb
[0579] wherein:
[0580] Ay3represents a linkage to L8;
[0581] Ly1and Ly2each independently comprise an alkylene;
[0582] Ty1and Ty2are each independently a bond or a self-immolative moiety; and
[0583] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0584] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXc or a pharmaceutically acceptable salt thereof:
[0585] Ay3
[0586] >3y1
[0587] Ly\ ^By2
[0588]
[0589] Gy3^ Ty2
[0590] XIXc
[0591] wherein:
[0592] Ay3represents a linkage to L8; and
[0593] Ly1and Ly2each independently comprise an alkylene;
[0594] FH30010189.1Attorney Docket: LCH-04425
[0595] o o AAy
[0596] Gy1, Gy2, and Gy3are each independently an alkylene,
[0597]
[0598] Ry, orRy;
[0599] each Ry1is independently H, alkyl, or aralkyl;
[0600] Ty1and Ty2are each independently a bond or a self-immolative moiety; and
[0601] By1and By2are each independently an active agent (e.g., a drug or a toxin).
[0602] In some embodiments, V2is CH or C, valence permitting, and V2, T2and B2together represent a branched moiety having a structure represented by Formula XlXd or a pharmaceutically acceptable salt thereof:
[0603]
[0604] XlXd
[0605] wherein:
[0606] Ay3represents a linkage to L8;
[0607] Ly1, Ly2, and Ly3each independently comprise an alkylene;
[0608] Ty1, Ty2, and Ty3are each independently a bond or a self-immolative moiety; and
[0609] By1, By2, By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0610] In some embodiments, Ly1comprises a C1-C100 alkylene. In some embodiments, Ly1comprises a C1-C50 alkylene. In some embodiments, Ly1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0611] In some embodiments, Ly2comprises a C1-C100 alkylene. In some embodiments, Ly2comprises a C1-C50 alkylene. In some embodiments, Ly2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0612] In some embodiments, Ly3comprises a C1-C100 alkylene. In some embodiments, Ly3comprises a C1-C50 alkylene. In some embodiments, Ly3further comprises an oligoethylene 40
[0613] FH30010189.1Attorney Docket: LCH-04425
[0614] glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0615] In some embodiments, T2, Ty1, Ty2, or Ty3has a structure represented by Formula XX or a pharmaceutically acceptable salt thereof:
[0616] J Ih2
[0617] .O.
[0618] Ry3
[0619] Ry2
[0620] XD
[0621] .Ay5
[0622] Wy1
[0623]
[0624] XX
[0625] wherein
[0626] each Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group;
[0627] each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;
[0628] each Wy1is independently -*C(O)-, -*C(O)N(Ry7)-, -*N(Ry7)C(O)-, -*(CH2)tyiN(Ry7)C(O)-, -*C(O)O-, -*S(O2)N(
[0629]
[0630] Ry7)-, -*P(O)( Ry8)N(Ry7)-, -*S(O)N(Ry7)-, or -*P(O2)N(Ry7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XX,
[0631] Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;
[0632] Jb1is H or alkyl;
[0633] Jb2is H or alkyl; or
[0634] Jb1and Jb2combine to form an oxo;
[0635] tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0636] nyl is 0, 1, 2, or 3;
[0637] FH30010189.1Attorney Docket: LCH-04425
[0638] Ay4represents a linkage to B1, By1, By2, or By3; and
[0639] Ay5represents a linkage to L8, Ly1, Ly2, or Ly3.
[0640] In some embodiments, each Ry2is H. In some embodiments, each Ry3is H. In some embodiments, each Ry4is H. In some embodiments, each Ry5is H. In some embodiments, each Ry2, Ry3, Ry4, and Ry5is H. In some embodiments, each nyl is 0. In some embodiments, each Wy1is -*C(O)N(Ry7)-. In some embodiments, each Ry7is H. In some embodiments, each Wy1is -*C(O)N(Ry7)-, and each Ry7is H. In some embodiments, Jb1is H. In some embodiments, Jb2is H. In some embodiments, Jb1and Jb2combine to form oxo. In some embodiments, B2is an active agent. In some embodiments, m2 is 1. In some embodiments, m2 is 2. In some embodiments, m2 is 3. In some embodiments, each T2is a bond. In some embodiments, each B2is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).
[0641] In some embodiments, L9comprises a Ci-Cioo alkylene. In some embodiments, L9comprises a C1-C50 alkylene. In some embodiments, L9further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In some embodiments, the oligoethylene glycol further comprises an amido moiety. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, the oligoethylene glycol comprises 1 or 2 amido moieties. In some embodiments, L9further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L9further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L9further comprises a structure represented by Formula XXIa or XXIb:
[0642] N=N N=N
[0643]
[0644] XXIa XXIb
[0645] wherein:
[0646] each Az1represents a linkage to V3; and
[0647] each Az2represents a linkage to Y4.
[0648] In some embodiments, L9is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments,
[0649] 42
[0650] FH30010189.1Attorney Docket: LCH-04425
[0651] the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moi eties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, L9is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g, carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g, dimethylamino). In some embodiments, L9further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L9further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.
[0652] In some embodiments, V3is a bond. In some embodiments, V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIa or a pharmaceutically acceptable salt thereof:
[0653] Az3
[0654] Jz1 / Tz2
[0655]
[0656] Bz1^ ^Lz1Tz2^Bz2
[0657] XXIIa
[0658] wherein:
[0659] Az3represents a linkage to L9;
[0660] Lz1and Lz2each independently comprise an alkylene;
[0661] Tz1and Tz2are each independently a bond or a self-immolative moiety; and
[0662] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).
[0663] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb, Formula XXIIc, or Formula XXIId, or a pharmaceutically acceptable salt thereof:
[0664] 43
[0665] FH30010189.1Attorney Docket: LCH-04425
[0666] Az3
[0667] XXIIb,
[0668] Az3
[0669] T3z1
[0670] Bz1 / Lz1 / Lz2 / Bz2
[0671] ^Tz1^Gz2X3z3^Tz2
[0672] XXIIc,
[0673] Az3
[0674] Bz1 / Lz1 / Lz2 / Bz2
[0675] ^Tz1~^Tz2
[0676] Lz3
[0677] \ -z3
[0678]
[0679] Bz3
[0680] XXIId,
[0681] wherein:
[0682] Az3represents a linkage to L9;
[0683] Lz1, Lz2, and Lz3each independently comprise an alkylene;
[0684] 0 O
[0685] 1111
[0686] Gz1, Gz2, and Gz3are each independently an alkylene,
[0687]
[0688] ^z, or ^z;
[0689] each Rz1is independently H, alkyl, or aralkyl;
[0690] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and
[0691] Bz1, Bz2, andBz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0692] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb or a pharmaceutically acceptable salt thereof:
[0693] Az3
[0694] Tz1 / Tz2
[0695]
[0696] Bz1^ ^Lz1^Lz2^Bz2
[0697] XXIIb
[0698] 44
[0699] FH30010189.1Attorney Docket: LCH-04425
[0700] wherein:
[0701] Az3represents a linkage to L9;
[0702] Lz1and Lz2each independently comprise an alkylene;
[0703] Tz1and Tz2are each independently a bond or a self-immolative moiety; and
[0704] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0705] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIc or a pharmaceutically acceptable salt thereof:
[0706] Az3
[0707] >3z1
[0708] Bz1 / Lz1 / Lz2 / Bz2
[0709]
[0710] ^Tz1^Gz2X3z3^Tz2
[0711] XXIIc
[0712] wherein:
[0713] Az3represents a linkage to L9;
[0714] Lz1and Lz2each independently comprise an alkylene;
[0715] O O
[0716] ykNA ANAy
[0717] ' 1 D 1
[0718] Gz1, Gz2, and Gz3are each independently an alkylene, , or ^z;
[0719] each Rz1is independently H, alkyl, or aralkyl;
[0720] Tz1and Tz2are each independently a bond or a self-immolative moiety; and
[0721] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).
[0722] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIId or a pharmaceutically acceptable salt thereof:
[0723] Az3
[0724] Bz1 / Lz1.Lz2 / Bz2
[0725] ^Tz1~^Tz2
[0726] Lz3
[0727]
[0728] Bz3
[0729] XXIId
[0730] wherein:
[0731] 45
[0732] FH30010189.1Attorney Docket: LCH-04425
[0733] Az3represents a linkage to L9;
[0734] Lz1, Lz2, and Lz3each independently comprise an alkylene;
[0735] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and
[0736] Bz1, Bz2, Bz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
[0737] In some embodiments, Lz1comprises a C1-C100 alkylene. In some embodiments, Lz1comprises a C1-C50 alkylene. In some embodiments, Lz1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0738] In some embodiments, Lz2comprises a C1-C100 alkylene. In some embodiments, Lz2comprises a C1-C50 alkylene. In some embodiments, Lz2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0739] In some embodiments, Lz3comprises a C1-C100 alkylene. In some embodiments, Lz3comprises a C1-C50 alkylene. In some embodiments, Lz3further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.
[0740] In some embodiments, T3, Tz1, Tz2, or Tz3have a structure represented by Formula XXIII or a pharmaceutically acceptable salt thereof:
[0741]
[0742] XXIII
[0743] 46
[0744] FH30010189.1Attorney Docket: LCH-04425
[0745] wherein
[0746] each Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;
[0747] Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(RZ7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(RZ7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XXIII,
[0748] Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;
[0749] Jc1is H or alkyl;
[0750] Jc2is H or alkyl; or
[0751] Jc1and Jc2combine to form an oxo;
[0752] tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0753] nzl is 0, 1, 2, or 3;
[0754] Az4represents a linkage to B3, Bz1, Bz2, or Bz3; and
[0755] Az5represents a linkage to L9, Lz1, Lz2, or Lz3.
[0756] In some embodiments, Rz2is H. In some embodiments, Rz3is H. In some embodiments, Rz4is H. In some embodiments, Rz5is H. In some embodiments, each Rz2, Rz3, Rz4, and Rz5is H. In some embodiments, nzl is 0. In some embodiments, Wz1is -*C(O)N(Rz7)-. In some embodiments, Rz7is H. In some embodiments, Wz1is -*C(O)N(Rz7)-, and Rz7is H. In some embodiments, Jc1is H. In some embodiments, Jc2is H. In some embodiments, Jc1and Jc2combine to form oxo. In some embodiments, B3is an active agent. In some embodiments, m3 is 1. In some embodiments, m3 is 2. In some embodiments, m3 is 3. In some embodiments, each T3is a bond. In some embodiments, each B3is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).
[0757] In some embodiments, each of L7, L8and L9independently comprises a C1-C100 alkylene. In some embodiments, each of L7, L8and L9independently comprises a C1-C50 alkylene. In some embodiments, each of L7, L8and L9independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene
[0758] 47
[0759] FH30010189.1Attorney Docket: LCH-04425
[0760] glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, each of L7, L8and L9independently further comprises an amido moiety. In some embodiments, each of L7, L8and L9independently further comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, each of L7, L8and L9independently further comprises 1 or 2 amido moieties. In some embodiments, each of L7, L8and L9independently further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, each of L7, L8and L9independently further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In some embodiments, each of L7, L8and L9independently further comprises a structure represented by Formula XVa or XVb:
[0761]
[0762] 'N-AX=
[0763] XVa XVb
[0764] wherein:
[0765] each Ax1represents a linkage to V1, V2or V3; and
[0766] each Ax2represents a linkage to Y2, Y3or Y4.
[0767] In some embodiments, each of L7, L8and L9is independently substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g, carboxyethyl) or amino (e.g, dimethylamino). In some embodiments, each of L7, L8and L9is independently substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, each of L7, L8and L9comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, each of L7, L8and L9further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, each of L7, L8and L9further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine,
[0768] FH30010189.1Attorney Docket: LCH-04425
[0769] histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.
[0770] In some embodiments, each of Lx1, Lx2and Lx3independently comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Lx1, Lx2and Lx3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moi eties, preferably 1, 2, 3, or 4 ethylene glycol moi eties.
[0771] In some embodiments, each of Ly1, Ly2and Ly3independently comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Ly1, Ly2and Ly3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
[0772] In some embodiments, each of Lz1, Lz2and Lz3comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Lz1, Lz2and Lz3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
[0773] In some embodiments, each T1, T2, and T3is independently a bond. In some embodiments, each B1, B2, and B3is independently an active agent. In some embodiments, each B1, B2, and B3is independently H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).
[0774] 49
[0775] FH30010189.1Attorney Docket: LCH-04425
[0776] In some embodiments, the conjugate comprises
[0777]
[0778] embodiments, the conjugate comprises
[0779]
[0780] ° . In some embodiments, the conjugate
[0781]
[0782] In some embodiments, each active agent is independently a chemotherapeutic agent or a toxin. In some embodiments, each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, or an antiparasitic agent.
[0783] In some embodiments, each active agent is independently selected from:
[0784] (a) a microtubule targeting agent (e.g., maytansinoid, maytansine, DM1, DM4, maytansinol, auristatin, dolastatin 10, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), eribulin, Halichondrin B, tubulysin, cryptophycin, EG5 inhibitors, SB- 715992 (ispinesib), orfilanesib (ARRY-520));
[0785] (b) a DNA damaging agent (e.g., enediyne, calicheamicin, uncialamycin, topoisomerase inhibitors, topotecan, camptothecin, SN-38, irinotecan (CPT-11), exatecan, Dxd, FL1 18, pyrrol obenzodiazepine (PBD), PBD dimer, duocarmycin, Duocarmycin A, CC-1065);
[0786] (c) an RNA targeting agent (e.g., thailanstatin, amatoxin, a-amanitin, P-amanitin); (d) an affinity ligand (e.g., the affinity ligand is a substrate, inhibitor, active agent, neurotransmitter, radioactive isotope, or mixtures thereof);
[0787] (e) a radioactive label (e.g., 32P or 35S), a fluorescent dye, an electron dense reagent, an enzyme, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or mixtures thereof;
[0788] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, an anti -parasitic agent, or mixtures thereof;
[0789] 50
[0790] FH30010189.1Attorney Docket: LCH-04425
[0791] (g) an estrogen receptor modulator (e.g., tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone or toremifene);
[0792] (h) an aromatase inhibitor(e.g., 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole or anastrozole);
[0793] (i) a nonsteroidal antiandrogen (NSAA) (e.g., flutamide, nilutamide, bicalutamide);
[0794] (j) an aromatase inhibitor;
[0795] (k) a protein kinase inhibitor;
[0796] (l) a lipid kinase inhibitor;
[0797] (m) an antisense oligonucleotide;
[0798] (n) a ribozyme;
[0799] (o) a vaccine;
[0800] (p) an anti -angiogenic agent;
[0801] (q) a Bcl-xL inhibitor;
[0802] (r) a NAMPT inhibitor; and
[0803] (s) a Carmaphycin.
[0804] In some embodiments, each active agent is independently selected from:
[0805] (a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine, altretamine, tri ethyl enem el amine, tri ethyl enephosphorami de, tri ethyl enethi ophosphorami de, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, deruxtecan, SN-38, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancrati statin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carubicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubucin, liposomal
[0806] 51
[0807] FH30010189.1Attorney Docket: LCH-04425
[0808] doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidamol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2’, 2” -tri chlorotri ethylamine, T-2 toxin, verracurin A, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates, or acids of any of the foregoing;
[0809] (b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a, tumor necrosis factor-p, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL-1, IL-loc, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;
[0810] (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a-amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, SG2057, cryptophycin,
[0811] 52
[0812] FH30010189.1Attorney Docket: LCH-04425
[0813] an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;
[0814] (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing;
[0815] (e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing;
[0816] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an antibacterial agent, an anti-fungal agent, and an anti -parasitic agent, or a combination of any of the foregoing;
[0817] (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapri stone, or toremifene;
[0818] (h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;
[0819] (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;
[0820] (j) an aromatase inhibitor;
[0821] (k) a protein kinase inhibitor;
[0822] (l) a lipid kinase inhibitor;
[0823] (m) an antisense oligonucleotide;
[0824] (n) a ribozyme;
[0825] (o) a vaccine; and
[0826] (p) an anti -angiogenic agent.
[0827] In some embodiments, each active agent is independently selected from: Calicheamicin, Monomethyl auristatin E(MMAE), Monomethyl auristatin F(MMAF), Mertansine (DM1), Ravtansine (DM4), SN-38, Deruxtecan (Dxd), FL118, exatecan, pyrrolobenzodiazepines (PBD), PBD dimers, duocarmycin, Duocarmycin A, and Auristatin E.
[0828] In some embodiments, the conjugate comprises:
[0829] 53
[0830] FH30010189.1Attorney Docket: LCH-04425
[0831]
[0832] FH30010189.1Attorney Docket: LCH-04425
[0833]
[0834] FH30010189.1Attorney Docket: LCH-04425
[0835] H
[0836] N
[0837]
[0838] or a pharmaceutically acceptable salt thereof;
[0839] wherein MMAE is monomethyl auri statin E.
[0840] In various embodiments, a conjugate disclosed herein has a structure represented by the conjugates shown in any one of FIGs. 1-6.
[0841] In various embodiments, a conjugate disclosed herein has a structure represented by
[0842]
[0843] 56
[0844] FH30010189.1Attorney Docket: LCH-04425
[0845] , or
[0846]
[0847] wherein
[0848]
[0849] is Ab.
[0850] In certain aspects, the present disclosure provides a pharmaceutical composition comprising a conjugate disclosed herein and a pharmaceutically acceptable excipient.
[0851] In certain aspects, the present disclosure provides a pharmaceutical composition for use in preventing or treating a cancer, the composition comprising a conjugate disclosed herein. In some embodiments, the cancer is a cancer associated with CEACAM5 expression. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is selected from colorectal cancer, stomach cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, lung cancer, uterus cancer, cervical cancer, pancreatic cancer, esophagus cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrium cancer, bladder cancer, neuroendocrine cancer,
[0852] 57
[0853] FH30010189.1Attorney Docket: LCH-04425
[0854] endometrial cancer, breast cancer, liver cancer, prostate cancer, cholangiocarcinoma, and skin cancer.
[0855] In certain aspects, the present disclosure provides a method of treating or preventing a cancer in a subject in need thereof comprising administering a conjugate disclosed herein or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, the cancer is a cancer associated with CEACAM5 expression. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is selected from colorectal cancer, stomach cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, lung cancer, uterus cancer, cervical cancer, pancreatic cancer, esophagus cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrium cancer, bladder cancer, neuroendocrine cancer, endometrial cancer, breast cancer, liver cancer, prostate cancer, cholangiocarcinoma, and skin cancer.
[0856] Antibody or Antigen-Binding Fragment thereof
[0857] The present disclosure provides an antibody or antigen-binding fragment thereof that binds to carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). As described herein, the antibody or antigen-binding fragment thereof according to the present disclosure is a polypeptide comprising one or more complementarity-determining areas or regions (CDRs).
[0858] In some embodiments, the CDR is included in a “framework” region, and the framework orients the CDR(s) so that the CDR(s) can have appropriate antigen-binding properties.
[0859] In certain aspects, the present disclosure provides antibody-drug conjugates comprising an anti-CEACAM5 antibody or antigen-binding fragment thereof that binds to CEACAM5. In certain embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to CEACAM5 expressed in (e.g., on cell surface) a cancer cell and may be used to deliver a drug to the cell. In certain embodiments, the antibody drug conjugates disclosed herein have improved stability as compared to antibody drug conjugates known in the art.
[0860] In certain embodiments, the antibody comprises, but is not limited to, a monoclonal antibody, a bispecific antibody, a diabody, a multispecific antibody, a polyantibody, a minibody, a domain antibody, an antibody mimetic (or synthetic antibody), a chimeric antibody, a humanized antibody, a human antibody or an antibody fusion (or antibody conjugate), and a fragment thereof, and includes various forms of antibodies disclosed herein.
[0861] 58
[0862] FH30010189.1Attorney Docket: LCH-04425
[0863] In certain embodiments, an antibody fragment of the antibody according to the present disclosure includes Fab, Fab', F(ab')2, scFab, Fv, dsFv, scFV, scFV-Fc, a minibody, a diabody, sc Ab, or dAb.
[0864] In certain embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure may consist of a polypeptide of only light chains or only heavy chains including the variable regions shown in Tables 1-6.
[0865] CDR sequences that may be included in the heavy and light chain variable regions of the antibody or antigen-binding fragment thereof according to an embodiment of the present disclosure are shown in Tables 1-6, respectively.
[0866] An antibody or antigen-binding fragment thereof according to the present disclosure shares certain regions or sequences with other antibodies disclosed herein. In certain embodiments, the constant region of the antibody or antigen-binding fragment thereof may be shared. In certain embodiments, Fc regions may be shared. In certain embodiments, the frame of a variable region may be shared.
[0867] The heavy chain variable region and the light chain variable region according to the present disclosure may be linked to at least a part of a human constant region. The selection of a constant region may be determined partially by whether or not antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and / or complementdependent cytotoxicity is required. For example, human isotypes IgGl and IgG3 have complement-dependent cytotoxicity, and human isotypes IgG2 and IgG4 do not have such cytotoxicity. In addition, human IgGl and IgG3 induce a cell-mediated effector function stronger than that of human IgG2 and IgG4. The light chain constant region may be lambda or kappa.
[0868] A variable region of an immunoglobulin chain generally has the same overall structure and includes a comparatively conserved framework region (FR) linked by three hypervariable regions called “complementarity determining areas or regions or domains” or complementarity determining regions (CDRs). The CDRs of a variable region derived from each chain including a heavy chain / light chain pair are typically aligned by a framework region to form a structure specifically binding to a specific epitope of a target protein. These factors of naturally occurring light chain and heavy chain variable regions are typically included from the N-terminus to the C-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The positions of amino acid sequences corresponding to each variable region, and the positions of the CDRs and FRs, may be determined using various well known definitions in the art, e.g.,
[0869] 59
[0870] FH30010189.1Attorney Docket: LCH-04425
[0871] Kabat (Kabat et al., (1983) U.S. Dept, of Health and Human Services, “Sequences of Proteins of Immunological Interest”), Chothia (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)), international ImMunoGeneTics database (IMGT) (on the worldwide web at imgt.cines.fr / ), AbM (see, e.g., Johnson et al., Nucleic Acids Res., 29:205-206 (2001), or in a manner related to the OPAL library (Hye Young Yang et. al., 2009 Mol. Cells 27: 225). The CDRs determined by each definition, when compared to each other, may be subsets which overlap or where one includes another. Those of ordinary skill in the art will be readily able to easily select CDR sequences according to the definitions above, given a variable region sequence of an antibody.
[0872] In certain embodiments, amino acid sequences of CDRs and FRs are defined according to Kabat definition. In certain embodiments, amino acid sequences of CDRs and FRs are defined according to IMGT definition. However, it is well known to those skilled in the art that CDRs of an antibody can be defined in the art according to a variety of methods, such as Chothia definition based on the location of a structural loop region (Al-Lazikani, B et al., J Mol Biol 273: 927-48 (1997)), and Kabat definition based on sequence variability (Kabat et al., “Sequences of proteins of immunological interest,” fifth edition, National Institutes of Health, Bethesda, MD. (1991)). It is also well known to those skilled in the art that CDR and FR sequences identified using one numbering scheme or definition may be converted or translated to corresponding sequences under a different numbering scheme or definition using tools available in the art. For example, the CDR and FR sequences may be converted using IMGT Scientific chart (imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html) or using the IgBLAST tool (ncbi.nlm.nih.gov / igblast).
[0873] In certain embodiments, amino acid residues in variable region sequences may also be determined using a Combined definition that incorporates both Kabat definition and Chothia definition. The Combined definition refers to the combination of the ranges of Kabat definition and Chothia definition. It should be understood by those skilled in the art that unless otherwise specified, the terms “CDR” and “complementarity determining region” of a given antibody or region thereof (e.g., a variable region) should be understood to encompass the complementarity determining region as defined according to any of the embodiments described in the present disclosure, or complementarity determining region sequences under corresponding numbering schemes. For example, CDR amino acid sequences defined by the Kabat definition for any specific antibody or antigen-binding fragment thereof of the present disclosure should be understood to encompass the amino acid sequences as identified by the sequence identifiers
[0874] 60
[0875] FH30010189.1Attorney Docket: LCH-04425
[0876] (SEQ ID NOs) of the present disclosure, and to encompass corresponding amino acid sequences that will be identified under, e.g., IMGT or Chothia definitions.
[0877] Although the scope of protection claimed in the claims of the present disclosure is based on the sequences defined according to Kabat definition or IMGT definition, as disclosed herein, amino acid sequences defined according to other CDRs definitions should also fall within the scope of protection of the present disclosure.
[0878] In certain embodiments, the antibody according to the present disclosure is a humanized antibody. A humanized antibody refers to any antibody in which the constant region of a nonhuman antibody is completely substituted with a human form of the constant region, and at least a portion of the variable region of a non-human antibody, except for the three loops of an amino acid sequence outside each variable region that binds to a target structure, is completely or partially substituted with the corresponding portion of a human antibody. In certain embodiments, the antibody according to the present disclosure is a human antibody.
[0879] Certain mutations may be introduced to the framework region to enhance the stability of antibodies while maintaining their antigen binding activity. Stabilization of therapeutic antibodies can result in improved serum half-life, lower dosage requirements, reduced sideeffects, improved shelf-life and reduced shipping and storage costs.
[0880] In certain embodiments, the present disclosure discloses one or more amino acid sequences having substantial sequence identity to one or more amino acid sequences disclosed herein. Substantial identity means that the effects disclosed herein are maintained in the presence of sequence variations. In certain embodiments, the amino acid sequence has about 90% identity, about 95% identity, or about 99% identity to the heavy chain variable regions shown in Tables 1-6. In another embodiment, the amino acid sequence has about 90% identity, about 95% identity, or about 99% identity to the light chain variable regions shown in Tables 1-6. For example, in the case of variants exhibiting 90% identity, 95% identity, or 99% identity to the sequence of the antibody or antigen-binding fragment thereof according to the present disclosure, any mutation occurs in the framework of the variable region rather than the CDRs.
[0881] In certain embodiments, a nucleic acid encoding the antibody or fragment thereof according to the present disclosure is a nucleic acid encoding a full-length antibody including the CDRs disclosed herein, the variable region including the CDRs, and the variable region, and the constant region. Once the amino acid sequence is determined, the nucleic acid sequence may be easily determined in consideration of a known reverse transcription program, codon usage, and the like.
[0882] 61
[0883] FH30010189.1Attorney Docket: LCH-04425
[0884] Antigen Specificity and Affinity for Antibody
[0885] In certain preferred embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure has specificity to a CEACAM5 antigen and affinity suitable for use as an antibody therapeutic / diagnostic agent. In certain embodiments, the affinity for aggregates may be KD < 1,000 nM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM, and may be, for example, 10'6M to 10'12M.
[0886] Production of Antibody
[0887] In the present disclosure, a non-human antibody may be derived from, for example, any antibody-producing animal, for example, a mouse, a rat, a rabbit, a goat, a donkey, or non-human primates (e.g., monkeys such as cynomolgus or rhesus monkey) or apes (e.g., chimpanzees). A non-human antibody may be produced by immunizing an animal by using a method known in the art. For a method for producing a humanized antibody, according to an embodiment of the present disclosure, refer to US Patent No. 15 / 532,598. A fully human antibody may be produced by administering an antigen to a transformed animal including a human immunoglobulin gene locus, or by treating a phage display library expressing a human antibody repertory with an antigen, and then selecting the target antibody. The antibody may be polyclonal or monoclonal, or may be synthesized within a cell host through the expression of recombinant DNA.
[0888] A monoclonal antibody (mAb) may be produced using a conventional monoclonal antibody method, for example, a standard somatic hybridization technique in the literature (Kohler and Milstein, 1975, Nature 256:495).
[0889] Method for Expressing Antibody
[0890] The antibody disclosed herein may be expressed in a hybridoma cell line or an expression cell line other than a hybridoma. An expression construct encoding the antibody may be used to transform a mammalian, an insect or a microbial host cell. A construct such as a plasmid may be produced, as described in the foregoing description, using any of various known methods for introducing a polynucleotide into a host cell. The specific method may vary according to the type of host cell. Methods for introducing a heterogeneous polynucleotide into a mammalian cell are widely known in the art, and include, but are not limited to, for example, dextran-mediated transfer, calcium phosphate precipitation, polybrene-mediated transfer,
[0891] 62
[0892] FH30010189.1Attorney Docket: LCH-04425
[0893] protoplast fusion, electrophoresis, capsulation of a transferred polynucleotide using liposomes, mixing of a nucleic acid and a positively charged lipid, and direct microinjection of DNA into the nucleus.
[0894] Use of Anti-CEACAM5 Antibody Drug-Conjugates for Therapeutic Purposes
[0895] The expression of CEACAM5 in cancer is associated with unfavorable prognosis of cancer patients and is known to also affect cancer metastasis. For example, CEACAM5 is overexpressed on the surface of colorectal, gastric, lung, breast, prostate, ovary, cervix, and bladder tumor cells. For anticancer antibody treatment, for example, the anti-CEACAM5 antibody may, as described herein, be used in a form linked to various active agents (e.g., toxins) via a linker to remove CE AC AM5 -overexpressing cancer cells.
[0896] Treatment Method: Pharmaceutical Formulation and Administration Route
[0897] In some aspects, the present disclosure provides a treatment method using an antibodydrug conjugate or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof is provided to a patient. The antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof inhibits cancer cell growth or metastasis by binding to CEACAM5 expressed on the surface of cancer cells. In certain embodiments, the antibody binds to CEACAM5 expressed on the surface of cancer cells in a form bonded to an active agent (e.g., a toxin), thereby specifically delivering the active agent bonded to the antibody to cancer cells, to induce the death of the cancer cells. In certain embodiments, the antibody binds to CEACAM5 expressed on the surface of cancer cells in the form of an antibody specific to the same target or another target, thereby increasing specificity of multiple antibodies for cancer cells or inducing connections between cancer cells and other types of cells such as immune cells, to induce the death of the cancer cells.
[0898] Pharmaceutical Compositions
[0899] The compositions and methods disclosed herein may be utilized to treat an individual in need thereof. In certain embodiments, the individual is a mammal such as a human, or a nonhuman mammal. When administered to an animal, such as a human, the composition or the conjugate is preferably administered as a pharmaceutical composition comprising, for example, a conjugate described herein and a pharmaceutically acceptable carrier. Pharmaceutically
[0900] 63
[0901] FH30010189.1Attorney Docket: LCH-04425
[0902] acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration ( / .<?., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment. The composition may include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, or a combination thereof.
[0903] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
[0904] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a conjugate such as a conjugate described herein. Such physiologically acceptable agents include, for
[0905] 64
[0906] FH30010189.1Attorney Docket: LCH-04425
[0907] example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a selfemulsifying drug delivery system or a selfmicroemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a conjugate described herein. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
[0908] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin). The conjugate may also be formulated for inhalation. In certain embodiments, a conjugate may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.
[0909] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the conjugate which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent. The dosage of the pharmaceutical composition may range, for example, from 10 pg / kg to about 30 mg / kg, optionally from 0.1 mg / kg to about 30 mg / kg, or alternatively from 0.3 mg / kg to about 20 mg / kg per adult. The
[0910] 65
[0911] FH30010189.1Attorney Docket: LCH-04425
[0912] pharmaceutical composition may be administered once a day, multiple times a day, once every 1 to 4 weeks, or once to 12 times a year.
[0913] Methods of preparing these formulations or compositions include the step of bringing into association an active conjugate, such as a conjugate described herein, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a conjugate described herein with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0914] Formulations of the disclosed conjugates suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a conjugate described herein as an active ingredient. Compositions or conjugates may also be administered as a bolus, electuary or paste.
[0915] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium conjugates; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0916] 66
[0917] FH30010189.1Attorney Docket: LCH-04425
[0918] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surfaceactive or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered conjugate moistened with an inert liquid diluent.
[0919] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[0920] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0921] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0922] 67
[0923] FH30010189.1Attorney Docket: LCH-04425
[0924] Suspensions, in addition to the active conjugates, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0925] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active conjugate may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
[0926] The ointments, pastes, creams and gels may contain, in addition to an active conjugate, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0927] Powders and sprays can contain, in addition to an active conjugate, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0928] Transdermal patches have the added advantage of providing controlled delivery of a conjugate described herein to the body. Such dosage forms can be made by dissolving or dispersing the active conjugate in the proper medium. Absorption enhancers can also be used to increase the flux of the conjugate across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the conjugate in a polymer matrix or gel.
[0929] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active conjugates in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats,
[0930] 68
[0931] FH30010189.1Attorney Docket: LCH-04425
[0932] solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0933] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the disclosed conjugates include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0934] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
[0935] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0936] Injectable depot forms are made by forming microencapsulated matrices of the subject conjugates in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
[0937] For use in the methods described herein, active conjugates can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[0938] 69
[0939] FH30010189.1Attorney Docket: LCH-04425
[0940] Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow-release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a conjugate at a particular target site.
[0941] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0942] The selected dosage level will depend upon a variety of factors including the activity of the particular conjugate or combination of conjugates employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular conjugate(s) being employed, the duration of the treatment, other drugs, conjugates and / or materials used in combination with the particular conjugate(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[0943] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical composition or conjugate at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a conjugate that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the conjugate will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the conjugate, and, if desired, another type of therapeutic agent being administered with the conjugate described herein. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).
[0944] In general, a suitable daily dose of an active conjugate used in the compositions and methods described herein will be that amount of the conjugate that is the lowest dose effective
[0945] 70
[0946] FH30010189.1Attorney Docket: LCH-04425
[0947] to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
[0948] If desired, the effective daily dose of the active conjugate may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments, the active conjugate may be administered two or three times daily. In preferred embodiments, the active conjugate will be administered once daily.
[0949] The patient receiving this treatment is any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.
[0950] In certain embodiments, conjugates described herein may be used alone or conjointly administered with another type of therapeutic agent.
[0951] The present disclosure includes the use of pharmaceutically acceptable salts of conjugates described herein in the compositions and methods described herein. In certain embodiments, contemplated salts described herein include, but are not limited to, alkyl, dialkyl, trialkyl or tetra-alkyl ammonium salts. In certain embodiments, contemplated salts described herein include, but are not limited to, L-arginine, benethamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, IH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, l-(2-hydroxyethyljpyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts described herein include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts. In certain embodiments, contemplated salts described herein include, but are not limited to, 1 -hydroxy -2 -naphthoic acid, 2, 2-di chloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, 1-malic acid, malonic acid, mandelic acid, methanesulfonic acid ,
[0952] 71
[0953] FH30010189.1Attorney Docket: LCH-04425
[0954] naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, 1 -pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid salts.
[0955] The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent.
[0956] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0957] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BEIT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0958] Definitions
[0959] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the art.
[0960] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N.Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al.,
[0961] 72
[0962] FH30010189.1Attorney Docket: LCH-04425
[0963] “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N.Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).
[0964] Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C.A. (1985).
[0965] The term “agent” is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known.
[0966] A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
[0967] “Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
[0968] The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and / or clinically significant amount.
[0969] 73
[0970] FH30010189.1Attorney Docket: LCH-04425
[0971] “Administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0972] Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and / or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
[0973] As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.
[0974] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to situations where the alkyl may be substituted as well as where the alkyl is not substituted.
[0975] It is understood that substituents and substitution patterns on the compounds described herein can be selected by one of ordinary skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those
[0976] 74
[0977] FH30010189.1Attorney Docket: LCH-04425
[0978] methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
[0979] As used herein, the term “optionally substituted” refers to the optional replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2 or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” refers to the optional replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are optionally replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.
[0980] In the present disclosure, “linker” refers to a compound which covalently bonds a cytotoxic compound to an antibody.
[0981] The term “conjugates” as used herein refers to cell binding agents that are covalently bonded to one or more molecules of a cytotoxic compound. In this regard, "cell binding agent" is a molecule having affinity for a biological target, and may be, for example, an antibody, particularly a monoclonal antibody, or an antibody fragment, and the binding agent functions to direct a biologically active compound to a biological target. In certain embodiments, the conjugate may be designed to target tumor cells through cell surface antigens. The antigen may be a cell surface antigen that is overexpressed or expressed in an abnormal cell type. Specifically, the target antigen may be expressed only on proliferative cells (e.g., tumor cells). The target antigen may be selected on the basis of different expression, usually between proliferative tissues and normal tissues. In the present disclosure, the antibody is bonded to the linker.
[0982] In the present disclosure, a “variant” of a polypeptide, for example, an antigen-binding fragment, a protein, or an antibody, is a polypeptide in which insertion, deletion, addition, and / or substitution have occurred at one or more amino acid residues compared to other polypeptide sequences, and includes fusion polypeptides. Protein variants also include those modified by protein enzymatic cleavage, phosphorylation or other post-translational modifications, but retaining the biological activity of the antibody disclosed herein, such as binding and specificity to CEACAM5. Variants may have about 99% identity, about 98% identity, about 97% identity, about 96% identity, about 95% identity, about 94% identity, about
[0983] 75
[0984] FH30010189.1Attorney Docket: LCH-04425
[0985] 93% identity, about 92% identity, about 91% identity, about 90% identity, about 89% identity, about 88% identity, about 87% identity, about 86% identity, about 85% identity, about 84% identity, about 83% identity, about 82% identity, about 81% identity, or about 80% identity to the sequence of the antibody or antigen-binding fragment thereof according to the present disclosure. Percent identity (%) or homology may be calculated by methods known in the art.
[0986] In certain embodiments, the percent homology or identity can be calculated by 100X[(same position) / min(TGA, TGB)], wherein TGA and TGB are the sum of the number of residues and internal gap positions in sequences A and B to be compared (Russell et al., J. Mol Biol., 244: 332-350 (1994).
[0987] The term “derivative” of a polypeptide as used herein refers to a polypeptide that has chemical modification at one or more residues through conjugation with other chemical moi eties, different from insertion, deletion, addition or substitution variants.
[0988] The term “percent sequence identity” or “percent identity” between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence. The percentage of sequence identity is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The comparison of sequences and determination of percent sequence identity between two sequences can be accomplished using readily available software programs. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences. One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of program available from the U.S. government's National Center for Biotechnology Information BLAST web site (at world wide web at blast.ncbi.nlm.nih.gov). B12seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other
[0989] 76
[0990] FH30010189.1Attorney Docket: LCH-04425
[0991] suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at world wide web at ebi.ac.uk / Tools / psa.
[0992] As used herein, “homology” with respect to a peptide, polypeptide or antibody sequence refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art needed to achieve maximal alignment over the full length of the sequences being compared.
[0993] The term “affinity” or “avidity” refers to the strength of interaction between an antibody or its antigen-binding fragment and an antigen, determined by characteristics of the antigen such as size, shape, and / or charge, and the CDR sequences of the antibody or antigen-binding fragment. Methods for determining such affinities are known in the art and may also be referenced herein.
[0994] Antibodies or their antigen-binding fragments used herein are said to “specifically bind” to the target, such as the antigen, when the dissociation constant (KD) is <10'6M. Antibodies bind “with high affinity” to the target when KD is <lx 10'8M.
[0995] As used in the present disclosure, the “antigen-binding fragment” of a chain (heavy chain or light chain) of an antibody or immunoglobulin includes a part of an antibody which lacks some amino acids compared to a full-length chain, but can specifically bind to an antigen. This fragment can be considered as having biological activity, in that the fragment can specifically bind to a target antigen, or can compete with other antibodies or antigen binding fragments thereof to bind to a specific epitope. In certain embodiments, such a fragment includes at least one CDR present in a full-length light chain or heavy chain, and in some embodiments, includes a short-chain heavy chain and / or light chain, or part thereof. This biological active fragment may be produced by a recombinant DNA technique or may be produced, for example, by cleaving an intact antibody enzymatically or chemically. An immunologically functional immunoglobulin fragment includes, but is not limited to, Fab, Fab',
[0996] 77
[0997] FH30010189.1Attorney Docket: LCH-04425
[0998] F(ab')2, scFab, dsFv, Fv, scFV, scFV-Fc, diabody, minibody, scAb, and dAb, and may be derived from any mammal, including, but not being limited to, a human, a mouse, a rat, a camelid, or a rabbit. The functional parts of antibodies such as the one or more CDRs disclosed in the present disclosure may be linked with a secondary protein or a small compound by a covalent bond, and thereby used as a targeted therapeutic agent for a specific target.
[0999] In the present disclosure, the “Fc” region includes two heavy chain fragments including CH2 and CH3 domains of an antibody. These two heavy chain fragments are linked to each other by hydrophobic interaction of two or more of disulfide bonds and a CH3 domain.
[1000] In the present disclosure, the “Fab fragment” consists of one light chain and one heavy chain including a variable region and CHI only. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. In an scFab, two molecules of Fab are linked by a flexible linker.
[1001] In the present disclosure, the “Fab' fragment” includes a Fab fragment and additionally a region between CHI and CH2 domains of a heavy chain. A disulfide bond may form between two heavy chains of Fab' fragments of two molecules, forming a F(ab')2 molecule.
[1002] In the present disclosure, as described above, the “F(ab')2 fragment” includes two light chains and two heavy chains including a variable region CHI and part of a constant region between the CHI and CH2 domains, with an inter-chain disulfide bond formed between the two heavy chains. Accordingly, a F(ab')2 fragment consists of two Fab' fragments, and the two Fab' fragments are joined to each other by the disulfide bond therebetween.
[1003] In the present disclosure, the “Fv region” is a fragment of an antibody which includes each variable region of a heavy chain and a light chain, but does not include constant regions. In an sdFV, a heavy chain and a light chain are linked by a disulfide bond. In an scFc, the Fv is linked by a flexible linker. In a scFv-Fc, a Fc is linked to a scFV. In a minibody, CH3 is linked to a scFV. A diabody includes the scFVs of two molecules.
[1004] In the present disclosure, the “single chain Fv” or “scFv” antibody fragment includes the VH and VL domains of an antibody, and these domains are present within a single polypeptide chain. An Fv polypeptide may additionally include a polypeptide linker between a VH domain which enables the scFv to form the target structure for antigen binding, and a VL domain.
[1005] In the present disclosure, the “single-chain antibody (scAb)” is a single polypeptide chain including one constant region of a heavy chain or a light chain constant region in which heavy chain and light chain variable regions are linked by a flexible linker. For a single-chain
[1006] 78
[1007] FH30010189.1Attorney Docket: LCH-04425
[1008] antibody, U.S. Pat. No. 5,260,203 may be referred to, and short-chain antibody is disclosed herein by reference.
[1009] In the present disclosure, the “domain antibody (dAb)” is an immunologically functional immunoglobulin fragment including only a variable region of a heavy chain or a variable region of a light chain. In certain embodiments, two or more VH regions are linked by a covalent bond via a peptide linker, to form a bivalent domain antibody. Two VH regions of this bivalent domain antibody may target the same or different antigens.
[1010] In the present disclosure, “complementarity determining region” (CDR; that is, CDR1, CDR2, and CDR3) denotes amino acid residues of the variable region of an antibody, which are necessary for binding to antigen. Each variable region typically has three CDR domains, identified as CDR1, CDR2, and CDR3.
[1011] In the present disclosure, the “framework region” (FR) is a variable region residue other than the CDR residues. Each variable region typically has four FRs, identified as FR1, FR2, FR3, and FR4.
[1012] In the present disclosure, the “bivalent antigen-binding protein” or “bivalent antibody” includes two antigen-binding sites. The two antigen-binding sites included in a bivalent antibody may have the same antigen specificity, or may be a bispecific antibody where the antigen-biding sites bind to different antigens.
[1013] In the present disclosure, the “multispecific antigen-binding protein” or “multispecific antibody” targets two or more antigens or epitopes.
[1014] As used herein, a “chimeric antibody” refers to an antibody (immunoglobulin) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., Proc. Nat’l Acad. Sci. USA, 81:6851-55 (1984)). Chimeric antibodies of interest herein include PRIMATIZED® antibodies wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with an antigen of interest.
[1015] “Humanized” forms of non-human (e.g., murine) antibodies, are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from
[1016] 79
[1017] FH30010189.1Attorney Docket: LCH-04425
[1018] an CDR of the recipient are replaced by residues from an CDR of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and / or capacity. In some instances, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance, such as binding affinity. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the FR regions are those of a human immunoglobulin sequence, although the FR regions may include one or more individual FR residue substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, and the like. The number of these amino acid substitutions in the FR is typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see, e.g., Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, for example, Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994); and U.S. Patent Nos. 6,982,321 and 7,087,409.
[1019] A “human antibody” is one that possesses an amino-acid sequence corresponding to that of an antibody, produced by a human and / or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phagedisplay libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.
[1020] 77 (1985); Boerner et al., J. Immunol., 147(l):86-95 (1991). See also van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 regarding
[1021] 80
[1022] FH30010189.1Attorney Docket: LCH-04425
[1023] XENOMOUSETM technology). See also, for example, Li et al., Proc. Nat’l Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
[1024] A “human consensus framework” is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). Examples include for the VL, the subgroup may be subgroup kappa I, kappa II, kappa III or kappa IV as in Kabat et al., supra. Additionally, for the VH, the subgroup may be subgroup I, subgroup II, or subgroup III as in Kabat et al., supra.
[1025] An “affinity-matured” antibody is one with one or more alterations in one or more CDRs thereof that result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody that does not possess those alteration(s). In one embodiment, an affinity-matured antibody has nanomolar or even picomolar affinities for the target antigen. Affinity -matured antibodies are produced by procedures known in the art. For example, Marks et al., Bio / Technology 10:779-783 (1992) describes affinity maturation by VH- and VL-domain shuffling. Random mutagenesis of CDR and / or framework residues is described by, for example: Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al. Gene 169:147- 155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al, J. Mol. Biol. 226:889-896 (1992).
[1026] As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to Ci-Cio straight-chain alkyl groups or Ci-Cio branched-chain alkyl groups. Preferably, the “alkyl” group refers to Ci-Ce straight-chain alkyl groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkyl” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkyl groups. Examples of “alkyl” include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1 -pentyl, 2-pentyl, 3 -pentyl, neo-pentyl, 1 -hexyl, 2-hexyl, 3 -hexyl, 1 -heptyl, 2-heptyl, 3 -heptyl, 4-heptyl, 1 -octyl, 2-octyl, 3 -octyl or 4-octyl and the like. Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or
[1027] 81
[1028] FH30010189.1Attorney Docket: LCH-04425
[1029] more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.
[1030] As used herein, the term “alkylene” refers to a bivalent saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkylene groups. Preferably, the “alkylene” group refers to Ci-Ce straight-chain alkylene groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkylene” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkylene groups. Examples of “alkylene” include, but are not limited to, methylene, ethylene, 1 -propylene, 2-propylene, n-butylene, sec-butylene, tert-butylene, 1 -pentylene, 2-pentylene, 3 -pentylene, neo-pentylene, 1-hexylene, 2-hexylene, 3 -hexylene, 1 -heptylene, 2-heptylene, 3 -heptylene, 4-heptylene, 1-octylene, 2-octylene, 3 -octylene or 4-octylene and the like. The “alkylene” group may be optionally substituted.
[1031] The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
[1032] The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.
[1033] The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.
[1034] The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
[1035] The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
[1036] The term “Cx-y” or “Cx-Cy”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A Ci-ealkyl group, for example, contains from one to six carbon atoms in the chain.
[1037] The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.
[1038] The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
[1039] The term “amido”, as used herein, refers to a group such as
[1040] 82
[1041] FH30010189.1Attorney Docket: LCH-04425
[1042] 0 R9 0
[1043] YW YR,° AA
[1044]
[1045] R10, O; Or R10
[1046] wherein R9and R10each independently represent a hydrogen or hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
[1047] The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
[1048] R9R9
[1049] N or N-R10
[1050]
[1051] R10R1°’
[1052] wherein R9, R10, and R10’ each independently represent a hydrogen or a hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
[1053] The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.
[1054] The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group.
[1055] The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
[1056] The term “carbamate” is art-recognized and refers to a group
[1057] O OAOAN-R’° or ^NA0'R,°
[1058]
[1059] R9R9
[1060] wherein R9and R10independently represent hydrogen or a hydrocarbyl group.
[1061] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.
[1062] The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated 83
[1063] FH30010189.1Attorney Docket: LCH-04425
[1064] and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-lH-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
[1065] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.
[1066] The term “carbonate” is art-recognized and refers to a group -OCO2-.
[1067] The term “carboxy”, as used herein, refers to a group represented by the formula -CO2H.
[1068] The term “cleavage group” refers to a chemical moiety which dissociates when subjected to a stimulus, such as acidic conditions, basic conditions, reducing conditions, oxidizing conditions, light, or heat, or an enzyme, such as an esterase.
[1069] The term “cycloalkyl” includes substituted or unsubstituted non-aromatic single ring structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The term “cycloalkyl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is cycloalkyl and the substituent (e.g., R100) is attached to the cycloalkyl ring, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, denzodioxane, tetrahydroquinoline, and the like.
[1070] The term “ester”, as used herein, refers to a group -C(O)OR9wherein R9represents a hydrocarbyl group.
[1071] 84
[1072] FH30010189.1Attorney Docket: LCH-04425
[1073] The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
[1074] The term “guanidinyl”, as used herein, refers to a group of the formula -NRa-C(=NRb)-NRbRc, wherein Ra, Rb, and Rcare each independently H or hydrocarbyl.
[1075] The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
[1076] The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
[1077] The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
[1078] The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
[1079] The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.
[1080] The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
[1081] 85
[1082] FH30010189.1Attorney Docket: LCH-04425
[1083] The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =0 or =S substituent, and typically has at least one carbonhydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =0 substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
[1084] The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.
[1085] The term “hydroxylamino” is art-recognized and refers to a group
[1086] ,< Ry
[1087] RzN
[1088] ix
[1089] RX, wherein Rx, Ry, and Rzindependently represent hydrogen or a hydrocarbyl group.
[1090] The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).
[1091] The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the poly cycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
[1092] The term “sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.
[1093] The term “sulfonamido” is art-recognized and refers to the group represented by the general formulae
[1094] 86
[1095] FH30010189.1Attorney Docket: LCH-04425
[1096] p10
[1097] o R10 /
[1098] S-N or s
[1099]
[1100] o R’
[1101] wherein R9and R10independently represents hydrogen or hydrocarbyl.
[1102] The term “sulfoxide” is art-recognized and refers to the group-S(O)-.
[1103] The term “sulfonate” is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.
[1104] The term “sulfone” is art-recognized and refers to the group -S(O)2-.
[1105] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. The heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
[1106] The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group.
[1107] The term “thioester”, as used herein, refers to a group -C(O)SR9or -SC(O)R9wherein R9represents a hydrocarbyl.
[1108] The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
[1109] 87
[1110] FH30010189.1Attorney Docket: LCH-04425
[1111] The term “urea” is art-recognized and may be represented by the general formula O A JL pio
[1112] N^N'R
[1113] R9R9
[1114] wherein R9and R10independently represent hydrogen or a hydrocarbyl.
[1115] The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
[1116] The term “DBCO” used herein refers to an optionally substituted dibenzocyclooctyne moiety, e.g., the following structure:
[1117]
[1118] The term “sugar moiety” used herein refers to a naturally occurring sugar or a modified sugar which is part of a larger molecule and is connected to the remainder of the larger molecule through, for example, one of the hydroxyl groups present on the sugar. For example, in some embodiments the sugar is connected to the remainder of the larger molecule via the hydroxyl group on the anomeric carbon. Examples of sugar moieties include, but are not limited to, glucuronosyl and galactosyl.
[1119] A “glycosidase” is an enzyme that breaks down glycosidic bonds in carbohydrates, glycoproteins, and glycolipids. Examples of glycosidases are P-glucuronidase and P-galactosidase. P-glucuronidase is a type of glucuronidase that catalyzes hydrolysis of P-D-glucuronic acid or P-glucuronosyl residues. P-Galactosidase is a glycoside hydrolase enzyme that catalyzes hydrolysis of terminal non-reducing P-D-galactose or P-galactosyl residues in P-D-galactosides.
[1120] The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[1121] “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.
[1122] The term “pharmaceutically acceptable acid addition salt” as used herein means any non-toxic organic or inorganic salt of any base compounds represented by Formula la.
[1123] 88
[1124] FH30010189.1Attorney Docket: LCH-04425
[1125] Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula la are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of Formula la for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
[1126] The term “pharmaceutically acceptable basic addition salt” as used herein means any non-toxic organic or inorganic base addition salt of any acid compounds represented by Formula la or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.
[1127] Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.
[1128] Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.
[1129] “Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the compound of the present disclosure (e.g., compounds of formula la). Typical examples of
[1130] 89
[1131] FH30010189.1Attorney Docket: LCH-04425
[1132] prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U.S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound of Formula la. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.
[1133] The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol / liter.
[1134] Examples
[1135] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.
[1136] Example 1: Production of Exemplified Humanized CEACAM5 Specific Antibodies CEACAM5 (CEA Cell Adhesion Molecule 5) is commonly overexpressed on the surface of solid tumors. An exemplified anti-CEACAM5 antibody clone 81E3A8-06, which specifically binds to CEACAM5, was produced by the method described in International Patent Application No. PCT / KR2024 / 016648, the entirety of which is incorporated herein by reference. The amino acid sequences of the exemplified antibody clone 81E3A8-06 are shown in Table 1 below. The amino acid sequences of the CDRs below are defined according to the Kabat definition.
[1137] Table 1. Amino Acid Sequences of Exemplified CEACAM5 Antibody Clone 81E3A8-06
[1138] 81E3A8-06 Heavy Chain SEQ IDNO:
[1139]
[1140] 90
[1141] FH30010189.1Attorney Docket: LCH-04425
[1142] FR1 QIQLVQSGSELKKPGASVKVSCKASGYTFT 1 CDR1 NFGMN 2
[1143] FR2 WVRQAPGQGLEWMG 3 CDR2 WINTYTGKPTYDDDFKG 4
[1144] FR3 RF VF SLDTS VST AYLQIS SLKAEDT AVYYC AR 5 CDR3 EAGKDYAMDY 6
[1145] FR4 WGQGTLVTVSS 7
[1146] VH OIOLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVR 15 QAPGOGLEWMGWINTYTGKPTYDDDFKGRFVFSLDTSV ST AYLQIS SLKAEDT AVYYC AREAGKD YAMDYWGQGT LVTVSS HC OIOLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVR 17 OAPGOGLEWMGWINTYTGKPTYDDDFKGRFVFSLDTSV ST AYLQIS SLKAEDT AVYYC AREAGKD YAMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK
[1147] 81E3A8-06 Light Chain SEQ IDNO: FR1 DIQLTQSPSTLSASVGDRVTITC 8 CDR1 SASSSVTFMH 9
[1148] FR2 WYQQKPGKAPKRLIY 10 CDR2 DTSKLAS 11
[1149] FR3 GVPSRFSGSGSGTEYTLTISSLQPDDAATYYC 12 CDR3 QQWNNYPWT 13
[1150] FR4 FGGGTKVEIK 14
[1151] VL DIQLTQSPSTLSASVGDRVTITCSASSSVTFMHWYQQKPG 16 KAPKRLIYDTSKLASGVPSRFSGSGSGTEYTLTISSLQPDD AATYYCQQWNNYPWTFGGGTKVEIK LC DIQLTQSPSTLSASVGDRVTITCSASSSVTFMHWYQQKPG 18 KAPKRLIYDTSKLASGVPSRFSGSGSGTEYTLTISSLQPDD AATYYCQQWNNYPWTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
[1152]
[1153] QGLSSPVTKSFNRGEC
[1154] 91
[1155] FH30010189.1Attorney Docket: LCH-04425
[1156] For ADC synthesis, an exemplified antibody Clone2 was constructed by introducing a CaaX peptide moiety (GGGGGGGCVIM, SEQ ID NO: 22) to the C-terminus of the light chain of SEQ ID NO: 18 in Table 1 with the method disclosed in International Patent Application No. PCT / IB2012 / 001065, the entirety of which is incorporated herein by reference. Additionally, LALA mutations (L236A / L237A according to amino acid positions in SEQ ID NO: 17) were introduced into the heavy chain constant region of the antibody clone 81E3A8-06. The amino acid sequences of Clone2 are shown in Table 2 below.
[1157] Table 2. Amino Acid Sequences of Exemplified CEACAM5 Antibody Clone2
[1158] CEACAM5 Antibody Clone2 Heavy Chain SEQ ID NO: HC QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVR 23 QAPGQGLEWMGWINTYTGKPTYDDDFKGRFVFSLDTSV ST AYLQIS SLKAEDT AVYYCAREAGKD YAMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK CEACAM5 Antibody Clone2 Light Chain SEQ ID NO: LC DIQLTQSPSTLSASVGDRVTITCSASSSVTFMHWYQQKPG 19 KAPKRLIYDTSKLASGVPSRFSGSGSGTEYTLTISSLQPDD AATYYCQQWNNYPWTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH OGLS SP VTKSFNRGECGGGGGGGC VIM
[1159]
[1160] An exemplified anti-CEACAM5 antibody Precemtabart, which specifically binds to CEACAM5, was produced by the method described in International Patent Application No. PCTZEP2021 / 072595, the entirety of which is incorporated herein by reference. The amino acid sequences of the exemplified antibody Precemtabart are shown in Table 3 below. The amino acid sequences of the CDRs below are defined according to the IMGT definition.
[1161] 92
[1162] FH30010189.1Attorney Docket: LCH-04425
[1163] Table 3. Amino Acid Sequences of Exemplified CEACAM5 Antibody Precemtabart Precemtabart Heavy Chain SEQ ID NO: FR1 EVQLQESGPGLVKPSQTLSLTCTVS 24
[1164] CDR1 DGSVSRGGYY 25
[1165] FR2 LTWIRQHPGKGLEWIGY 26
[1166] CDR2 IYYSGST 27
[1167] FR3 YFNPSLRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYC 28
[1168] CDR3 ARGIAVAPFDY 29
[1169] FR4 WGQGTLVTVSS 30
[1170] VH EVOLQESGPGLVKPSOTLSLTCTVSDGSVSRGGYYLTWIR 31 QHPGKGLEWIGYIYYSGSTYFNPSLRSRVTMSVDTSKNO FSLKLSSVTAADTAVYYCARGIAVAPFDYWGQGTLVTVSS HC EVOLQESGPGLVKPSOTLSLTCTVSDGSVSRGGYYLTWIR 32 QHPGKGLEWIGYIYYSGSTYFNPSLRSRVTMSVDTSKNO FSLKLSSVTAADTAVYYCARGIAVAPFDYWGOGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPPVAGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPG
[1171] Precemtabart Light Chain SEQ ID NO: FR1 EIVLTQSPATLSVSPGERATLSCRTS 33
[1172] CDR1 QSVRSN 34
[1173] FR2 LAWYQQKPGQAPRLLIY 35
[1174] CDR2 AAS 36
[1175] FR3 TRATGIPARF SGSGSGTEFTLTIS SLQSEDFAVYYC 37
[1176] CDR3 QQYTNWPFT 38
[1177] FR4 FGPGTKVDIK 39
[1178] VL EIVLTQSPATLSVSPGERATLSCRTSQSVRSNLAWYQQKP 40 GQAPRLLIYAAS TRATGIPARF SGSGSGTEFTLTIS SLQSED FAVYYCQOYTNWPFTFGPGTKVDIK LC EIVLTOSPATLSVSPGERATLSCRTSOSVRSNLAWYOQKP 41 GQAPRLLIYAAS TRATGIPARF SGSGSGTEFTLTIS SLQSED FAVYYCQQYTNWPFTFGPGTKVDIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
[1179]
[1180] GLSSPVTKSFNRGEC
[1181] For ADC synthesis, an exemplified antibody Cloned was constructed by introducing a CaaX peptide moiety (GGGGGGGCVIM, SEQ ID NO: 22) to the C-terminus of the light chain of SEQ ID NO: 41 in Table 3 with the method disclosed in International Patent Application
[1182] 93
[1183] FH30010189.1Attorney Docket: LCH-04425
[1184] No. PCT / IB2012 / 001065, the entirety of which is incorporated herein by reference. The amino acid sequences of Clone2 are shown in Table 4 below.
[1185] Table 4. Amino Acid Sequences of Exemplified CEACAM5 Antibody Clone4
[1186] CEACAM5 Antibody Clone4 Heavy Chain SEQ IDNO: HC EVQLQESGPGLVKPSQTLSLTCTVSDGSVSRGGYYLTWIR 32 OHPGKGLEWIGYIYYSGSTYFNPSLRSRVTMSVDTSKNO FSLKLSSVTAADTAVYYCARGIAVAPFDYWGOGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPPVAGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPG CEACAM5 Antibody Clone4 Light Chain SEQ IDNO: LC EIVLTQSPATLSVSPGERATLSCRTSQSVRSNLAWYQQKP 42 GQAPRLLIYAASTRATGIPARF SGSGSGTEFTLTIS SLQSED FAVYYCOOYTNWPFTFGPGTKVDIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
[1187]
[1188] GLSSPVTKSFNRGECGGGGGGGCVIM
[1189] An exemplified anti-CEACAM5 antibody Tusamitamab, which specifically binds to CEACAM5, was produced by the method described in International Patent Application No. PCT / EP2013 / 074291, the entirety of which is incorporated herein by reference. The amino acid sequences of the exemplified antibody Tusamitamab are shown in Table 5 below. The amino acid sequences of the CDRs below are defined according to the IMGT definition (Lefranc et al. Dev. Comp. Immunol., 2003, 27(l):55-77; www.imgt.org).
[1190] Table 5. Amino Acid Sequences of Exemplified CEACAM5 Antibody Tusamitamab CEACAM5 Antibody Tusamitamab Heavy Chain SEQ IDNO: FR1 EVQLQESGPGLVKPGGSLSLSCAAS 43
[1191] CDR1 GFVFSSYD 44
[1192] FR2 MSWVRQTPERGLEWVAY 45
[1193] CDR2 ISSGGGIT 46
[1194] FR3 YAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYC 47
[1195] CDR3 AAHYFGSSGPFAY 48
[1196] FR4 WGQGTLVTVSS 49
[1197] VH EVOLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRO 50
[1198]
[1199] TPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTL
[1200] 94
[1201] FH30010189.1Attorney Docket: LCH-04425
[1202] YLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTV SS HC EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQ 51 TPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTL YLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTV SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG CEACAM5 Antibody Tusamitamab Light Chain SEQ ID NO: FR1 DIQMTQSPASLSASVGDRVTITCRAS 52
[1203] CDR1 ENIFSY 53
[1204] FR2 LAWYQQKPGKSPKLLVY 54
[1205] CDR2 NTR 55
[1206] FR3 TLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYC 56
[1207] CDR3 QHHYGTPFT 57
[1208] FR4 FGSGTKLEIK 58
[1209] VL DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKP 59 GKSPKLLVYNTRTLAEGVPSRF SGSGSGTDF SLTIS SLQPE DFATYYCQHHYGTPFTFGSGTKLEIK LC DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKP 60 GKSPKLLVYNTRTLAEGVPSRF SGSGSGTDF SLTIS SLQPE DFATYYCQHHYGTPFTFGSGTKLEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
[1210]
[1211] GLSSPVTKSFNRGEC
[1212] For ADC synthesis, an exemplified antibody Clone6 was constructed by introducing a CaaX peptide moiety (GGGGGGGCVIM, SEQ ID NO: 22) to the C-terminus of the light chain of SEQ ID NO: 60 in Table 5 with the method disclosed in International Patent Application No. PCT / IB2012 / 001065, the entirety of which is incorporated herein by reference. Additionally, LALA mutations (L237A / L238A according to amino acid positions in SEQ ID NO: 51) were introduced into the heavy chain constant region of the antibody Tusamitamab. The amino acid sequences of Clone6 are shown in Table 6 below.
[1213] Table 6. Amino Acid Sequences of Exemplified CEACAM5 Antibody Clone6
[1214] CEACAM5 Antibody Clone6 Heavy Chain SEQ ID NO: HC EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQ 61
[1215] TPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTL
[1216]
[1217] YLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTV
[1218] 95
[1219] FH30010189.1Attorney Docket: LCH-04425
[1220] SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG CEACAM5 Antibody Clone6 Light Chain SEQ IDNO: LC DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKP 62 GKSPKLLVYNTRTL AEGVPSRF SGSGSGTDF SLTIS SLQPE DFATYYCQHHYGTPFTFGSGTKLEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
[1221]
[1222] GLSSPVTKSFNRGECGGGGGGGCVIM
[1223] 96
[1224] FH30010189.1Attorney Docket: LCH-04425
[1225] Example 2 : Preparation of Compound 5
[1226]
[1227] Preparation of Compound 2
[1228] Compound 1 (1.5 g, 0.67 mmol; Compound 1 was produced by the method described in International Patent Application No. PCT / KR2023 / 018766, the entirety of which is 97
[1229] FH30010189.1Attorney Docket: LCH-04425
[1230] incorporated herein by reference) was dissolved in 24 mL of dichloromethane. Then, 0.22 mL of pyridine (2.68 mmol) and 0.79 g of bis(pentafluorophenyl) carbonate (2.01 mmol) were added at room temperature under a nitrogen atmosphere and stirred for 16 hours. The reaction solution was diluted with 80 mL of ethyl acetate, rinsed with 50 mL x 2 of saturated aqueous sodium hydrogen carbonate, followed by 50 mL of brine, and dehydrated using anhydrous sodium sulfate. Compound 2 (2.06 g) was obtained after filtering and concentration under reduced pressure, without additional purification, and was subsequently utilized in the next process. ESLMS m / z : [M+H]+2670.3, ['AM+H] 1335.7, [AM+H] 890.8.
[1231] Preparation of Compound 3
[1232] Compound 2 (100 mg, 0.04 mmol) was dissolved in N,N-dimethylformamide (3 mL), followed by sequential addition of exatecan mesylate (44 mg, 0.08 mmol), N,N-diisopropylethylamine (0.05 mL, 0.28 mmol), and 1 -hydroxy-7 -benzotriazole (HO At, 2.55 mg, 0.02 mmol) at room temperature under nitrogen atmosphere with stirring for 3 hours. The reaction mixture was diluted with ethyl acetate (40 mL), washed successively with saturated ammonium chloride aqueous solution (30 mL), saturated sodium bicarbonate aqueous solution (30 mL), and brine (30 mL), then dried over anhydrous sodium sulfate. Compound 3 (140 mg) was obtained after filtering and concentration under reduced pressure, without additional purification. ESLMS m / z : f' / ZM+H] 1587.5, [AM+H] 1058.8.
[1233] Preparation of Compound 4
[1234] Compound 3 (550 mg, 0.17 mmol) was dissolved in methanol (7 mL), tetrahydrofuran (7 mL) and then a solution of lithium hydroxide (65.8 mg, 1.57 mmol) dissolved in distilled water (8 mL) was added gradually at -40 °C, under nitrogen atmosphere. Then the mixture was agitated for 2 hours as the temperature of the reaction was incrementally increased to 0 °C. The reaction mixture was neutralized using acetic acid, condensed under reduced pressure, purified via HPLC, and then freeze-dried to provide Compound 4 (236 mg, 44%) in the form of a yellow solid. ESLMS m / z : ['AM+H] 1446.7, [AM+H] 964.9.
[1235] Preparation of Compound 5
[1236] Compound 4 (236 mg, 0.08 mmol) was dissolved in acetonitrile (10 mL) and phosphoric acid (85%, 5 mL) was added at 0°C. After stirring at room temperature for 4 hours,
[1237] 98
[1238] FH30010189.1Attorney Docket: LCH-04425
[1239] the reaction mixture was purified by HPLC, followed by freeze-drying to afford yellow solid Compound 5 (138 mg, 61%). ESI-MS m / z : [M / 2+H]+1340.5, [M / 3+H]+894.1.
[1240] Example 3 : Preparation of Compound 12
[1241] o Vs -% . H H2N N310 N^'N H A H H A H
[1242]
[1243] Preparation of Compound 6
[1244] To a solution of A-Boc-hydroxylamine (5.0 g, 37.55 mmol) in
[1245]
[1246] -di methyl form am ide (20 mL) were added potassium carbonate (8.8 g, 63.84 mmol) and ethyl-2 -bromoisobutyrate (15.38 g, 78.86 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4CI solution (50 mL), distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 6 (10.5 g, 100%). 'H-NMR (400 MHz, CDCI3) 84.21 (p, J= 6.8 Hz, 2H), 1.49 (s, 6H), 1.47 (s, 9H), 1.31 (q, J= 6.9 Hz, 3H).
[1247] Preparation of Compound 7
[1248] To a solution of Compound 6 (47 g, 190.1 mmol) in methanol (400 mL) was added lithium hydroxide monohydrate (16 g, 380 mmol) in water (100 mL). After stirring at room temperature for 3 hours, the reaction mixture was adjusted to pH 3.0 with 1 M HC1 solution and concentrated. Then the reaction mixture was extracted with ethyl acetate (200 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 7 (38 g, 91%) as a white solid.1H-NMR. (400 MHz, CDCI3) 67.32 (s, 1H), 1.53 (s, 6H), 1.49 (s, 9H).
[1249] FH30010189.1Attorney Docket: LCH-04425
[1250] Preparation of Compound 8
[1251] To a solution of bi s(2 -hydroxy ethyl)ether (20 g, 188.5 mmol) in dichloromethane (400 mL) were added -toluenesulfonyl chloride (79 g, 414.6 mmol) and potassium hydroxide (42 g, 753.9 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was washed with saturated aq. NH4CI solution (100 mL x 2) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 8 (78 g, 99%) as a white solid. 'H-NMR (400 MHz, CDCI3) 57.79-7.77 (m, 4H), 7.36-7.34 (m, 4H), 4.10-4.08 (m, 4H), 3.62-3.60 (m, 4H), 2.45 (s, 6H).
[1252] Preparation of Compound 9
[1253] To a solution of Compound 8 (78 g, 188.2 mmol) in AA-dimethylform amide (470 mL) was added sodium azide (61 g, 940.9 mmol) under N2. After stirring at 80 °C for 18 hours, the reaction mixture was diluted with ethyl acetate (1 L) and washed with saturated aq. NH4CI solution (500 mL x 2) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 9 (24 g, 83%) as a pale yellow oil. 'H-NMR (400 MHz, CDCI3) 83.70-3.67 (m, 4H), 3.43-3.40 (m, 4H).
[1254] Preparation of Compound 10
[1255] To a solution of Compound 9 (24 g, 153.7 mmol) in ethyl acetate (500 mL) were added triphenylphosphine (40 g, 153.7 mmol) and 1 MHC1 solution (284 mL) at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was concentrated under reduced pressure and then the residue was adjusted to pH 10 with 1 M sodium hydroxide solution. The residue was extracted with dichloromethane (100 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 10 (9.6 g, 48%) as a colorless oil. ‘H-NMR (400 MHz, CDCI3) 63.68 (t, J= 4.8 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H), 3.40 (t, J= 4.8 Hz, 2H), 3.90 (t, J= 4.8 Hz, 2H), 1.37 (bs, 2H).
[1256] Preparation of Compound 11
[1257] To a solution of Compound 10 (8.9 g, 68.4 mmol) in dichloromethane (150 mL) were added Compound 7 (15 g, 68.4 mmol), 7\(A,A’,A’-tetramethyl-O-(U / -benzotriazol-l-
[1258] 100
[1259] FH30010189.1Attorney Docket: LCH-04425
[1260] yl)uronium hexafluorophosphate (HBTU, 33.8 g, 88.95 mmol), and N,N-diisopropylethylamine (23.8 mL, 137 mmol) under N2. After stirring at room temperature for 14 hours, the reaction mixture was washed with saturated aq. NH4CI solution (20 mL), saturated aq. NaHCCh solution (20 mL), and brine (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 11 (20 g, 88%) as a yellow oil. 'H-NMR (400 MHz, CDCI3) 87.04 (s, 1H), 3.66 (t, J= 5.0 Hz, 2H), 3.58 (s, 2H), 3.47 (t, J= 5.6 Hz, 2H), 3.41 (t, J= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H). ESLMS m / z : [M+H]+332.249.
[1261] Preparation of Compound 12
[1262] To a solution of Compound 11 (21 g, 63.3 mmol) in tetrahydrofuran (150 mL) were added triphenylphosphine (18 g, 69.7 mmol) and distilled water (22 mL) at 0 °C under N2. After stirring at 80 °C for 20 hours, the reaction mixture was concentrated and the resulting residue was purified by column chromatography to afford Compound 12 (15 g, 77%) as a yellow oil. 'H-NMR (400 MHz, CDCI3) 63.56 (t, J= 5.4 Hz, 2H), 3.53-3.48 (m, 4H), 3.46 (q, J= 5.5 Hz, 2H), 2.90 (t, J= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H). ESLMS m / z : [M+H]+306.279.
[1263] Example 4 : Preparation of Compound 17 and 19
[1264] 13 14
[1265] 15 16 17 HO
[1266]
[1267] Preparation of Compound 13
[1268] To a mixture of hexaethylene glycol (30 g, 106 mmol), silver (I) oxide (29.55 g, 128 mmol) and potassium iodide (1.76 g, 10.6 mmol) in dichloromethane (2 mL) was added p-toluenesulfonyl chloride (20.26 g, 106 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After 16 hours, the reaction mixture was filtered through a celite pad, concentrated under reduced pressure and purified by column chromatography to yield Compound 13 (28.5 g, 61%) as a colorless oil. ‘H-NMR (400 MHz, CDCI3) 67.80 (d, J= 8.4
[1269] 101
[1270] FH30010189.1Attorney Docket: LCH-04425
[1271] Hz, 2H), 7.34 (d, J= 8.4 Hz, 2H), 4.16 (m, 2H), 3.72-3.58 (m, 22H), 2.97 (br, 1H), 2.45 (s, 3H). ESI-MS m / z : [M+H]+437.79.
[1272] Preparation of Compound 14
[1273] Compound 13 (28 g, 64.1 mmol) and sodium azide (6.25 g, 96.2 mmol) were dissolved in -di methyl form am ide (70 mL). Then the reaction mixture was heated to 100 °C. After stirring for 3 hours, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography to yield Compound 14 (11.3 g, 57%) as a colorless oil. 'H-NMR (400 MHz, CDC13) 8 3.77-3.69 (m, 2H), 3.71-3.63 (m, 18H), 3.67-3.58 (m, 2H), 3.40 (t, J= 5.1 Hz, 2H). ESI-MS m / z : [M+H]+308.65.
[1274] Preparation of Compound 15
[1275] To a solution of Compound 14 (10 g, 32.5 mmol) in tetrahydrofuran (60 mL) were added triphenylphosphine (9.39 g, 35.8 mmol) and distilled water (5.9 mL, 325 mmol) at 0 °C under N2. The reaction mixture was heated to 85 °C and stirred for 4 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to yield Compound 15 (7.7 g, 84%) as a colorless oil. 'H-NMR (400 MHz, CDCI3) 63.75-3.57 (m, 22H), 3.56-3.49 (m, 2H), 2.92-2.83 (m, 2H). ESI-MS m / z : [M+H]+282.34.
[1276] Preparation of Compound 16
[1277] To a solution of Compound 15 (7.7 g, 27.4 mmol) in acetonitrile (50 mL) were added benzyl chloroformate (4.7 mL, 32.8 mmol) and a solution of sodium bicarbonate (6.9 g, 82.1 mmol) in distilled water (60 mL). After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 16 (9.27 g, 82%). 'H-NMR (400 MHz, CDCI3) 67.35 (d, J= 4.7 Hz, 5H), 5.10 (d, J= 3.8 Hz, 2H), 3.77-3.50 (m, 22H), 3.40 (t, J= 5.6 Hz, 2H), 3.01 (d, J= 6.5 Hz, 1H). ESI-MS m / z : [M+H]+416.34.
[1278] 102
[1279] FH30010189.1Attorney Docket: LCH-04425
[1280] Preparation of Compound 17
[1281] To a solution of Compound 16 (2.2 g, 5.30 mmol) in dichloromethane (50 mL) were added triethylamine (2.23 mL, 15.89 mmol) and -toluenesulfonyl chloride (1.31 g, 6.88 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with aq. 10% citric acid solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 17 (1.9 g, 63%) as a colorless oil. ES MS m / z : [M+H]+570.07.
[1282] Preparation of Compound 18
[1283] To a solution of hexaethylene glycol (65.37 g, 232 mmol) in tetrahydrofuran (100 mL) was added sodium hydride (60% dispersion in mineral oil, 151 mg, 6.29 mmol) at 0 °C. After stirring at 0 °C for 30 minutes, the reaction mixture was added tert-butyl acrylate (10 mL, 68.7 mmol). After stirring at room temperature for 16 hours, the reaction mixture was quenched by adding acetic acid (1 mL) and concentrated under reduced pressure. Then, the resulting residue was diluted with distilled water (500 mL) and extracted with ethyl acetate (500 mL x 4). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 18 (28 g, 100%) as a colorless oil, which was used without further purification. ESLMS m / z : [M+Na]+433.18.
[1284] Preparation of Compound 19
[1285] To a solution of Compound 18 (900 mg, 2.19 mmol) in dichloromethane (20 mL) were added triethylamine (0.92 mL, 6.58 mmol) and -toluenesulfonyl chloride (627 mg, 3.29 mmol) at 0 °C. After stirring at room temperature for 25 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. ammonium chloride solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 19 (900 mg, 73%) as a pale yellow oil. 'H-NMR. (400 MHz, CDC13) 8 7.83-7.76 (m, 2H), 7.37-7.31 (m, 2H), 4.19-4.12 (m, 2H), 3.75-3.66 (m, 4H), 3.66-3.43 (m, 22H), 2.50 (t, J= 6.6 Hz, 2H), 2.45 (s, 4H), 1.45 (s, 9H). ESLMS m / z :
[1286] [M+Na]+587.33.
[1287] 103
[1288] FH30010189.1Attorney Docket: LCH-04425
[1289] Example 5 : Preparation of Compound 26
[1290]
[1291] Preparation of Compound 20
[1292] To a solution of methyl 3,4,5-trihydroxybenzoate (methyl gallate, 70 g, 380.1 mmol) in A'A -di methyl form am ide (600 mL) were added 4-methoxybenzyl chloride (51.8 mL, 380.1 mmol), potassium bicarbonate (114.17 g, 1140.4 mmol), and potassium iodide (0.38 g, 0.006 mmol). The reaction mixture was heated to 60 °C under N2. After 16 hours, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting mixture was diluted with water (300 mL) and extracted with di chloromethane (300 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 20 (58.17 g, 50%) as a white solid. 'H-NMR (400 MHz,
[1293] 104
[1294] FH30010189.1Attorney Docket: LCH-04425
[1295] CDC13) 67.30 (d, J= 8.0 Hz, 2H), 7.19 (s, 2H), 6.90 (d, J= 8.0 Hz, 2H), 5.40 (s, 2H), 5.05 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H). ESI-MS m / z : [M+H]+305.31.
[1296] Preparation of Compound 21
[1297] To a solution of Compound 20 (1.5 g, 4.93 mmol) in A'A -di methyl form am ide (10 mL) were added potassium bicarbonate (3.41 g, 24.6 mmol) and Compound 17 (6.46 g, 11.34 mmol) under N2. After stirring at 80 °C for 17 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated, and purified by column chromatography to afford Compound 21 (5.6 g, 100%) as a yellow oil. ESLMS m / z : [M+H]+1100.46.
[1298] Preparation of Compound 22
[1299] To a solution of Compound 21 (3.6 g, 3.28 mmol) in dichloromethane (30 mL) were added anisole (5.3 mL, 49.1 mmol) and trifluoroacetic acid (1.3 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 22 (3.6 g, 100%) as a pale yellow oil. ESLMS m / z : [M+H]+979.45.
[1300] Preparation of Compound 23
[1301] To a solution of Compound 22 (2.0 g, 2.04 mmol) in A'A -di methyl form am ide (10 mL) were added potassium bicarbonate (1.02 g, 10.21 mmol) and Compound 19 (1.6 g, 2.86 mmol) under N2. The reaction mixture was stirred at 65 °C for 12 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4CI solution (10 mL x 3), saturated aq. NaHCCL solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to afford Compound 23 (1.9 g, 68%) as a pale yellow oil. ESLMS m / z : [M+H]+1371.69.
[1302] Preparation of Compound 24
[1303] To a solution of Compound 23 (1.8 g, 1.31 mmol) in methanol (12 mL) was added aq.
[1304] 1 NNaOH solution (6.56 mL, 6.56 mmol) at 0 °C under N2. After 7 hours, the reaction mixture
[1305] 105
[1306] FH30010189.1Attorney Docket: LCH-04425
[1307] was titrated with aq. 1 N HC1 solution to pH 3~4 at 0 °C, and the mixture was extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure and purified by column chromatography to afford Compound 24 (914 mg, 51%) as a yellow oil. ESI-MS m / z : [M+Na]+1379.60.
[1308] Preparation of Compound 25
[1309] To a solution of Compound 24 (190 mg, 0.14 mmol) in A,A-dimethylformamide (5 mL) were added Compound 12 (45 mg, 0.15 mmol), 7\ / A,A’,A’-tetramethyl-O-(lJ / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and A,A-diisopropylethylamine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 25 (140 mg, 61%). ESLMS m / z : [M+H]+1645.04, [M / 2+H]+823.39.
[1310] Preparation of Compound 26
[1311] To a solution of Compound 25 (140 mg, 0.09 mmol) in methanol (5.0 mL) was added palladium / charcoal (10 wt.%, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 26 (90 mg, 77%) as a yellow oil. ESLMS m / z :
[1312] [M+H]+1376.80, [M / 2+H]+689.21.
[1313] 106
[1314] FH30010189.1Attorney Docket: LCH-04425
[1315] Example 6 : Preparation of Compound 30
[1316]
[1317] Preparation of Compound 28
[1318] To a solution of Compound 27 (5 g, 8.70 mmol; Compound 27 was prepared by the method described in the U.S. Patent No. 11,173,214 B2, the entirety of which is incorporated herein by reference) in di chloromethane (100 mL) were added bis(pentafluorophenyl)carbonate (4.11 g, 10.44 mmol) and A, A-diisopropylethylamine (1.35 ml, 10.44 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 28 (6.4 g, 94%). ESLMS m / z : [M+Na]+806.79.
[1319] Preparation of Compound 29
[1320] To a solution of Compound 28 (6.4 mg, 8.16 mmol) in A, A-dimethylformamide (20 mL) were added exatecan mesylate (5.20 g, 9.79 mmol) and A / V’-diisopropylethylamine (3.41 mL, 19.58 mmol). After stirring at room temperature for 1 hour, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 29 (7.66 g, 90%). ESLMS m / z : [M+H]+1035.85.
[1321] Preparation of Compound 30
[1322] 107
[1323] FH30010189.1Attorney Docket: LCH-04425
[1324] To a solution of Compound 29 (6.6 g, 6.37 mmol) in dichloromethane (5 mL) and methanol (20 mL) were added palladium / charcoal (10 wt. %, 330 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 30 (4.7 g, 77%).1H-NMR(400 MHz, DMSO-de), 68.07 (d, J= 8.4 Hz, 1H), 7.77 (d, J= 11.2 Hz, 1H), 7.65 (s, 1H), 7.58 (d, J= 8.8 Hz, 1H), 7.31 (s, 1H), 7.22 (d, J= 8.4 Hz, 1H), 6.52 (s, 1H), 5.76 (s, 1H), 5.61 (d, J= 8.0 Hz, 1H), 5.49-5.39 (m, 3H), 5.31-5.22 (m, 3H), 5.18-5.03 (m, 4H), 4.74 (d, J = 9.6 Hz, 1H), 3.63 (s, 3H), 3.3-3.05 (m, 3H), 2.38 (s, 3H), 2.35-2.15 (m, 2H), 2.02 (s, 3H), 1.98 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H). ESLMS m / z : [M+H]+945.78.
[1325] Example 7 : Preparation of Compound 33
[1326]
[1327] Preparation of Compound 31
[1328] To a solution of Compound 26 (170 mg, 0.10 mmol) and Compound 30 (199 mg, 0.21 mmol) in A, A-dimethylformamide (4 mL) were added N, N,N’, N ’-tetramethyl -<9-(l H- benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 95 mg, 0.25 mmol) and N,N’~ diisopropylethylamine (0.087 mL, 0.50 mmol) at 0 °C. After stirring at room temperature for 2 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL), and dried over anhydrous sodium sulfate. The organic layer was filtered, concentrated under reduced pressure, and purified by column 108
[1329] FH30010189.1Attorney Docket: LCH-04425
[1330] chromatography to afford Compound 31 (223 mg, 71%). ESI-MS m / z : [M / 2+H]+1616.94, [M / 3+H]+1078.32.
[1331] Preparation of Compound 32
[1332] To a solution of Compound 31 (223 mg, 0.069 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (23 mg, 0.55 mmol) in water (1.5 mL) at -50 °C under N2. The reaction mixture was warmed up to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized using acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 32 (115 mg, 56%). ESI-MS [M / 2+H]+1476.80, [M / 3+H]+937.17.
[1333] Preparation of Compound 33
[1334] To a solution of Compound 32 (115 mg, 0.039 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) 0°C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 33 (75 mg, 69%) as a yellow solid. ESI-MS m / z : [M / 2+H]+1398.80, [M / 3+H]+932.86.
[1335] Example 8 : Preparation of Compound 40
[1336] N3
[1337]
[1338] 34
[1339] Preparation of Compound 34
[1340] To a solution of Compound 14 (2.0 g, 6.51 mmol) in dichloromethane (15 mL) were added triethylamine (1.37 mL, 9.76 mmol) and -toluenesulfonyl chloride (1.49 g, 7.81 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4CI solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 34 (2.04 g, 70%) as a pale yellow oil. 'H-NMR. (400 MHz, CDCI3) 8 7.80 (m, J= 8.1, 4.3 Hz, 2H), 7.35 (m, J= 7.6, 4.2 Hz, 2H), 4.16 (d, J= 5.5 Hz, 2H), 3.84-3.48 (m, 21H), 3.39 (d, J= 5.3 Hz, 2H), 2.45 (d, J= 4.0 Hz, 3H). ESI-MS m / z :
[1341] [M+Na]+484.243.
[1342] 109
[1343] FH30010189.1Attorney Docket: LCH-04425
[1344]
[1345] Preparation of Compound 35
[1346] To a solution of Compound 20 (30 g, 98.6 mmol) in
[1347]
[1348] -di methyl form am ide (300 mL) were added cesium carbonate (70.67 g, 217 mmol) and Compound 34 (104.66 g, 227 mmol) under N2. The mixture was stirred at 50 °C for 4 hours. The reaction mixture concentrated under reduced pressure and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4CI solution (100 mL), saturated aq. NaHCCL solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 35 (82 g, 94%) as a yellow oil. ESLMS m / z : [M+H]+855.77.
[1349] Preparation of Compound 36
[1350] To a solution of Compound 35 (88 g, 99.7 mmol) in dichloromethane (250 mL) were added anisole (162 mL, 1495 mmol) and trifluoroacetic acid (38 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 36 (63 g, 83%) as a pale yellow oil. ES MS m / z : [M+H]+763.68.
[1351] Preparation of Compound 37
[1352] To a solution of Compound 36 (23 g, 30.2 mmol) in
[1353]
[1354] -di methyl form am ide (150 mL) were added cesium carbonate (14.74 g, 45.2 mmol) and Compound 19 (20.43 g, 36.2 mmol)
[1355] 110
[1356] FH30010189.1Attorney Docket: LCH-04425
[1357] under N2. The mixture was stirred at 50 °C for 4 hours. The reaction mixture concentrated under reduced pressure and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4CI solution (100 mL), saturated aq. NaHCCh solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 37 (20 g, 57%) as a yellow oil. ES MS m / z : [M+Na]+1178.06.
[1358] Preparation of Compound 38
[1359] To a solution of Compound 37 (20 g, 17.3 mmol) in isopropyl alcohol / distilled water (250 mL / 250 mL) was added NaOH (1.04 g, 26.0 mmol) at 0 °C under N2. After 5 hours, the reaction mixture was titrated with aq. 1 N HC1 solution to pH 3~4 at 0 °C and extracted with ethyl acetate (250 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure to afford Compound 38 (19 g, 96%) as a brown oil, which was used for the next step without further purification. ESLMS m / z : [M+Na]+1164.04.
[1360] Preparation of Compound 39
[1361] To a solution of Compound 38 (19 g, 16.6 mmol) in A f-di methyl form ami de (100 mL) were added Compound 12 (6.10 g, 20.0 mmol), MMA’,A’-tetramethyl- -( IT / -benzotriazol- l-yl)uronium hexafluorophosphate (HBTU, 7.58 g, 20.0 mmol), and A,A-diisopropylethylamine (14 mL, 83.2 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (300 mL) and washed with saturated aq. NH4CI solution (200 mL), saturated aq. NaHCCL solution (200 mL) and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 39 (19.6 g, 82%). ESLMS m / z : [M+H]+1430.42.
[1362] Preparation of Compound 40
[1363] To a solution of Compound 39 (5.00 g, 3.50 mmol) in methanol (20 mL) was added aq.
[1364] 1 N NaOH solution (28.0 mL, 28.0 mmol) at 0 °C under N2. After 24 hours, the reaction mixture was titrated with aq. 1 N HC1 solution to pH 3~4 at 0 °C and extracted with dichloromethane (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The
[1365] 111
[1366] FH30010189.1Attorney Docket: LCH-04425
[1367] filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 40 (5.0 g, 100%) as a yellow oil. ESI-MS m / z : [M+Na]+1395.22.
[1368]
[1369] Preparation of Compound 41
[1370] To a solution of tri s(hydroxymethyl)aminom ethane (5 g, 41.2 mmol) in dimethyl sulfoxide (20 mL) was added 5 M NaOH solution (1.05 mL, 5.25 mmol) at 0 °C. Then tertbutyl acrylate (60 mL, 412 mmol) was added slowly at 0 °C. The reaction mixture was gradually warmed up to room temperature. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 41 (12.8 g, 61 %). 'H-NMR (400 MHz, CDC13) 83.64 (t, J= 4.2 Hz, 6H), 3.32 (s, 6H), 2.45 (t, J= 4.1 Hz, 6H), 1.45 (s, 27H). ESLMS m / z : [M+H]+506.62.
[1371] Preparation of Compound 42
[1372] To a solution of Compound 40 (4.80 g, 3.50 mmol) in
[1373]
[1374] -di methyl form am ide (50 mL) were added Compound 41 (2.65 g, 5.25 mmol), 7\ / A,A’,A’-tetramethyl-O-(lZ / -benzotriazol-l- 112
[1375] FH30010189.1Attorney Docket: LCH-04425
[1376] yl)uronium hexafluorophosphate (HBTU, 1.99 g, 5.25 mmol), and A,A-diisopropylethylamine (3.0 mL, 17.5 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4CI solution (100 mL), saturated aq. NaHCCL solution (100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 42 (4.22 g, 65%). ESLMS m / z : [M+H]+1860.82.
[1377] Preparation of Compound 43
[1378] To a solution of Compound 42 (4.22 g, 2.27 mmol) in tetrahydrofuran (30 mL) were added triphenylphosphine (1.43 g, 5.44 mmol) and distilled water (0.82 mL, 45.4 mmol) at 0 °C under nitrogen. The reaction mixture was stirred at 60 °C for 12 hours. After concentrating under reduced pressure, the resulting residue purified by column chromatography to afford Compound 43 (4.0 g, 97%). ESLMS m / z : [M+H+] 1808.21.
[1379] Preparation of Compound 45
[1380] To a solution of Compound 44 (525 mg, 1.08 mmol; Compound 44 was prepared by the method described in the U.S. Patent No. 11,173,214 B2, the entirety of which is incorporated herein by reference) in A Mdi methylformamide (5 mL) were added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (283 mg, 1.48 mmol), 1-hydroxybenzotriazole (199 mg, 1.48 mmol), Compound 43 (890 mg, 0.49 mmol), and N-methylmorpholine (0.32 mL, 2.95 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NaHCCL solution (50 mL) and saturated aq. NH4CI solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 45 (890 mg, 66%). ESLMS m / z : [M / 2+H]+1370.61, [M / 3+H]+914.14.
[1381] Preparation of Compound 46
[1382] To a solution of Compound 45 (890 mg, 0.32 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (384 mg, 0.97 mmol) and pyridine (0.10 mL, 1.30 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was concentrated under reduced pressure, and then was diluted with ethyl acetate (100 mL)
[1383] 113
[1384] FH30010189.1Attorney Docket: LCH-04425
[1385] and washed with brine (50 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 46 (1.28 g, crude), which was used without further purification. ESI-MS m / z : [M / 2+H]+1580.56, [M / 3+H]+1054.06.
[1386] Example 10 : Preparation of Compound 49
[1387]
[1388] Preparation of Compound 47 To a solution of Compound 46 (450 mg, 0.14 mmol) in
[1389]
[1390] -di methyl form am ide (2 mL) was added exatecan mesylate (159 mg, 0.30 mmol) in A'A -di methyl form am ide (3 mL) and 7V,7V’-diisopropylethylamine (0.20 mL, 1.14 mmol) at room temperature under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford Compound 47 (550 mg, crude), which was used without further purification. ES MS m / z : [M / 2+H]+1831.35, [M / 3+H]+1221.44.
[1391] Preparation of Compound 48
[1392] To a solution of Compound 47 (115 mg, 0.031 mmol) in tetrahydrofuran / methanol (0.5 mL / 0.5 mL) was added lithium hydroxide monohydrate (10 mg, 0.25 mmol) in water (0.5 mL) at -50 °C under N2. The reaction mixture was warmed up to 0 °C and kept for 3 hours at this
[1393] 114
[1394] FH30010189.1Attorney Docket: LCH-04425
[1395] temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. Then the resulting residue was purified by HPLC to afford Compound 48 (60 mg, 56%). ESI-MS m / z : [M / 2+H]+1691.42, [M / 3+H]+1128.07.
[1396] Preparation of Compound 49
[1397] To a solution of Compound 48 (60 mg, 0.018 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C. After stirring at room temperature for 5 hours, the reaction mixture was purified by HPLC to afford Compound 49 (37 mg, 67%) as a yellow solid. ESLMS m / z : [M / 2+H]+1558.64, [M / 3+H]+1039.39.
[1398] Example 11 : Preparation of Compound 50
[1399]
[1400] Compound 50 was produced with the method disclosed in U.S. Patent No. 11,654,197, the entirety of which is herein included in the present specification by reference. ESLMS m / z : [M+H]+1698.2, [M / 2+H]+849.6.
[1401] Example 12 : Preparation of Compound 56
[1402] ^ _
[1403] 51 52
[1404] 53 54
[1405] ll 44 ^ >
[1406]
[1407] 55 56 Preparation of Compound 51
[1408] To a solution of pentaethylene glycol (10 g, 41.97 mmol) in di chloromethane (45 mL) were added -toluenesulfonyl chloride (16 g, 83.94 mmol) and potassium hydroxide (18.84 g, 335.74 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After 16 hours, the reaction mixture was diluted with di chloromethane (80 mL) and washed with 115
[1409] FH30010189.1Attorney Docket: LCH-04425
[1410] distilled water (80 mL). The organic layer was dried over anhydrous sodium sulfate. Filtration and concentration under reduced pressure afforded Compound 51 (24 g, quant.) as a clear oil, which was used for the next step without further purification. 'H-NMR (400 MHz, CDCh) 6 7.79 (d, J= 6.4 Hz, 4H), 7.34 (d, J= 8.0 Hz, 4H), 4.15 (t, J= 4.8 Hz, 4H), 3.68 (t, J= 4.8 Hz, 4H), 3.60 (s, 4H), 3.58 (s, 8H), 2.45 (s, 6H).
[1411] Preparation of Compound 52
[1412] Compound 51 (28 g, 51.22 mmol) and sodium azide (13.32 g, 204.88 mmol) were dissolved in -di methyl form am ide (100 mL). And then the reaction mixture was heated to 80 °C. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (150 mL) and washed with saturated aq. NH4CI (85 mL) solution and distilled water (80 mL x 3). The organic layer was dried over anhydrous sodium sulfate. Filtration and concentration under reduced pressure afforded Compound 52 (14.3 g, 96.8%) as a clear oil, which was used for the next step without further purification. 'H-NMR. (400 MHz, CDCI3) 63.72-3.64 (m, 16H), 3.39 (t, J= 4.8 Hz, 4H). ESLMS m / z : [M+H]+311.41.
[1413] Preparation of Compound 53
[1414] To a solution of Compound 52 (14.3 g, 49.60 mmol) in ethyl acetate (180 mL) were added triphenylphosphine (13 g, 49.60 mmol) and 1 N aq. HC1 solution (91.76 mL, 91.76 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure and then the residue was adjusted to pH 14 with 1 M aq. sodium hydroxide solution. The mixture was extracted with di chloromethane (100 mL x 2). The combined organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 53 (11 g, 84%) as a clear oil, which was used for the next step without further purification. ESLMS m / z : [M+H]+263.43.
[1415] Preparation of Compound 54
[1416] To a solution of Compound 53 (1.04 g, 3.96 mmol) in 7V,7V-dimethylformamide (15 mL) were added Compound 7 (955 mg, 4.35 mmol), 7\ / 7V,7V’,7V’-tetramethyl-O-(U / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 2.25 g, 5.94 mmol), and / V,7V-diisopropylethylamine (1.37 mL, 7.91 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (60 mL) and washed with saturated aq. NH4CI solution (60 mL), saturated aq. NaHCCL solution (60 mL) and brine (30 mL). The organic layer was
[1417] 116
[1418] FH30010189.1Attorney Docket: LCH-04425
[1419] dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 54 (923 mg, 50%). ESI-MS m / z : [M+H]+464.42.
[1420] Preparation of Compound 55
[1421] To a solution of Compound 54 (923 mg, 1.99 mmol) in tetrahydrofuran (20 mL) were added triphenylphosphine (1.56 g, 5.97 mmol) and distilled water (0.35 mL, 19.9 mmol) at 0 °C under N2. The reaction mixture was heated to 85 °C and stirred for 16 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 55 (703 mg, 80%). ESI-MS m / z : [M+H]+438.22.
[1422] Preparation of Compound 56
[1423] To a solution of Compound 55 (703 mg, 1.61 mmol) in AA-dimethylform amide (8 mL) were added Compound 44 (702 mg, 1.45 mmol), A,A,A’,A’-tetramethyl-O-(U / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 916 mg, 2.41 mmol) and N,N-diisopropylethylamine (0.56 mL, 3.22 mmol) under N2 at 0 °C. After stirring at room temperature for 6 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI (50 mL) solution and distilled water (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 56 (780 mg, 53%). ESI-MS m / z : [M+H]+904.28.
[1424] 117
[1425] FH30010189.1Attorney Docket: LCH-04425
[1426] Example 13 : Preparation of Compound 62
[1427]
[1428] Preparation of Compound 58
[1429] To a solution of Compound 57 (500 mg, 0.35 mmol; Compound 57 was prepared by the method described in the U.S. Patent No. 11,654,197 B2, the entirety of which is incorporated herein by reference), in di chloromethane (20 mL) were added triphosgene (41 mg, 0.14 mmol), A^A-diisopropylethylamine (0.03 mL, 1.05 mmol) and dibutyltin dilaurate (0.02mL, 0.04 mmol) at 0 °C under N2. After stirring at 0 °C for 10 min, a solution of Compound 56 (411 mg, 0.45 mmol) and M A-diisopropylethylamine (0.03 mL, 1.05 mmol) in dichloromethane (20 mL) were added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 58 (403 mg, 48%). ESLMS m / z : [M / 2+H]+1177.32.
[1430] Preparation of Compound 59
[1431] To a solution of Compound 58 (403 mg, 0.17 mmol) in tetrahydrofuran (5 mL) and water (5 mL) was added acetic acid (5 mL) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (50 ml 2). The organic layer was dried over 118
[1432] FH30010189.1Attorney Docket: LCH-04425
[1433] anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 59 (360 g, 98%). ESI-MS m / z : [M+H]+2121.94
[1434] Preparation of Compound 60
[1435] To a solution of Compound 59 (360 mg, 0.16 mmol) in dichloromethane (30 mL) was added Dess-Martin periodinane (86 mg, 0.20 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with di chloromethane (30 mL) and washed with saturated aq. sodium bicarbonate solution (30 mL) and distilled water (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 60 (326 mg, 95%). ES MS m / z : [M+H]+2117.86.
[1436] Preparation of Compound 61
[1437] To a solution of Compound 60 (326 mg, 0.15 mmol) in THF / MeOH (12 mL / 12 mL) was added lithium hydroxide monohydrate (116 mg, 2.77 mmol) in distilled water (12 mL) at -50 °C under N2. The reaction mixture was warmed up to 0 °C and kept for 2 hours at this temperature. The reaction mixture was adjusted to pH 4~5 with acetic acid and concentrated under reduced pressure to afford Compound 61 (310 mg, crude), which was used without further purification. ESLMS m / z : [M+H]+1837.75.
[1438] Preparation of Compound 62
[1439] To a solution of Compound 61 (160 mg, 0.08 mmol) in di chloromethane (2 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford Compound 62 (81 mg, 52%) as a white solid. ESLMS m / z :
[1440] [M+H]+1738.41, [M / 2+H]+869.77.
[1441] 119
[1442] FH30010189.1Attorney Docket: LCH-04425
[1443] Example 14 : Preparation of Compound 63
[1444] O’ O'2
[1445] .TFA
[1446]
[1447] Compound 63 was produced with the method disclosed in U.S. Patent No. 11,173,214, the entirety of which is incorporated herein by reference. ESI-MS m / z : [M / 2+H]+1623.6, [M / 3+H]+1082.8.
[1448] The structure of MMAE (Monomethyl auristatin E) in Compound 63 is as follows:
[1449]
[1450] Example 15: Preparation of Exemplified ADCs
[1451] Exemplified anti-CEACAM5 antibody-drug conjugates (ADC1, ADC2, ADC3, ADC4, ADC5, ADC6, ADC8, ADC10) were produced with the following two steps. LCB14-0606 was produced with the method disclosed in U.S. Patent No. 9,669,107 B2, the entirety of which is incorporated herein by reference. The structural formula of LCB14-0606 is as follows:
[1452]
[1453] LCB 14-0606
[1454] Step 1: Production of Prenylated Antibody with LCB14-0606
[1455] Exemplified anti-CEACAM5 antibody clones Clone2, Clone4, and Clone6 were prepared following the procedures outlined in Example 1. Individual reaction mixtures for the prenylation reaction for each antibody clone were prepared by combining anti-CEACAM5 antibody Clone2, Clone4, or Clone6 respectively with FTase (WB pharma) and LCB 14-0606 in a buffer solution, and incubating at 30 °C for 16 hours. The reaction mixture for each
[1456] 120
[1457] FH30010189.1Attorney Docket: LCH-04425
[1458] antibody clone contained 24 pM of the antibody clone, 600 nM FTase, and 144 pM LCB14-0606 in a buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCh, 10 pM ZnCh, 0.25 mM DTT). To facilitate the assembly of the reduced antibody, an oxidation step was carried out by adding 10 molar equivalents of DHAA (dehydroascorbic acid) and stirring the mixture at 25 °C and 80 rpm for 4 hours. After the reaction, the prenylated antibody clones were desalted using an Amicon® Ultra centrifugal filter (Merck Millipore, 10 MWCO) equilibrated with PBS buffer.
[1459] Step 2: Drug-Conjugation Method
[1460] Oxime Bond Reaction of ADC1, ADC2, ADC3, ADC8 and ADC10 (conjugation by oxime bond formation)
[1461] The oxime bond formation between the prenylated antibody clone and the linkerpayload compound was performed by mixing 100 mM sodium acetate buffer (pH 4.5 or 5.2), 10% DMSO, 10 mg / ml of prenylated antibody clone, and 10 equivalents (100 mg / ml) of the linker-payload (Compounds 5, 33, or 49 prepared in Examples 2, 7, or 10). The reaction mixture was stirred at 80 rpm for 24 hours at 30 °C. Afterward, any excess low molecular weight substances were removed using an Amicon® Ultra centrifugal filter (Merck Millipore, 30MWCO), and the desired protein fraction was collected and concentrated.
[1462] Oxime Bond Reaction of ADC4, ADC5, and ADC6 (conjugation by oxime bond formation)
[1463] The oxime bond formation between the prenylated antibody clone and the linkerpayload compound was performed by combining 100 mM sodium acetate buffer (pH 4.5 or 5.2), 10% DMSO, 10 mg / ml of prenylated antibody clone, and 10 equivalents (100 mg / ml) of the linker-payload (Compounds 50, 62, or 63 prepared in Examples 11, 13, or 14). The reaction mixture was stirred at 80 rpm for 18 hours at 30 °C. Afterward, any excess low molecular weight substances were removed using an Amicon® Ultra centrifugal filter (Merck Millipore, 30MWKD), and the desired protein fraction was collected and concentrated.
[1464] The drug-to-antibody ratio (DAR) and monomer purity of the exemplified ADCs were analyzed using conventional HIC-HPLC and SEC-HPLC method, respectively, according to standard protocols. For certain reference ADCs, including ADC7 and ADC9, DAR and monomer purity values were obtained from supplier-provided specifications. Exemplified ADCs prepared by the above two steps and analysis results are presented in Table 7 below.
[1465] 121
[1466] FH30010189.1Attorney Docket: LCH-04425
[1467] Additional linker-payloads or compounds may be prepared according to methods disclosed in U.S. Provisional Application Serial No. 63 / 802493 and U.S. Provisional Application Serial No. 63 / 802463, the contents of which are incorporated herein by reference in their entirety.
[1468] Table 7. Exemplified ADCs and Analysis Results
[1469] Monomer Average DAR
[1470] ADC Antibody Linker-Payload Purity (HIC-HPLC)
[1471] (SEC-HPLC) ADC1 Compound 5 4.0 97.9% ADC2 Compound 33 4.0 99.3% ADC3 Compound 49 4.0 98.9%
[1472] Clone 2
[1473] ADC4 Compound 50 2.0 99.4% ADC5 Compound 62 2.0 99.9% ADC6 Compound 63 3.9 99.9%
[1474] N-succinimidyl 4-(2- *ADC7 Tusamitamab ~3.8 99.0%
[1475] py ri dy 1 dithi o)butanoate-DM4
[1476] ADC8 Clone 4 Compound 33 4.0 99.0%
[1477] Mal-Gly-PAB-Exatecan-D- *ADC9 Precemtabart ~ 8.5 98.9%
[1478] glucuronic acid
[1479]
[1480] ADC10 Clone 6 Compound 33 4.0 99.9% *ADC7 indicated Tusamitamab ravtansine biosimilar purchased from MedChemExpress * ADC9 indicated Precemtabart tocentecan biosimilar purchased from MedChemExpress
[1481] Experimental Example 1: Assessment of the Binding Affinity of Anti-CEACAM5 Antibody to Cancer Cells
[1482] The binding affinity of the anti-CEACAM5 antibody Clone2, prepared in Example 1, was assessed using two CE AC AM5 -positive gastric cancer cell lines, MKN-45 and SNU-16, and one CE AC AM5 -negative lung cancer cell line, A-549.
[1483] Specifically, the above cancer cell lines were cultured, and the cells were divided into two groups: one treated with control IgG antibody and the other with the anti-CEACAM5 antibody Clone2. The cells were then incubated at 4 °C for 1 hour in a phosphate-buffered saline solution containing 5% fetal bovine serum to eliminate non-specific antibody binding. Afterward, each antibody, either the control IgG or the anti-CEACAM5 antibody Clone2, was added to the respective cell groups and incubated at 4 °C for 1 hour to allow binding to the CEACAM5 proteins on the cancer cell surface. Unbound antibodies were then washed off using the phosphate-buffered saline solution with 5% fetal bovine serum.
[1484] Subsequently, the cells were incubated with fluorescently labeled secondary antibodies specific to the control IgG and anti-CEACAM5 antibody Clone2 for 1 hour at 4 °C. After 122
[1485] FH30010189.1Attorney Docket: LCH-04425
[1486] removing any unbound secondary antibodies using phosphate-buffered saline, the fluorescence intensity of the cells was measured using a flow cytometer. The fluorescence intensity of the cell lines in the anti-CEACAM5 antibody Cl one2 -treated group was compared to the control IgG-treated group to confirm the binding affinity of the antibody to the cancer cell lines. The results are represented in Table 8 below. In CEACAM5-positive cell lines, binding of the anti-CEACAM5 antibody clone 2 was confirmed, whereas no binding was observed in CEACAM5-negative cell line.
[1487] Table 8. Fluorescence Intensity of Anti-CEACAM5 Antibody in Cancer Cell Lines Median PE (Fold- Value)
[1488] CEACAM5 CEACAM5 Test Sample Positive Negative MKN-45 SNU-16 A-549 Anti-CEACAM5 Antibody
[1489] 4.3 2.6 ND.
[1490]
[1491] Clone2 / Control IgG
[1492] Experimental Example 2: Evaluation of Selective Binding to Recombinant CEACAM5 (rCEA) versus Soluble CEACAM5 (sCEA)
[1493] To evaluate the selective binding characteristics, antibody-bead complexes were prepared by conjugating the antibodies (81E3A8-06, Tusamitamab and Precemtabart) and a negative control, human IgG (hlgG) to specific beads. The prepared complexes were separately introduced into a recombinant CEACAM5 (rCEA) solution and human serum containing soluble CEACAM5 (sCEA), and incubated under identical conditions for a predetermined period.
[1494] Following incubation, the antibody-CEACAM5 complexes were removed from the samples by capturing the beads. The amount of residual CEACAM5 (rCEA or sCEA) remaining in the supernatant was quantitatively analyzed.
[1495] To account for differences in antibody concentration and potential serum matrix effects, the amount of residual CEACAM5 in the negative control (hlgG) group was normalized to 100%. The residual rates for rCEA and sCEA were calculated as follows:
[1496] Residual Rate (%)
[1497] Amount of residual CEACAM5 after Antibody treatment x 100
[1498]
[1499] Amount of residual CEACAM5 after IgG treatment Based on these residual rates, a selectivity index (fold value) was calculated to evaluate the relative binding preference of each antibody, according to the following equation:
[1500] 123
[1501] FH30010189.1Attorney Docket: LCH-04425
[1502] sCEA Residual Rate (%)
[1503] Fold Value =a n— — — — - ——
[1504]
[1505] rCEA Residual Rate (%)
[1506] As shown in Table 9, the fold values for each antibody were determined to be 15.5 for 81E3A8-06, 3.7 for Tusamitamab, and 1.6 for Precemtabart.
[1507] These results suggest that 81E3A8-06 exhibits reduced binding to soluble CEACAM5 relative to recombinant CEACAM5, compared to Tusamitamab and Precemtabart. Accordingly, 81E3A8-06 may reduce non-specific consumption (antigen sink effect) due to binding to circulating soluble CEACAM5 in vivo.
[1508] Table 9. Fold Value of Exemplified Antibodies for rCEA versus sCEA
[1509] Antibody Fold value 81E3A8-06 15.5 Tusamitamab 3.7
[1510] Precemtabart 1.6
[1511]
[1512] Experimental Example 3: In vitro Evaluation of Cell Toxicity for Exemplified ADCs in the Presence of Soluble CEACAM5 Antigen
[1513] The cytotoxicity of ADC6 and ADC7 was evaluated in the presence or absence of soluble CEACAM5 (sCEACAM5) antigen to assess the impact of circulating antigens on cytotoxicity activity of ADC. The commercially available lung cancer cell line H3122, which expresses a high level of CEACAM5 (antibody binding capacity (ABC): approximately 95,135), was used for this assay. Human serum containing sCEACAM5 was diluted to a final concentration of 40 ng / mL for the treatment.
[1514] H3122 cells were seeded at a density of 5,000 cells per well in a 96-well plate and incubated for 24 hours. The cells were then treated with ADCs at various concentrations using a 5-fold serial dilution, in the presence or absence of 40 ng / mL sCEACAM5. After 144 hours of incubation, cell viability was measured using SRB (Sulforhodamine B) assay.
[1515] IC50 values were determined, and the fold change in IC50 values was calculated as the ratio of the IC50 value in the presence of sCEACAM5 to that in its absence. The results are summarized in Table 10.
[1516] As shown in Table 10, ADC6 exhibited a minimal fold change (1.24-fold), indicating that its cytotoxic potency was largely maintained in the presence of soluble antigen. In contrast,
[1517] 124
[1518] FH30010189.1Attorney Docket: LCH-04425
[1519] ADC7 showed a substantially increased fold change (4.93-fold) under the same conditions indicating reduced cytotoxic activity.
[1520] These results demonstrate that while the cytotoxic activity of ADC7 is significantly compromised in the presence of sCEACAM5, the cytotoxic activity of ADC6 is less affected by soluble CEACAM5 in serum.
[1521] Table 10. Fold Change of Exemplified ADCs With or Without sCEACAM5
[1522] Fold Change ofIC50
[1523] Cell line
[1524] ADC6 ADC7 H3122 1.24 4.93
[1525]
[1526] Experimental Example 4: In vitro Evaluation of Cell Toxicity for Exemplified CEACAM5 ADCs
[1527] The cell proliferation inhibitory activity of exemplified ADCs (ADC1, ADC2, ADC3, ADC4, ADC5, ADC6, ADC8 and ADC 10), prepared in Example 15, as well as reference ADCs (ADC7 and ADC9) purchased from MedChemExpress (Cat. Nos. HY-P99542 and HY- 177434), was evaluated against various cancer cell lines.
[1528] The CEACAM5-positive pancreatic cancer cell line (HPAF-II), gastric cancer cell lines (MKN-45, SNU-16), colorectal cancer cell line (LS174T) and CE AC AM5 -negative lung cancer cell lines (A-549, H1299, H1650) were used. Each cell line was seeded at a density of 5,000 cells per well in a 96-well plate and cultured for 24 hours. Subsequently, the cells were treated with exemplified ADCs at concentrations ranging from 0.512 pM to 200 nM, using a 5-fold serial dilution. After 144 hours, cell viability was measured using SRB (Sulforhodamine B) staining, and the results are presented in Table 11 below.
[1529] Table 11. In vitro Cytotoxicity Concentration of Exemplified ADCs in CEACAM5- Positive and CEACAM5-Negative Cancer Cell Lines
[1530] CC50(nM)
[1531] Test CEACAM5-Positive CEACAM5-Negative Samples HPAF-II MKN-45 SNU-16 LS174T A-549 H1299 H1650 ADC1 3.3 23.9 0.8 80.4 77.8 225.7 ADC2 1.8 0.5 10.9
[1532] ADC3 3.3
[1533] ADC4 0.1 0.2 0.1
[1534] ADC5 0.1 0.1 0.1 0.1
[1535] ADC6 0.1 0.1 0.3 0.2 108.1 386.8 142.1
[1536]
[1537] ADC7 0.8 1.1 0.3 1.2 6.0 32.2 44.7
[1538] 125
[1539] FH30010189.1Attorney Docket: LCH-04425
[1540] ADC8 0.2 0.2 6.4
[1541] ADC9 0.7 2.3
[1542]
[1543] ADC10 1.1 0.5 6.9
[1544] As shown in Table 11, the ADCs comprising exatecan (ADC1, ADC2, ADC3, ADC8 and ADC 10), pyrrol obenzodiazepine (PBD) (ADC4 and ADC5), or MMAE (ADC6) exhibited potent cytotoxicity in CE AC AM5 -positive cancer cell lines. In contrast, these ADCs showed markedly reduced cytotoxicity in CE AC AM5 -negative cancer cell lines, indicating targetdependent activity. Compared to the reference ADC (ADC7), the exemplified ADCs exhibited improved selectivity toward CE AC AM5 -positive cells.
[1545] Additionally, the cell proliferation inhibitory activity of exemplified ADCs (ADC1, ADC2, ADC3, ADC4, ADC5, ADC6, ADC8 and ADC10), prepared in Example 15, as well as reference ADCs (ADC7 and ADC9) purchased from MedChemExpress (Cat. Nos. HY- P99542 and HY-177434), was evaluated against various normal cell lines.
[1546] Commercially available human cell lines were used: kidney (HK-2), skin (HaCaT), breast (HMEC), bronchial (BEAS-2B), lung (MRC-5), peripheral blood mononuclear cells (PBMC), and hematopoietic stem cells (CD34+ HSC). Each cell line was seeded according to provider’s instructions and cultured for 24 hours in a 96-well plate. Afterward, the cells were treated with exemplified ADCs at concentrations ranging from 2.56 pM to 1 pM using a 5-fold serial dilution. Following 144 hours of incubation, the number of viable cells was measured using either the colorimetric SRB (Sulforhodamine B) assay or a luminescent-based assay that quantifies ATP levels. The results are presented in Table 12 below.
[1547] Table 12. In vitro Cytotoxicity Concentration of Exemplified ADCs in Normal Cell Lines CC50(nM)
[1548] Test BEAS- CD34+ HK-2 HaCaT HMEC MRC-5 PBMC
[1549] Samples 2B HSC ADC1 116.4 20.2 23.0 154.5 439.0 575.0 996.5 ADC2 68.4 >1000 >1000 ADC3 61.6
[1550] ADC4 575.0 17.5 ADC5 868.1 24.0 946.8 34.0 ADC6 680.3 50.7 534.4 ND. 308.5 181.9 ADC7 278.8 3.8 49.1 56.5 141.0 3.0 ADC8 >1000 >1000 ADC9 59.1 483.5 165.2
[1551]
[1552] ADC10 101.8 852.6
[1553] 126
[1554] FH30010189.1Attorney Docket: LCH-04425
[1555] As shown in Table 12, the exemplified ADCs (ADC1, ADC2, ADC3, ADC4, ADC5, ADC6, ADC8 and ADC 10) generally exhibited reduced cytotoxicity in normal cell lines, with substantially higher CCso values compared to those observed in CE AC AM5 -positive cancer cell lines.
[1556] These results demonstrate that the exemplified ADCs maintain a favorable selectivity profile, exhibiting potent cytotoxic activity in CE AC AM5 -positive cancer cells while showing limited cytotoxicity in normal cells.
[1557] Experimental Example 5: In vivo Evaluation of Anti-cancer Efficacy for Exemplified ADCs
[1558] The anti -tumor efficacy of the exemplified ADCs prepared in Example 15 was evaluated using mouse tumor xenograft models.
[1559] Specifically, various cancer cell lines including non-small cell lung cancer (NCI-H2122, NCI-H3122), pancreatic cancer (HPAF-II), gastric cancer (MKN45), and colorectal cancer (SW-1463) were cultured and used for tumor implantation. For each cell line, 3,000,000 to 5,000,000 cells were prepared and subcutaneously injected into mice to establish xenograft models.
[1560] For xenograft models established in commercially available BALB / c nude mice, NCI- 143122, NCI-H2122, and SW-1463 cells were suspended in a mixture of 100 pL of PBS and 100 pL of Matrigel prior to injection, whereas MKN45 cells were suspended in 100 pL of PBS alone. For xenograft model established in commercially available SCID mice, HPAF-II cells were suspended in a mixture of 100 pL of PBS and 100 pL of Matrigel.
[1561] When the tumor volume reached approximately 100-200 mm3, ADCs were administered intravenously according to the dosing regimens set forth in Table 13. Tumor volumes were measured prior to the first administration (Day 1) and at predetermined time points thereafter.
[1562] The results are shown in FIGs. 7 to 11.
[1563] Table 13. Dosing Regimens of Exemplified ADCs in In CDX Models
[1564] Test
[1565] NCI-H3122 HPAF-II MKN-45 NCI-H2122 SW-1463 Samples
[1566] 5, 10 mg / kg
[1567] ADC1
[1568] (single)
[1569] 3, 6, 9 mg / kg 4, 8 mg / kg 4, 8 mg / kg 4, 8 mg / kg ADC2
[1570]
[1571] (single) (single) (single) (single)
[1572] 127
[1573] FH30010189.1Attorney Docket: LCH-04425
[1574] 0.3, 0.9 mg / kg 0.3, 0.6 mg / kg ADC5
[1575] (single) (single) 2.5, 5, 10 mg / kg
[1576] ADC6
[1577] (single)
[1578] 2.5, 5, 10 mg / kg
[1579] ADC7
[1580] (single)
[1581] 4, 8 mg / kg 4, 8 mg / kg
[1582] ADC8
[1583] (single) (single)
[1584] 4 mg / kg 4 mg / kg 4 mg / kg ADC9
[1585]
[1586] (single) (single) (single)
[1587] As shown in FIG.7, ADC1 and ADC6 significantly inhibited tumor growth in the NCI- H3122 Cell Line-Derived Xenograft (CDX) model compared to ADC7. ADC 1 and ADC6 demonstrated dose-dependent tumor growth inhibition across all tested dose levels, with marked tumor regression observed at 10 mg / kg. No tumor regrowth was observed up to 60 days post-treatment. In contrast, ADC7 showed partial responses and only partial tumor growth inhibition under the same conditions.
[1588] Additionally, as shown in FIG. 8, ADC2 and ADC5 exhibited superior anti-tumor activity in the HPAF-II CDX model, with tumor regression observed at most tested dose levels.
[1589] As shown in FIG. 9A, ADC2 and ADC8 demonstrated significant tumor growth inhibition in the MKN-45 CDX model compared to the vehicle control group. Marked tumor suppression was observed across the tested dose levels, particularly at 8 mg / kg, where tumor volumes were maintained near baseline levels throughout the observation period. In contrast, ADC9, which has a higher DAR of approximately 8, showed only partial tumor growth inhibition and exhibited lower efficacy compared to ADC2 and ADC8 (DAR 4) at corresponding dose levels.
[1590] Additionally, as shown in FIG. 9B, ADC5, at the low dosage tested, also inhibited tumor growth in the MKN-45 CDX model compared to the vehicle control group. No significant changes in body weight were observed in any treatment group, indicating that the ADCs were well tolerated (FIG. 9C).
[1591] As shown in FIG. 10A, ADC2 and ADC8 exhibited potent anti-tumor efficacy in the NCI-H2122 CDX model, with substantial tumor growth inhibition compared to the vehicle control group. In contrast, ADC9, which has a higher DAR of approximately 8, showed only partial tumor growth inhibition and exhibited lower efficacy compared to ADC2 and ADC8 (DAR 4) at corresponding dose levels. No significant changes in body weight were observed in any treatment group, indicating that the ADCs were well tolerated (FIG. 10B).
[1592] 128
[1593] FH30010189.1Attorney Docket: LCH-04425
[1594] As shown in FIG. 11 A, ADC2 showed superior antitumor activity in the SW1463 CDX model, with tumor growth effectively controlled across the tested doses. Additionally, as shown in FIG. 11B, ADC5 also showed clear dose-dependent anti -tumor effect, with superior tumor growth inhibition efficacy. No significant changes in body weight were observed in any treatment group, indicating good tolerability (FIG. 11C).
[1595] Finally, to quantitatively evaluate the anti-tumor efficacy across the three CDX models (MKN-45, NCI-H2122, and SW1463), tumor growth inhibition (TGI, %) values were calculated for each treatment group. TGI (%) was calculated according to the following formula:
[1596] TGI (%) = (1 -2kzZk) x 100
[1597]
[1598] ct~co
[1599] wherein Ttand To represent the mean tumor volumes of the treated group at time t and at the initial time point, respectively, and Ct and Co represent the mean tumor volumes of the control group at time t and at the initial time point, respectively. The TGI results for all three in vivo models are summarized in Table 14 below.
[1600] Taken together, anti-CEACAM5 antibody -based ADCs described herein exhibit a favorable profile, characterized by strong anti-tumor activity and low toxicity.
[1601] Table 14. Tumor Growth Inhibition (TGI, %) of Exemplified ADCs in MKN-45, NCI-112122, and SW1463 Xenograft Models
[1602] Model Group D14 D21 D28
[1603] ADC2, 4 mpk 96.20 104.13 94.75 ADC2, 8 mpk 106.21 111.78 104.29 ADC8, 4 mpk 86.48 99.64 95.32 MKN45
[1604] ADC8, 8 mpk 100.57 109.43 103.81 ADC9, 4 mpk 90.74 96.54 90.48 ADC5, 0.6 mpk 24.23 37.31 49.51 ADC2, 4 mpk 89.42 92.99 88.81 ADC2, 8 mpk 88.88 95.93 95.87 NCI-H2122 ADC8, 4 mpk 84.11 89.28 81.77 ADC8, 8 mpk 94.58 96.57 93.34 ADC9, 4 mpk 91.65 90.74 74.15 ADC2, 4 mpk 99.38 101.88 98.36 ADC2, 8 mpk 99.80 103.00 104.08 SW1463 ADC9, 4 mpk 100.20 103.07 100.80 ADC5, 0.3 mpk 60.92 63.11 42.32
[1605]
[1606] ADC5, 0.6 mpk 78.71 86.63 80.19
[1607] 129
[1608] FH30010189.1Attorney Docket: LCH-04425
[1609] Experimental Example 6: In vivo Evaluation of Anti-Tumor Efficacy Using PDX Models (Single-Mouse Clinical Trial)
[1610] The anti-cancer efficacy of the exemplified ADCs was further evaluated using patient-derived xenograft (PDX) models in a single-mouse preclinical trial (SMPT) format. PDX models derived from lung cancer and colon cancer were used to assess in-vivo efficacy.
[1611] The efficacy evaluation comprised an initial tumor amplification phase followed by an efficacy evaluation phase. Briefly, cryopreserved PDX tumor fragments were thawed and subcutaneously engrafted into female NOG mice (NOD.Cg-PrkdcscldI12rgtmlSug / JicTac). The mice were maintained under specific pathogen-free (SOPF) conditions to allow in vivo expansion of the tumoral material. The expanded tumor fragments were subcutaneously implanted into female CB17 SCID (CB17 / Icr-Prkdcscid / IcrIcoCrl) mice for the efficacy evaluation.
[1612] When tumor volumes reached approximately 100 to 200 mm3, the mice were randomized into vehicle control and treatment groups. Exemplified ADCs were administered intravenously according to predefined dosing regimens set forth in Table 15, and tumor volumes were at predetermined time points.
[1613] Table 15. Dosing Regimens of Exemplified ADCs in In PDX Models
[1614] Test Samples NIC-0087 NIC-0011 NIC-0084
[1615] 4, 8 mg / kg 4, 8 mg / kg 4, 8 mg / kg
[1616] ADC2
[1617] (single) (single) (single)
[1618] 4 mg / kg 4 mg / kg 4 mg / kg
[1619] ADC9
[1620] (single) (single) (single)
[1621] Test Samples LRB-004P IGR-048M LRB-010P
[1622] 4, 8 mg / kg 4, 8 mg / kg 4, 8 mg / kg
[1623] ADC2
[1624] (single) (single) (single)
[1625] 4 mg / kg 4 mg / kg 4 mg / kg
[1626] ADC9
[1627]
[1628] (single) (single) (single)
[1629] In the lung cancer PDX models (LUN-NIC-0087, LUN-NIC-0011, and LUN-NIC-0084; FIGs. 12 to 14), ADC2 at 8 mg / kg demonstrated potent and sustained anti-tumor effect compared to the other tested ADCs. Specifically, in the LUN-NIC-0087 model (FIG. 12), marked tumor regression was observed, with tumor volumes reduced to near complete regression and maintained at low levels an over extended period. In the LUN-NIC-0011 model (FIG. 13), tumor volumes were suppressed, and tumor volumes were maintained near-baseline levels without any significant rebound throughout the prolonged observation period of over 90
[1630] 130
[1631] FH30010189.1Attorney Docket: LCH-04425
[1632] days. In the LUN-NIC-0084 model (FIG. 14), tumor regression was observed, with tumor volumes reduced to near complete regression and largely maintained at low levels an over extended period..
[1633] In contrast, ADC9 at 4 mg / kg showed only transient tumor growth inhibition, followed by tumor regrowth over time across all three models. At the same dose level (4 mg / kg), ADC2 exhibited greater tumor growth inhibition and maintained tumor suppression for a longer duration compared to ADC9 in LUN-NIC-0011 and LUN-NIC-0084 PDX models. Notably, despite having a lower drug-to-antibody ratio (DAR) of 4, ADC2 demonstrated improved and more sustained antitumor activity relative to ADC9 (DAR of approximately 8) in multiple PDX models.
[1634] Similarly, in colon cancer PDX models (FIGs. 15 to 17), ADC2 generally exhibited potent and sustained tumor growth suppression. In most models, particularly at 8 mg / kg, tumor volumes were maintained near baseline levels over an extended period. At 4 mg / kg, both ADC2 and ADC9 showed partial tumor growth inhibition, with comparable levels of efficacy despite differences in drug-to-antibody ratio (DAR).
[1635] Experimental Example 7: Analysis of Pharmacokinetics in SD Rat Model
[1636] To analyze the pharmacokinetics of exemplified ADCs prepared in Example 15, ADC2 was intravenously administered to commercially available Sprague Dawley (SD) rats at a single dose of 3 mg / kg.
[1637] Plasma samples were taken at various time points and stored frozen for analysis. Specifically, plasma samples were collected at 0 minutes, 3 minutes, 3 hours, and at 1, 2, 3, 7, 9, and 14 days post-administration to measure the concentrations of ADC2, as well as the corresponding total antibody. The plasma concentrations of ADC2 and total antibody at the indicated time points were determined by immunoaffinity LC-MS / MS analysis following sample preparation, including protein capture and enzymatic digestion to generate signature peptides, according to methods known in the art. The result of pharmacokinetic analysis in the rat model of ADC2 is shown in FIG. 18.
[1638] ADC2 exhibited favorable pharmacokinetic profiles in rats, characterized by sustained plasma exposure and no rapid clearance. Notably, ADC2 showed comparable plasma concentration-time profiles between the conjugated forms and total antibody, indicating good in vivo stability with minimal deconjugation in circulation.
[1639] 131
[1640] FH30010189.1Attorney Docket: LCH-04425
[1641] Experimental Example 8: Analysis of Toxicokinetics in B6-hCEACAM5 Mouse Model To evaluate the toxicokinetic (TK) profile of exemplified ADCs prepared in Example 15, ADC1 was intravenously administered to commercially available B6-hCEACAM5 transgenic mice at a single dose of 200 mg / kg.
[1642] Plasma samples were collected at predetermined time points, including 0 minutes, 3 minutes, 1 day, 3 days, 7 days, and 14 days post-administration, and stored frozen until analysis. The plasma concentrations of ADC1, total antibody, and free payload were determined using immunoaffinity LC-MS / MS analysis following sample preparation procedures, including protein capture, enzymatic digestion, and analyte extraction, according to methods known in the art. The toxicokinetic profiles of ADC1 in the B6-hCEACAM5 transgenic mouse model are shown in FIG. 19.
[1643] As shown in FIG. 19, even at a high dose of 200 mg / kg, ADC1 exhibited a stable TK profile, with minimal decline in plasma concentration over the 14-day period. Notably, the plasma concentration of ADC closely overlapped with that of total antibody over time, indicating negligible deconjugation in vivo. In addition, only trace levels of free payload were detected in circulation. Together, these results demonstrate that ADC1 maintains outstanding in vivo stability, with highly preserved linker integrity and minimal systemic payload release.
[1644] Experimental Example 9: Analysis of Toxicokinetics in B6-hCEACAM5 Mouse Model To evaluate the toxicokinetic (TK) profile of exemplified ADCs prepared in Example 15, ADC5 was administered intravenously to commercially available B6-hCEACAM5 transgenic mice at a single dose of 3 mg / kg.
[1645] Plasma samples were collected at predetermined time points, including 0 minutes, 3 minutes, 1 day, 3 days, 7 days, and 14 days post-administration, and stored frozen until analysis. The plasma concentrations of ADC5, total antibody, and antibody-conjugated drug were determined using immunoaffinity LC-MS / MS analysis following sample preparation procedures, including protein capture, enzymatic digestion, and analyte release, according to methods known in the art. The pharmacokinetic profile of ADC5 in the B6-hCEACAM5 transgenic mouse model is shown in FIG. 20.
[1646] Quantitation of free payload was not performed, as comparable ADCs administered at similar dose levels exhibited payload concentrations below the limit of detection.
[1647] As shown in FIG. 20, ADC5 exhibited a stable PK profile, with sustained plasma exposure of both ADC and total antibody over time. The close correspondence between ADC 132
[1648] FH30010189.1Attorney Docket: LCH-04425
[1649] and total antibody concentrations indicates minimal deconjugation in circulation, which is consistent with high in vivo stability and well-preserved linker integrity.
[1650] Incorporation by Reference
[1651] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
[1652] Equivalents
[1653] While specific embodiments of the disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
[1654] 133
[1655] FH30010189.1
Claims
1. Attorney Docket: LCH-04425We claim:
1. A conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:[General Formula I]Ab-[LAb-(B)i]mwherein,Ab is an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein(i) CDRH1 comprises an amino acid sequence of SEQ ID NO: 2,CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,CDRL1 comprises an amino acid sequence of SEQ ID NO: 9,CDRL2 comprises an amino acid sequence of SEQ ID NO: 11, and CDRL3 comprises an amino acid sequence of SEQ ID NO: 13;(ii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 25,CDRH2 comprises an amino acid sequence of SEQ ID NO: 27,CDRH3 comprises an amino acid sequence of SEQ ID NO: 29,CDRL1 comprises an amino acid sequence of SEQ ID NO: 34,CDRL2 comprises an amino acid sequence of SEQ ID NO: 36, and CDRL3 comprises an amino acid sequence of SEQ ID NO: 38; or(iii) CDRH1 comprises an amino acid sequence of SEQ ID NO: 44,CDRH2 comprises an amino acid sequence of SEQ ID NO: 46,CDRH3 comprises an amino acid sequence of SEQ ID NO: 48,CDRL1 comprises an amino acid sequence of SEQ ID NO: 53,CDRL2 comprises an amino acid sequence of SEQ ID NO: 55, and CDRL3 comprises an amino acid sequence of SEQ ID NO: 57;134FH30010189.1Attorney Docket: LCH-04425each LAbis independently a linker;each B is independently an active agent; and1 and m are each independently 1 to 20.
2. The conjugate of claim 1, wherein Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:(i) VH comprisesthe amino acid sequence of SEQ ID NO: 15;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; andVL comprisesthe amino acid sequence of SEQ ID NO: 16;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 9, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 11, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 13;(ii) VH comprisesthe amino acid sequence of SEQ ID NO: 31;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence 135FH30010189.1Attorney Docket: LCH-04425of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 29; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 25, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 27, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 29; andVL comprisesthe amino acid sequence of SEQ ID NO: 40;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 16 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 34, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 36, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 38; or(iii) VH comprisesthe amino acid sequence of SEQ ID NO: 50;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 50 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 44, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 46, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 48; andVL comprises136FH30010189.1Attorney Docket: LCH-04425the amino acid sequence of SEQ ID NO: 59;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 59 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 53, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 55, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 57.
3. The conjugate of claim 1 or 2, wherein Ab comprises(i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 15 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 16;(ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 40; or(iii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 59.
4. The conjugate of any one of claims 1-3, wherein Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 15 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 16.
5. The conjugate of any one of claims 1-4, wherein Ab specifically binds to CEACAM5; optionally wherein Ab specifically binds to membrane-bound CEACAM5 and / or soluble CEACAM5.
6. The conjugate of any one of claims 1-5, wherein Ab is a humanized antibody or a human antibody.137FH30010189.1Attorney Docket: LCH-044257. The conjugate of any one of claims 1-6, wherein Ab is selected from a monoclonal antibody, a single chain antibody (scAb), a Fab fragment, a Fab' fragment, aF(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.
8. The conjugate of any one of claims 1-7, wherein Ab comprises an IgA, IgG, IgM, IgE, or IgD constant domain or is an IgA, IgG, IgM, IgE, or IgD antibody.
9. The conjugate of claim 8, wherein Ab comprises an IgG constant domain or is an IgG antibody; optionally wherein Ab comprises an IgGl, IgG2, IgG3, or IgG4 constant domain or is an IgGl, IgG2, IgG3, or IgG4 antibody.
10. The conjugate of claim 9, wherein Ab comprises an IgGl constant domain or is an IgGl antibody.
11. The conjugate of any one of claims 8-10, wherein(i) Ab comprises LALA mutations in a heavy chain constant domain, wherein the LALA mutations comprise L234A and L235A substitutions according to EU numbering convention; or(ii) Ab comprises leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 236-237 in SEQ ID NO: 17 or amino acids 237-238 in SEQ ID NO: 51.
12. The conjugate of any one of claims 1-11, wherein Ab at the C-terminus comprises an amino acid motif that is recognized by an isoprenoid transferase; optionally wherein the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase).
13. The conjugate of claim 12, wherein LAbis covalently bonded to Ab by a thioether bond and the thioether bond comprises a sulfur atom of a cysteine of the amino acid motif.
14. The conjugate of claim 12 or 13, wherein the amino acid motif comprises a CYaYaX sequence, wherein:138FH30010189.1Attorney Docket: LCH-04425C is cysteine;each Yais independently an aliphatic amino acid, optionally wherein each Yais independently selected from alanine, isoleucine, leucine, methionine, and valine; and X is selected from glutamine, glutamate, serine, cysteine, methionine, alanine, and leucine.
15. The conjugate of any one of claims 12-14, wherein the amino acid motif comprises a CVIM (SEQ ID NO: 20) or CVLL (SEQ ID NO: 21).
16. The conjugate of any one of claims 12-15, wherein at least one of the 1 to 20 amino acids preceding the amino acid motif is glycine.
17. The conjugate of any one of claims 12-16, wherein the amino acid motif has the sequence GGGGGGGCVIM (SEQ ID NO: 22).
18. The conjugate of claim 1, wherein Ab comprises:(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 18;(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 19;(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 18;(d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 19;(e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 41;(f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, and a light chain comprising the amino acid sequence of SEQ ID NO: 42;(g) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 60;(h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51, and a light chain comprising the amino acid sequence of SEQ ID NO: 62;(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 60; or139FH30010189.1Attorney Docket: LCH-04425(j) a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 62.
19. The conjugate of claim 18, wherein Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 23, and a light chain comprising the amino acid sequence of SEQ ID NO: 18.
20. The conjugate of any one of claims 1-19, wherein the conjugate has a structure represented by Formula la or a pharmaceutically acceptable salt thereof:Formula lawhereineach instance of G is independently a sugar or a sugar acid (e.g., a glucuronic acid or galactoside);R1and R2are each independently hydrogen, Ci-s alkyl, or C3-8 cycloalkyl; or R1and R2combine to complete a (Cs-Cs) cycloalkyl ring;each instance of W is independently -C(O)-, -C(O)N(R’)-, -C(O)O-, -SO2N(R’)-, -P(O)(R”)N(R’)-, -SON(R’)-, or -PO2N(R’)-;each instance of R’ and R” is independently H, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl or aryl;each instance of Z is independently alkyl, halo, cyano, or nitro;nl and n2 are each independently 1 to 20;each instance of n3 is independently 0, 1, 2, or 3; andY1is absent, C1-C50 alkylene, C1-C50 alkenylene, 1-50 atom heterocyclylene, or 1-50 atom heteroalkylene.
21. The conjugate of claim 20, wherein R1is H or methyl.140FH30010189.1Attorney Docket: LCH-0442522. The conjugate of claim 20 or 21, wherein R2is H or methyl.
23. The conjugate of any one of claims 20-22, wherein G has a structure represented by Formula II or a pharmaceutically acceptable salt thereof:R3aL-R3bwhereinR3and each R4is independently H, alkyl, aralkyl, or an oxygen protecting group;R3ais H or alkyl;R3bis H or alkyl; orR3aand R3bcombine to form an oxo;R3Ais H or a hydroxyl protecting group; andR3Bis H or a carboxyl protecting group.
24. The conjugate of claim 23, wherein R3is H or methyl.
25. The conjugate of any one of claims 20-24, wherein W is -C(O)N(R’)- and the C(O) is bonded to the phenyl ring and N(R’) is bonded to Y1.
26. The conjugate of any one of claims 20-25, wherein each R’ and R” is H.
27. The conjugate of any one of claims 20-26, wherein Z is halo (e.g., bromo) or cyano.
28. The conjugate of any one of claims 20-27, wherein n3 is 0 or 1.
29. The conjugate of any one of claims 20-28, wherein Y1comprises a C1-50 alkylene or Ci-50 heteroalkylene wherein the C1-50 alkylene or C1-50 heteroalkylene comprises one or more of:(i) one or more unsaturated bonds;141FH30010189.1Attorney Docket: LCH-04425(ii) a heteroarylene (e.g., a heteroarylene in the alkylene or heteroalkylene chain);(iii) at least one Cl -20 alkyl substituent; and(iv) at least one isoprenyl group having a structure represented by Formula III:IIIwherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
30. The conjugate of claim 29, wherein n4 is 1, 2, 3, or 4.
31. The conjugate of any one of claims 20-30, wherein Y1comprises a peptide comprising at least one hydrophilic amino acid.
32. The conjugate of claim 31, wherein the peptide comprises an amino acid having a side chain having a moiety that bears a charge at neutral pH in aqueous solution (e.g., an amine, guanidine, or carboxyl moiety).
33. The conjugate of claim 31 or 32, wherein the peptide comprises an amino acid selected from alanine, aspartate, asparagine, glutamate, glutamine, glycine, lysine, ornithine, proline, serine, histidine, arginine and threonine.
34. The conjugate of any one of claims 20-33, wherein Y1comprises a unit having a structure represented by Formula IVa or IVb:-(CH2)r(V(CH2)P)q- Formula IVa,-(CH2CH2X)W- Formula IVb;whereinV is a single bond, -O-, -S-, -NR5-, -C(O)NR6-, -NR7C(O)-, -NR8SO2-, or -SO2NR9-, preferably -O-;X is -O-, Ci-8 alkylene, or -NR5-, preferably -O-;142FH30010189.1Attorney Docket: LCH-04425R5to R9are each independently H, Ci-6 alkyl, Ci-6 alkyl C6-20 aryl, or C1-6 alkyl C3-20 heteroaryl;r is an integer of 1 to 10, preferably 2;p is an integer of 0 to 12, preferably 2;q is an integer of 1 to 20, preferably 2, 5, or 11; andw is an integer of 1 to 20, preferably 6 to 20.
35. The conjugate of claim 34, wherein V is -O-.
36. The conjugate of claim 34 or 35, wherein X is -O-.
37. The conjugate of any one of claims 34-36, wherein each R5, R6, R7, R8, and R9is H.
38. The conjugate of any one of claims 34-37, whereinr is 2;P is 2;q is 2, 5, or 11; andw is 6 to 20.
39. The conjugate of any one of claims 20-38, wherein Y1further comprises a binding unit formed by a reaction between an alkyne and an azide or between an aldehyde or ketone group and hydrazine or hydroxylamine.
40. The conjugate of any one of claims 20-38, wherein Y1further comprises a unit having a structure represented by Formula Va, Vb, Vc, Vd, or Ve:Vb Vc Vd Ve whereinL1is a single bond or C1-30 alkylene; andR10is H or Ci-10 alkyl.143FH30010189.1Attorney Docket: LCH-0442541. The conjugate of any one of claims 20-40, wherein Y1comprises an oxime.
42. The conjugate of claim 41, wherein the oxygen atom of the oxime is on the side of Y1that is linked to W and the carbon atom of the oxime is on the side of Y1that is linked to Ab.
43. The conjugate of claim 41, wherein the carbon atom of the oxime is on the side of Y1that is linked to W and the oxygen atom of the oxime is on the side of Y that is linked to Ab.
44. The conjugate of any one of claims 41-43, wherein the oxime has a structure represented by Formula Via:whereinR11is H, alkyl or cycloalkyl; andR12is H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl.
45. The conjugate of claim 44, wherein each R11and R12is independently H or alkyl, preferably methyl.
46. The conjugate of claim 44, wherein R11and R12combine to form a cycloalkyl, preferably cyclobutyl.
47. The conjugate of any one of claims 41-46, wherein the oxime has a structure represented by formula VIb:.12VIbwhereinR11and R12are independently H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl;X1and X2are each independently N(R13), O, or S; and144FH30010189.1Attorney Docket: LCH-04425R13is H, alkyl, aryl, or aralkyl.
48. The conjugate of claim 47, wherein X1is N(R13), further wherein R13is H.
49. The conjugate of claim 47 or 48, wherein X2is O.
50. The conjugate of any one of claims 20-49, wherein Y1further comprises an oligoethylene glycol.
51. The conjugate of claim 50, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties represented byL JorL J(e.g., 1, 2, 3, or 4 ethylene glycol moieties).
52. The conjugate of claim 50 or 51, wherein Y1comprises an oxime and the oligoethylene glycol covalently bonds the oxime to W.
53. The conjugate of any one of claims 20-52, wherein Y1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido.
54. The conjugate of any one of claims 20-52, wherein Y1is substituted with an oligoethylene glycol.
55. The conjugate of claim 54, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).
56. The conjugate of any one of claims 50-55, wherein the oligoethylene glycol is substituted with carboxyalkyl e.g., carboxyethyl) or amino (e.g., dimethylamino).145FH30010189.1Attorney Docket: LCH-0442557. The conjugate of any one of claims 20-56, wherein Y1further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).
58. The conjugate of any one of claims 20-57, wherein Y1further comprises an amino acid (e.g., a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.
59. The conjugate of claim 58, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.60 The conjugate of any one of claims 20-59, wherein Y1is linear.
61. The conjugate of any one of claims 20-59, wherein Y1is branched.
62. The conjugate of claim 61, wherein Y1comprises:i) a branching unit covalently coupled to Ab by a primary linker;ii) a first branch which couples a first B to the branching unit; andiiia) a second branch which couples a second B to the branching unit; oriiib) a second branch comprising an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) is covalently coupled to the branching unit.
63. The conjugate of claim 62, wherein Y1comprises a second branch which couples a second B, via a cleavage group, to the branching unit.
64. The conjugate of claim 62, wherein Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.
65. The conjugate of any one of claims 62-64, wherein the branching unit comprises an amino acid, preferably a lysine residue.146FH30010189.1Attorney Docket: LCH-0442566. The conjugate of any one of claims 62-64, wherein the branching unit has a structure represented by Formula Vila, Vllb, Vile, or Vlld:' N,15 _i Vila Vllb Vile Vlld whereinG1, G2, G3are each independently a bond,RRi4R14is H or alkyl;R15is H, alkyl or L5-CO2R16R16is H or alkyl; andL2, L3, L4, and L5are each independently a bond or alkylene.
67. The conjugate of any one of claims 62-64, wherein the branching unit has a structure represented by Formula Vlllb:HNR14Vlllbwherein R14is H or alkyl.
68. The conjugate of any one of claims 62-67, wherein the cleavage group has a structure represented by Formula IX or a pharmaceutically acceptable salt thereof:147FH30010189.1Attorney Docket: LCH-04425oIXwhereinBw is an active agent;each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkyl sulfonyl, or sulfonamido;each Ww1is independently -*C(O)-, -*C(O)N(Rw7)-, -*N(Rw7)C(O)-, - *(CH2)twiN(Rw7)C(O)-, -*C(O)O-, -*S(O2)N(RW7)-, -*P(O)( RW8)N(RW7)-, - *S(O)N(Rw7)-, or -*P(O2)N(RW7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula IX;Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nwl is 0, 1, 2, or 3;Jw1is H or alkyl;Jw2is H or alkyl; orJw1and Jw2combine to form an oxo; andAw2represents a linkage to the secondary linker.
69. The conjugate of any one of claims 61-68, wherein:at least one branched linker is covalently coupled to Ab; andat least two B are covalently coupled to the branched linker.148FH30010189.1Attorney Docket: LCH-0442570. The conjugate of claim 69, wherein the conjugate comprises 1, 2, 3, or 4 branched linkers and each branched linker comprises two B.
71. The conjugate of any one of claims 1-70, wherein the conjugate comprises a structureor a pharmaceutically acceptable salt thereof; whereinB' and B" are each an active agent;nil, n22, and n33 are each independently 0 to 30;AA is an amino acid group (e.g., a lysine); andthe wavy bond represents a connection to Ab.
72. The conjugate of any one of claims 1-19, wherein the conjugate comprises a structure represented by Formula X or a pharmaceutically acceptable salt thereof:149FH30010189.1Attorney Docket: LCH-04425_ m3Formula XL6comprises an alkylene;Y2and Y4are each independently O, N(R17), or S;Yxis H;X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,-OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;V1and V3are each independently a bond, N, NH, C, CH, or CH2;L7and L9each independently comprise an alkylene;T1and T3are each independently a bond, -O-, or a self-immolative moiety;B1and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1or V3, T3and B3together represent a branched moiety; andml and m3 are each independently 1, 2, or 3.
73. The conjugate of any one of claims 1-19, wherein the conjugate comprises a structure represented by Formula XI or a pharmaceutically acceptable salt thereof:FH30010189.1Attorney Docket: LCH-04425Formula XIwhereinL6comprises an alkylene;Y2, Y3, and Y4are each independently O, N(R17), or S;X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-, -OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, - N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;L7, L8, and L9each independently comprise an alkylene;T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.
74. The conjugate of claim 73, wherein each of Y2, Y3, and Y4is O.
75. The conjugate of claim 73 or 74, wherein X1is -C(O)N(R18)-, further wherein R18is H.
76. The conjugate of any one of claims 73-75, wherein L6comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.
77. The conjugate of any one of claims 73-76, wherein L6further comprises an oligoethylene glycol.
78. The conjugate of claim 77, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, 4, 5, or 6 ethylene glycol moieties, more preferably 5 ethylene glycol moieties.151FH30010189.1Attorney Docket: LCH-0442579. The conjugate of any one of claims 73-78, wherein L6is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido.
80. The conjugate of any one of claims 73-79, wherein L6further comprises a structure represented by Formula Xia or Formula Xlb:■3' .0.NXiaAt / O.X N2whereinA1represents a linkage to X1;A2represents a linkage to Ab;X3and X4are each independently O, S, or N(R23);R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl;R22is H or alkyl; andR23is H, alkyl, aryl, or aralkyl.
81. The conjugate of claim 80, wherein X3is N(R23), further wherein R23is H.
82. The conjugate of claim 80 or 81, wherein X4is O.
83. The conjugate of any one of claims 80-82, wherein each of R20and R21is independently alkyl (e.g., methyl).
84. The conjugate of any one of claims 80-83, wherein R20and R21combine to form a cycloalkyl (e.g., cyclobutyl).152FH30010189.1Attorney Docket: LCH-0442585. The conjugate of any one of claims 73-84, wherein L6further comprises a heteroaryl (e.g., pyrazolyl, triazolyl).
86. The conjugate of claim 85, wherein L6further comprises a structure represented by Formula Xllla or Xlllb:N=N N=NXllla Xlllbwhereineach A1represents a linkage to X1; andeach A2represents a linkage to Ab.
87. The conjugate of any one of claims 73-86, wherein L6further comprises a structure represented by Formula XIV:XIVwherein n5 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, preferably wherein n5 is 1, 2, 3, 4, or 5;each A1represents a linkage to X1; andeach A2represents a linkage to Ab.
88. The conjugate of any one of claims 73-87, wherein L6is substituted with an oligoethylene glycol.
89. The conjugate of claim 88, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).
90. The conjugate of claim 88 or 89, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino).
91. The conjugate of any one of claims 73-90, wherein L6further comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).153FH30010189.1Attorney Docket: LCH-0442592. The conjugate of claim 91, wherein L6comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).
93. The conjugate of any one of claims 73-92, wherein L6further comprises an amino acid (e.g., a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.
94. The conjugate of any one of claims 73-93, wherein L6further comprises a polypeptoid (e.g., polysarcosine).
95. The conjugate of claim 93, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.
96. The conjugate of any one of claims 73-95, wherein each of L7, L8and L9independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.
97. The conjugate of any one of claims 73-96, wherein each of L7, L8and L9independently further comprises an oligoethylene glycol.
98. The conjugate of claim 97, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 5 ethylene glycol moieties.
99. The conjugate of any one of claims 73-98, wherein each of L7, L8and L9independently further comprises an amido moiety, preferably 1, 2, 3, 4, 5, or 6 amido moieties, more preferably 1 or 2 amido moieties.
100. The conjugate of any one of claims 73-98, wherein each of L7, L8and L9independently further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do).
101. The conjugate of any one of claims 73-100, wherein each of L7, L8and L9independently further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).154FH30010189.1Attorney Docket: LCH-04425102. The conjugate of claim 101, wherein each of L7, L8and L9independently further comprises a structure represented by Formula XVa or XVb:N=NXVawherein:each Ax1represents a linkage to V1, V2or V3; andeach Ax2represents a linkage to Y2, Y3or Y4.
103. The conjugate of any one of claims 73-102, wherein each of L7, L8and L9is independently substituted with an oligoethylene glycol.
104. The conjugate of claim 103, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
105. The conjugate of claim 103 or 104, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino).
106. The conjugate of any one of claims 73-105, wherein each of L7, L8and L9is independently substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkyl sulfonyl, or sulfonamido.
107. The conjugate of any one of claims 73-106, wherein each of L7, L8and L9independently further comprises an amino acid (e.g, a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.
108. The conjugate of claim 107, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.
109. The conjugate of any one of claims 73-108, wherein V1is a bond.155FH30010189.1Attorney Docket: LCH-04425110. The conjugate of any one of claims 73-108, wherein V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIa or a pharmaceutically acceptable salt thereof:Ax3^Tx1 / Tx2Bx1^ ^Lx1^Lx2^Bx2XVIawherein:Ax3represents a linkage to L7;Lx1and Lx2each independently comprise an alkylene;Tx1and Tx2are each independently a bond or a self-immolative moiety; andBx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
111. The conjugate of any one of claims 73-108, wherein V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb, Formula XVIc, or Formula XVId, or a pharmaceutically acceptable salt thereof:Ax3 / Tx2Bx1Lx2^Bx2XVIb,XVIc,Ax3Bx3156FH30010189.1Attorney Docket: LCH-04425XVId,wherein:Ax3represents a linkage to L7;Lx1, Lx2, and Lx3each independently comprise an alkylene;0 O* 1 D 1 Gx1, Gx2, and Gx3are each independently an alkylene,, or ™ ;each Rx1is independently H, alkyl, or aralkyl;Tx Tx2, and Tx3are each independently a bond or a self-immolative moiety; andBx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
112. The conjugate of any one of claims 109-111, wherein each of Lx1, Lx2, and Lx3independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.
113. The conjugate of any one of claims 109-112, wherein each of Lx1, Lx2, and Lx3independently further comprises an oligoethylene glycol.
114. The conjugate of claim 113, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
115. The conjugate of any one of claims 110-114, wherein T1, Tx1, Tx2, or Tx3has a structure represented by Formula XVII or a pharmaceutically acceptable salt thereof:FH30010189.1Attorney Docket: LCH-04425XVIIwhereineach Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)txiN(Rx7)C(O)-, -*C(O)O-, -*S(O2)N(RX7)-, -*P(O)(RX8)N(RX7)-, -*S(O)N(RX7)-, or -*P(O2)N(RX7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Ja1is H or alkyl;Ja2is H or alkyl; orJa1and Ja2combine to form an oxo;tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nxl is 0, 1, 2, or 3;Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; andAx5represents a linkage to L7, Lx1, Lx2, or Lx3.
116. The conjugate of claim 115, wherein each of Rx2, Rx3, Rx4, and Rx5is H.
117. The conjugate of claim 115 or 116, wherein nxl is 0.
118. The conjugate of any one of claims 115-117, wherein Wx1is -*C(O)N(Rx7)-, further wherein Rx7is H.
119. The conjugate of any one of claims 115-118, wherein Ja1and Ja2combine to form oxo.
120. The conjugate of any one of claims 73-119, wherein V2is a bond.158FH30010189.1Attorney Docket: LCH-04425121. The conjugate of any one of claims 73-120, wherein V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXa or a pharmaceutically acceptable salt thereof:Ay3^•Ty1 / Ty2By1^ """'Ly1^Ly2^By2XIXawherein:Ay3represents a linkage to L8;Ly1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond, or a self-immolative moiety; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
122. The conjugate of any one of claims 73-120, wherein V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb, Formula XIXc, or Formula XlXd, or a pharmaceutically acceptable salt thereof:XlXb,Ay3>3y1Byl. / Ly\ ^Ly\ ^By2Ty1Gy2Gy3Ty2XIXc,Ay3Byl / Ly\ ^ / Ly\ / By2^Ty1Hy2Ly3y3By3159FH30010189.1Attorney Docket: LCH-04425XlXd, wherein:Ay3represents a linkage to L8;Ly1, Ly2, and Ly3each independently comprise an alkylene;O O\\A / -N-\ Gy1, Gy2, and Gy3are each independently an alkylene,, or ^z;each Ry1is independently H, alkyl, or aralkyl;Ty1, Ty2, andTy3are each independently a bond or a self-immolative moiety; and By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
123. The conjugate of claim 121 or 122, wherein each of Ly1, Ly2, and Ly3independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.
124. The conjugate of any one of claims 121-123, wherein each of Ly1, Ly2, and Ly3independently further comprises an oligoethylene glycol.
125. The conjugate of claim 124, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
126. The conjugate of any one of claims 73-125, wherein T2, Ty1, Ty2, or Ty3has a structure represented by Formula XX or a pharmaceutically acceptable salt thereof:Ry\0Jb1Jb2XX160FH30010189.1Attorney Docket: LCH-04425whereineach Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;each Wy1is independently -*C(O)-, -*C(O)N(Ry7)-, -*N(Ry7)C(O)-, -*(CH2)tyiN(Ry7)C(O)-, -*C(O)O-, -*S(O2)N(Ry7)-, -*P(O)( Ry8)N(Ry7)-, -*S(O)N(Ry7)-, or -*P(O2)N(Ry7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XX,Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jb1is H or alkyl;Jb2is H or alkyl; orJb1and Jb2combine to form an oxo;tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nyl is 0, 1, 2, or 3;Ay4represents a linkage to B2, By1, By2, or By3; andAy5represents a linkage to L8, Ly1, Ly2, or Ly3.
127. The conjugate of claim 126, wherein each of Ry2, Ry3, Ry4, Ry5, is H.
128. The conjugate of claim 126 or 127, wherein each nyl is 0.
129. The conjugate of any one of claims 126-128, wherein each Wy1is -*C(O)N(Ry7)-, further wherein Ry7is H.
130. The conjugate of any one of claims 126-129, wherein Jb1and Jb2combine to form oxo.
131. The conjugate of any one of claims 73-130, wherein V3is a bond.161FH30010189.1Attorney Docket: LCH-04425132. The conjugate of any one of claims 73-130, wherein V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIa or a pharmaceutically acceptable salt thereof:Az3Tz1 / Tz2Bz1\z1Tz2^Bz2XXIIawherein:Az3represents a linkage to L9;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a self-immolative moiety; andBz1and Bz2are each independently an active agent (e.g., a drug or a toxin).
133. The conjugate of any one of claims 73-130, wherein V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb, Formula XXIIc, or Formula XXIId, or a pharmaceutically acceptable salt thereof:Az3Tz1 / Tz2Bz1^ ^Lz1^Lz2^Bz2XXIIb,Az3T3z1Bz1 / Lz1 / L / Lz2 / Bz2^Tz1^Gz2X3z3^Tz2XXIIc,Az3Bz1 / Lz1 / Lz2 / Bz2^Tz1~^Tz2Lz3\ -z3Bz3XXIId,162FH30010189.1Attorney Docket: LCH-04425wherein:Az3represents a linkage to L9;Lz1, Lz2, and Lz3each independently comprise an alkylene;O OGz1, Gz2, and Gz3are each independently an alkylene,, or ^z;each Rz1is independently H, alkyl, or aralkyl;Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; andBz1, Bz2, andBz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.
134. The conjugate of claim 132 or 133, wherein each of Lz1, Lz2, and Lz3comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.
135. The conjugate of any one of claims 132-134, wherein each of Lz1, Lz2, and Lz3independently further comprises an oligoethylene glycol.
136. The conjugate of claim 135, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.
137. The conjugate of any one of claims 132-136, wherein T3, Tz1, Tz2, or Tz3have a structure represented by Formula XXIII or a pharmaceutically acceptable salt thereof:XXIII163FH30010189.1Attorney Docket: LCH-04425whereineach Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(RZ7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(RZ7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XXIII,Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jc1is H or alkyl;Jc2is H or alkyl; orJc1and Jc2combine to form an oxo;tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nzl is 0, 1, 2, or 3;Az4represents a linkage to B3, Bz1, Bz2, or Bz3; andAz5represents a linkage to L9, Lz1, Lz2, or Lz3.
138. The conjugate of claim 137, wherein each of Rz2, Rz3, Rz4, and Rz5is H.
139. The conjugate of claim 137 or 138, wherein nzl is 0.
140. The conjugate of any one of claims 137-139, wherein Wz1is -*C(O)N(Rz7)-, further wherein Rz7is H.
141. The conjugate of any one of claims 137-140, wherein Jc1and Jc2combine to form oxo.164FH30010189.1Attorney Docket: LCH-04425142. The conjugate of any one of claims 1-141, wherein the conjugate comprises° or .
143. The conjugate of any one of claims 73-142, wherein each of B1, B2, and B3is independently an active agent.
144. The conjugate of any one of claims 73-142, wherein each of B1, B2, and B3is independently H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).
145. The conjugate of any one of claims 73-144, wherein each of T1, T2, and T3is independently a bond.
146. The conjugate of any one of claims 1-145, wherein each active agent is independently a chemotherapeutic agent or a toxin.
147. The conjugate of any one of claims 1-145, wherein each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, or an antiparasitic agent.
148. The conjugate of any one of claims 1-145, wherein each active agent is independently selected from:(a) a microtubule targeting agent (e.g., maytansinoid, maytansine, DM1, DM4, maytansinol, auristatin, dolastatin 10, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), eribulin, Halichondrin B, tubulysin, cryptophycin, EG5 inhibitors, SB-715992 (ispinesib), orfilanesib (ARRY-520));(b) a DNA damaging agent (e.g., enediyne, calicheamicin, uncialamycin, topoisomerase inhibitors, topotecan, camptothecin, SN-38, irinotecan (CPT-11), exatecan, Dxd,165FH30010189.1Attorney Docket: LCH-04425FL118, pyrrolobenzodiazepine (PBD), PBD dimer, duocarmycin, Duocarmycin A, CC-1065);(c) an RNA targeting agent (e.g., thailanstatin, amatoxin, a-amanitin, P-amanitin);(d) an affinity ligand (e.g., the affinity ligand is a substrate, inhibitor, active agent, neurotransmitter, radioactive isotope, or mixtures thereof);(e) a radioactive label (e.g., 32P or 35S), a fluorescent dye, an electron dense reagent, an enzyme, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or mixtures thereof;(f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an antibacterial agent, an anti-fungal agent, an anti-parasitic agent, or mixtures thereof; (g) an estrogen receptor modulator (e.g., tamoxifen, raloxifene, droloxifene, 4- hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone or toremifene); (h) an aromatase inhibitor(e.g., 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole or anastrozole);(i) a nonsteroidal antiandrogen (NSAA) (e.g., flutamide, nilutamide, bicalutamide); (j) an aromatase inhibitor;(k) a protein kinase inhibitor;(l) a lipid kinase inhibitor;(m) an antisense oligonucleotide;(n) a ribozyme;(o) a vaccine;(p) an anti -angiogenic agent;(q) a Bcl-xL inhibitor;(r) a NAMPT inhibitor; and(s) a Carmaphycin.
149. The conjugate of any one of claims 1-145, wherein each active agent is independently selected from: Calicheamicin, Monomethyl auristatin E(MMAE), Monomethyl auristatin F(MMAF), Mertansine (DM1), Ravtansine (DM4), SN-38, Deruxtecan (Dxd), FL118, exatecan, pyrrolobenzodiazepines (PBD), PBD dimers, duocarmycin, Duocarmycin A, and Auristatin E.
150. The conjugate of any one of claims 1-19, wherein the conjugate comprises:166FH30010189.1Attorney Docket: LCH-04425167FH30010189.1Attorney Docket: LCH-04425FH30010189.1Attorney Docket: LCH-04425or a pharmaceutically acceptable salt thereof;wherein MMAE is monomethyl auri statin E.
151. The conjugate of any one of claims 1-19, wherein the conjugate comprises a structure represented by:169FH30010189.1Attorney Docket: LCH-04425, or; wherein is Ab.
152. A pharmaceutical composition comprising the conjugate of any one of claims 1-151 and a pharmaceutically acceptable excipient.
153. A pharmaceutical composition for use in preventing or treating a cancer, the composition comprising the conjugate of any one of claims 1-151.
154. The pharmaceutical composition for use of claim 153, wherein the cancer is a cancer associated with CEACAM5 expression.170FH30010189.1Attorney Docket: LCH-04425155. The pharmaceutical composition for use of claim 153 or 154, wherein the cancer is a solid tumor.
156. The pharmaceutical composition for use of any one of claims 153-155, wherein the cancer is selected from colorectal cancer, stomach cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, lung cancer, uterus cancer, cervical cancer, pancreatic cancer, esophagus cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrium cancer, bladder cancer, neuroendocrine cancer, endometrial cancer, breast cancer, liver cancer, prostate cancer, cholangiocarcinoma, and skin cancer.
157. A method of treating or preventing a cancer in a subject in need thereof comprising administering a conjugate of any one of claims 1-151 or a pharmaceutically acceptable salt thereof to the subject.
158. The method of claim 157, wherein the cancer is a cancer associated with CEACAM5 expression.
159. The method of claim 157 or 158, wherein the cancer is a solid tumor.
160. The method of any one of claims 157-159, wherein the cancer is selected from colorectal cancer, stomach cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, lung cancer, uterus cancer, cervical cancer, pancreatic cancer, esophagus cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrium cancer, bladder cancer, neuroendocrine cancer, endometrial cancer, breast cancer, liver cancer, prostate cancer, cholangiocarcinoma, and skin cancer.171FH30010189.1
